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A B S T R A C T
Background
Muscle soreness typically occurs after intense exercise, unaccustomed exercise or actions that involve eccentric contractions where the
muscle lengthens while under tension. It peaks between 24 and 72 hours after the initial bout of exercise. Many people take antioxidant
supplements or antioxidant-enriched foods before and after exercise in the belief that these will prevent or reduce muscle soreness after
exercise.
Objectives
To assess the effects (benefits and harms) of antioxidant supplements and antioxidant-enriched foods for preventing and reducing the
severity and duration of delayed onset muscle soreness following exercise.
Search methods
We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, the Cochrane Central Register of Controlled
Trials, MEDLINE, Embase, SPORTDiscus, trial registers, reference lists of articles and conference proceedings up to February 2017.
Selection criteria
We included randomised and quasi-randomised controlled trials investigating the effects of all forms of antioxidant supplementation
including specific antioxidant supplements (e.g. tablets, powders, concentrates) and antioxidant-enriched foods or diets on preventing
or reducing delayed onset muscle soreness (DOMS). We excluded studies where antioxidant supplementation was combined with
another supplement.
Data collection and analysis
Two review authors independently screened search results, assessed risk of bias and extracted data from included trials using a pre-
piloted form. Where appropriate, we pooled results of comparable trials, generally using the random-effects model. The outcomes
selected for presentation in the ’Summary of findings’ table were muscle soreness, collected at times up to 6 hours, 24, 48, 72 and 96
hours post-exercise, subjective recovery and adverse effects. We assessed the quality of the evidence using GRADE.
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Main results
Fifty randomised, placebo-controlled trials were included, 12 of which used a cross-over design. Of the 1089 participants, 961 (88.2%)
were male and 128 (11.8%) were female. The age range for participants was between 16 and 55 years and training status varied from
sedentary to moderately trained. The trials were heterogeneous, including the timing (pre-exercise or post-exercise), frequency, dose,
duration and type of antioxidant supplementation, and the type of preceding exercise. All studies used an antioxidant dosage higher
than the recommended daily amount. The majority of trials (47) had design features that carried a high risk of bias due to selective
reporting and poorly described allocation concealment, potentially limiting the reliability of their findings.
We tested only one comparison: antioxidant supplements versus control (placebo). No studies compared high-dose versus low-dose,
where the low-dose supplementation was within normal or recommended levels for the antioxidant involved.
Pooled results for muscle soreness indicated a small difference in favour of antioxidant supplementation after DOMS-inducing exercise
at all main follow-ups: up to 6 hours (standardised mean difference (SMD) -0.30, 95% confidence interval (CI) -0.56 to -0.04; 525
participants, 21 studies; low-quality evidence); at 24 hours (SMD -0.13, 95% CI -0.27 to 0.00; 936 participants, 41 studies; moderate-
quality evidence); at 48 hours (SMD -0.24, 95% CI -0.42 to -0.07; 1047 participants, 45 studies; low-quality evidence); at 72 hours
(SMD -0.19, 95% CI -0.38 to -0.00; 657 participants, 28 studies; moderate-quality evidence), and little difference at 96 hours (SMD
-0.05, 95% CI -0.29 to 0.19; 436 participants, 17 studies; low-quality evidence). When we rescaled to a 0 to 10 cm scale in order to
quantify the actual difference between groups, we found that the 95% CIs for all five follow-up times were all well below the minimal
important difference of 1.4 cm: up to 6 hours (MD -0.52, 95% CI -0.95 to -0.08); at 24 hours (MD -0.17, 95% CI -0.42 to 0.07); at
48 hours (MD -0.41, 95% CI -0.69 to -0.12); at 72 hours (MD -0.29, 95% CI -0.59 to 0.02); and at 96 hours (MD -0.03, 95% CI -
0.43 to 0.37). Thus, the effect sizes suggesting less muscle soreness with antioxidant supplementation were very unlikely to equate to
meaningful or important differences in practice. Neither of our subgroup analyses to examine for differences in effect according to type
of DOMS-inducing exercise (mechanical versus whole body aerobic) or according to funding source confirmed subgroup differences.
Sensitivity analyses excluding cross-over trials showed that their inclusion had no important impact on results.
None of the 50 included trials measured subjective recovery (return to previous activities without signs or symptoms).
There is very little evidence regarding the potential adverse effects of taking antioxidant supplements as this outcome was reported in
only nine trials (216 participants). From the studies that did report adverse effects, two of the nine trials found adverse effects. All six
participants in the antioxidant group of one trial had diarrhoea and four of these also had mild indigestion; these are well-known side
effects of the particular antioxidant used in this trial. One of 26 participants in a second trial had mild gastrointestinal distress.
Authors’ conclusions
There is moderate to low-quality evidence that high dose antioxidant supplementation does not result in a clinically relevant reduction
of muscle soreness after exercise at up to 6 hours or at 24, 48, 72 and 96 hours after exercise. There is no evidence available on subjective
recovery and only limited evidence on the adverse effects of taking antioxidant supplements. The findings of, and messages from,
this review provide an opportunity for researchers and other stakeholders to come together and consider what are the priorities, and
underlying justifications, for future research in this area.
P L A I N L A N G U A G E S U M M A R Y
Antioxidants for preventing and reducing muscle soreness after exercise
Background and aim of the review
Muscle soreness typically occurs after intense or unaccustomed exercise. It peaks between 24 and 72 hours after the initial bout of
exercise. Many people take antioxidant supplements such as vitamin C and/or E or antioxidant-enriched foods such as tart cherry or
pomegranate juice before and after exercise in the belief that these will prevent or reduce muscle soreness after exercise.
Results of the search
We searchedmedical databases up to February 2017 for studies that compared antioxidant supplementation with a control intervention
such as a placebo (a dummy pill or drink that had no antioxidant) or no treatment. We found 50 studies, all of which compared
antioxidant supplementation with a placebo. These reported results for a total of 1089 participants. Of these, nearly 9 out of 10 were
male. The age range for participants was between 16 and 55 years and their training status varied from sedentary to moderately trained.
2Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The studies were very varied such as in the type and dosage of the antioxidant supplement and the type of exercises used to cause muscle
soreness. All studies used an antioxidant dosage higher than the recommended daily amount.
Key results
There is evidence that high dose antioxidant supplementation may slightly reduce muscle soreness at up to 6 hours and at 24, 48 and
72 hours follow-up but not at 96 hours. However, these reductions were so small that they were unlikely to make any difference. None
of the trials reported on outcomes related to subjective recovery, such as return to previous activities without signs or symptoms.
Only nine studies reported on adverse effects and only two found adverse effects. All six participants in the antioxidant group of one
trial had diarrhoea and four of these also had mild indigestion; these are well-known side effects of the particular antioxidant used in
this study. One of 26 participants in a second trial had mild gastrointestinal distress.
Quality of the evidence
We considered the evidence for muscle soreness to be ’moderate’ or ’low’ quality. This was mainly because the majority of studies had
aspects that could have affected the reliability of their results and in some cases because of variation in the results of the studies. This
means there is some uncertainty about the findings and further research may provide evidence that could change our conclusions.
Authors’ conclusions
Antioxidant supplementation does not appear to reduce muscle soreness early on or at one, two, three or four days after exercise.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antioxidants compared with placebo or no treatment for preventing and reducing muscle soreness after exercise
Patient or population: mainly physically act ive individuals1 partaking in exercise2 designed to produce delayed onset muscle soreness
Settings: controlled laboratory studies and f ield-based studies
Intervention: ant ioxidant supplements3. These fell into 3 main categories: whole natural food source (e.g. bilberry juice, cherry, pomegranate juice); ant ioxidant extract or
m ixed ant ioxidants (e.g. black tea extract, curcumin); and vitamin C or E or both combined
Comparison: all were placebo controls
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control (placebo or no
antioxidants)
Antioxidant supple-
mentation
Muscle soreness
Follow-up: immediately
up to 6 hours post-exer-
cise
The mean level of mus-
cle soreness in the con-
trol group ranged f rom
1.0 to 8.3 cm (adjusted
to a 0 to 10 cm scale)
The mean level of mus-
cle soreness af ter an-
t ioxidant supplementa-
t ion was 0.30 standard
deviations lower
(0.56 to 0.04 lower)
SMD -0.30
(-0.56 to -0.04)
525
(21 studies4)
⊕⊕©©
low5
One ’rule of thumb’ is
that 0.2 represents a
small dif f erence, 0.5
a moderate dif ference
and 0.8 a large dif fer-
ence
Based on this ’rule
of thumb’, this result
equates to a small to
moderate dif ference in
favour of ant ioxidant
supplementat ion
However, when we
rescaled the data to a 0
to 10 cm scale, the MD
was lower by 0.52 cm
(0.95 to 0.08 cm lower)
. These are all under
the typical MID for pain
(taken here as 1.4 cm)4
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Muscle soreness
Follow-up: 24 hours
The mean level of mus-
cle soreness in the con-
trol group ranged f rom
0.21 to 8.8 cm (ad-
justed to a 0 to 10 cm
scale)
The mean level of mus-
cle soreness af ter an-
t ioxidant supplementa-
t ion was 0.13 standard
deviations lower
(0.27 to 0.00 lower)
SMD -0.13
(-0.27 to -0.00)
936
(41 studies4)
⊕⊕⊕©
moderate6
Based on the above
’rule of thumb’, this re-
sult equates to a small
dif f erence in favour of
ant ioxidant supplemen-
tat ion
However, when we
rescaled the data to a
0 to 10 cm scale, the
MD was lower by 0.17
cm (0.42 lower to 0.07
higher). These are all
under the typical MID
for pain (taken here as
1.4 cm)
Muscle soreness
Follow-up: 48 hours
The mean level of mus-
cle soreness in the con-
trol group ranged f rom
0.32 to 9.56 cm (ad-
justed to a 0 to 10 cm
scale)
The mean level of mus-
cle soreness af ter an-
t ioxidant supplementa-
t ion was 0.24 standard
deviations lower
(0.42 to 0.07 lower)
SMD -0.24
(-0.42 to -0.07)
1047
(45 studies7)
⊕⊕©©
low8
Based on the above
’rule of thumb’, this re-
sult equates to a small
dif f erence in favour of
ant ioxidant supplemen-
tat ion
However, when we
rescaled the data to a
0 to 10 cm scale, the
MD was lower by 0.41
cm (0.69 to 0.12 lower)
. These are all under
the typical MID for pain
(taken here as 1.4 cm)
Muscle soreness
Follow-up: 72 hours
The mean level of mus-
cle soreness in the con-
trol group ranged f rom
0.5 to 8.5 cm (adjusted
to a 0 to 10 cm scale)
The mean level of mus-
cle soreness af ter an-
t ioxidant supplementa-
t ion was 0.19 standard
deviations lower
(0.38 to 0.00 lower)
SMD -0.19
(-0.38 to -0.00)
657
(28 studies4)
⊕⊕⊕©
moderate6
Based on the above
’rule of thumb’, this re-
sult equates to a small
dif f erence in favour of
ant ioxidant supplemen-
tat ion
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When we rescaled the
data to a 0 to 10 cm
scale, the MDwas lower
by 0.29 cm (0.59 lower
to 0.02 higher). These
are all under the typical
MID for pain (taken here
as 1.4 cm)
Muscle soreness
Follow-up: 96 hours
The mean level of mus-
cle soreness in the con-
trol group ranged f rom
0.2 to 5.6 cm (adjusted
to a 0 to 10 cm scale)
The mean level of mus-
cle soreness af ter an-
t ioxidant supplementa-
t ion was 0.05 standard
deviations lower
(0.29 lower to 0.19
higher)
SMD -0.05
(-0.29 to 0.19)
436
(17 studies4)
⊕⊕©©
low8
Based on the above
’rule of thumb’, this re-
sult equates to a small
dif f erence in favour of
ant ioxidant supplemen-
tat ion but also includes
a small ef fect in favour
of placebo or no ant iox-
idants
However, when we
rescaled the data to a
0 to 10 cm scale, the
MD was lower by 0.03
cm (0.43 lower to 0.37
higher). These are all
under the typical MID
for pain (taken here as
1.4 cm)
Subjective recovery See comment See comment - See comment - None of the 50 stud-
ies included in this re-
view measured subjec-
t ive recovery (return to
previous act ivit ies with-
out signs or symptoms)
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Adverse events See comment See comment - See comment
9 studies
(216 part icipants)
⊕©©©
very low9
Adverse ef fects were
considered in only 9
studies and actual
events reported in 2
studies. One study re-
ported that all 6 par-
t icipants in the an-
t ioxidant supplementa-
t ion group10 had diar-
rhoea (5 mild, 1 se-
vere); 4 part icipants
also reported mild in-
digest ion. One placebo
group part icipant also
had mild indigest ion.
The second study re-
ported mild gastroin-
test inal distress in 1 of
26 part icipants taking
the ant ioxidant supple-
ment
CI: conf idence interval; RR: risk rat io; MD: mean dif ference; MID: minimal important dif f erence; SMD: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect. Thus we are conf ident that the true ef fect lies close to what was found in the
research
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate. Thus, the true ef fect is likely
to be close to what was found, but there is a possibility that it is substant ially dif f erent
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate. Thus, the true ef fect
may be substant ially dif f erent f rom what was found
Very low quality: We are very uncertain about the est imate.
1Although some part icipants were sedentary, the majority of part icipants were recreat ionally act ive or moderately trained
athletes. No data were included f rom highly trained elite athletes. Most trial part icipants were male.
2Muscle damage was induced either mechanically (e.g. resistance-based exercise) or through whole body aerobic exercise
(e.g. running, cycling, bench stepping).
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3Typically, supplementat ion was taken before, the day of and af ter exercise for up to several days. The supplements were
all taken orally, either as capsules, powders or drinks. All studies used an ant ioxidant dosage higher than the recommended
daily amount.
4In this analysis, one study tested two ant ioxidants compared with placebo control.
5We downgraded the quality of evidence one level for serious study lim itat ions (high/ unclear risk of bias) and one level for
serious inconsistency.
6We downgraded the quality of evidence one level for serious study lim itat ions (high/ unclear risk of bias).
7In this analysis, two studies tested two ant ioxidants compared with placebo control.
8We downgraded the quality of evidence one level for serious study lim itat ions (high/ unclear risk of bias) and one level for
serious inconsistency.
9We downgraded the quality of evidence three levels for very serious study lim itat ions, in part icular ref lect ing bias relat ing
failure to record or report on adverse events by the majority of trials.
10Notably the ant ioxidant used was NAC (N-acetylcysteine), which is a prescript ion medicine with ant ioxidant propert ies.
Listed side ef fects of NAC include nausea, vomit ing and diarrhoea or const ipat ion.
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B A C K G R O U N D
Description of the condition
Muscle soreness after exercise is commonly referred to as delayed
onset muscle soreness (DOMS) (Cheung 2003). DOMS is com-
mon in individuals who engage in strenuous and unaccustomed
exercise and physical activity. It is classified as a grade 1 muscle
strain injury and is characterised by localised tenderness and sore-
ness (Cheung 2003). DOMS typically peaks between 24 to 72
hours after a bout of exercise but eventually disappears after five
to seven days (Armstrong 1984; Bieuzen 2013; Bleakley 2012;
Byrnes 1986; Cleak 1992; Costello 2015).
DOMS is particularly associated with exercise involving eccentric
muscle action, such as in downhill running. An eccentric action is
where a muscle generates tension to control the rate it lengthens
(Close 2005), and it can cause significant muscle damage. DOMS
could be detrimental for athletes who are returning to training
from a prolonged period of inactivity. In addition, DOMS could
deter individuals from adhering to an exercise programme. For
some individuals, DOMS could result from excessive physical ac-
tivity associated with daily living, particularly if repeated eccentric
movements or unaccustomed physical activity are involved.
Several theories have beenproposed to explain themechanisms un-
derlying DOMS. These include lactate accumulation (Asmussen
1953), inflammation (Smith 1991), muscle spasm (De Vries
1966), muscle damage (Hough 1900), connective tissue dam-
age (Weinstock 1997), and increased muscle temperature (Davies
1972). A common feature of several of these proposedmechanisms
is an increased production of free radicals (Maughan 1989), and
reactive oxygen species. Indeed, it has been shown that reactive
oxygen species are produced in nearly every biological process and
that they also play a crucial role as signalling molecules for trans-
lating the exercise signals to appropriate adaptations (Margaritelis
2016).
Description of the intervention
Taking dietary antioxidants in the form of supplements (e.g.
tablets, capsules, powders) or antioxidant-enriched foods (e.g.
food concentrates) in doses much higher than the recommended
amounts (up to 10 times the recommended daily amounts) sev-
eral days before and after exercise has been proposed as a way
to prevent or reduce muscle soreness after exercise. Two sources
of antioxidants exist: exogenous (i.e. from dietary sources) and
endogenous (i.e. produced by the body) (Watson 2010). Exoge-
nous antioxidants include vitamin C, vitamin E, polyphenols,
glutathione, carotenoids and coenzyme Q10. These are typically
found in plant sources such as dark-coloured vegetables, citrus
fruits, legumes, nuts, grains, seeds and oils. Endogenous antiox-
idants include plasma proteins, bilirubin, uric acid and the en-
zymes superoxide dismutase, glutathione peroxidase and catalase
(Watson 2010).
How the intervention might work
It has been reported that although physical activity is beneficial
to health, any type of exercise causes oxidative stress, partly due
to increased oxygen consumption, and could deplete the body’s
antioxidant defences and increase the rate of free radical produc-
tion (Powers 2008; Ramel 2004; Witt 1992). Moreover, unaccus-
tomed, eccentric or exhaustive exercise may also induce inflam-
matory reactions that can contribute to increased reactive oxygen
species production and reduced antioxidant defences (Tsai 2001),
causing exercise-induced muscle damage and resulting in DOMS
(Cheung 2003). Dietary antioxidants may counteract oxidative
stress by reducing the concentration of free radicals and reactive
oxygen species associated with exercise (Powers 2008). Reducing
DOMS could be beneficial to athletes when returning to training
from injury (i.e. after a period of inactivity), and it could help
sedentary and older individuals recover from unaccustomed phys-
ical activity.
Why it is important to do this review
The ease of taking antioxidant supplements to prevent and re-
duce muscle soreness after exercise and enhance recovery makes
this an attractive option for physically active individuals. More-
over, antioxidant supplements are available to buy from supermar-
kets and health food stores and some are marketed to enhance
recovery. However, our initial look at the evidence based on a
small sample of the trials testing antioxidants for reducing DOMS
showed that the evidence to support these claims was mixed (Bryer
2006; Howatson 2010; Mastaloudis 2006). There is conflicting
evidence, too, on the potential for adverse effects of taking antiox-
idant supplements including impairment of post-exercise adap-
tations both acutely (Gomez-Cabrera 2008; Ristow 2009) and
chronically (Paulsen 2014). All these pointed to the need for a
systematic review of all the available trials.
O B J E C T I V E S
To assess the effects (benefits and harms) of antioxidant supple-
ments and antioxidant-enriched foods for preventing and reduc-
ing the severity and duration of delayed onset muscle soreness fol-
lowing exercise.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
All randomised controlled trials and quasi-randomised controlled
trials (amethod of allocating participants to groups that is not truly
random; e.g. allocation by date of birth, day of the week, medical
record number) investigating the effects of dietary antioxidants
on preventing or reducing delayed onset muscle soreness. Only
studies that measured muscle soreness and/or muscle tenderness
were included in this study.
Types of participants
People of any age and level of physical or sports activity, performing
exercise (i.e. eccentric, high-intensity, unaccustomed exercise) that
is likely to induce DOMS.We included studies that used any type
of exercise protocol.
Types of interventions
All forms of antioxidant supplementation including specific an-
tioxidant supplements (i.e. tablets, powders, concentrates) and an-
tioxidant-enriched foods or diets. No restrictions were placed on
timing (pre-exercise or post-exercise), frequency, dose or duration,
or type of antioxidant supplementation. Interventions that used
more than one antioxidant (e.g. a combination of vitamins C and
E) were also included.
We set out two comparisons.
• Antioxidant supplementation versus placebo or no
supplementation.
• High-dose versus low-dose, where the low-dose
supplementation is within normal or recommended levels for the
antioxidant involved.
Types of outcome measures
Trials that did not recordmuscle soreness (pain) were not included
in the review.
Primary outcomes
1. Muscle soreness (pain) - typically measured by a visual
analogue scale (i.e. subjective)
2. Subjective recovery (return to previous activities without
signs or symptoms)
3. Adverse effects (e.g. intestinal discomfort, diarrhoea)
Secondary outcomes
1. Muscle tenderness - typically measured using a handheld
algometer
2. Performance variables (e.g. vertical jump, speed, agility)
3. Muscle force production (objective measures of muscle
strength or power)
4. Range of motion
Timing of outcome measurement
Where appropriate, we extracted outcome data for the following
time periods: the day of exercise, and daily up to seven days post-
exercise.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Bone, Joint andMuscle Trauma Group
SpecialisedRegister (6 February 2017), theCochraneCentral Reg-
ister of Controlled Trials (CENTRAL) (2017, Issue 2), MED-
LINE (including Epub Ahead of Print, In-Process & Other Non-
Indexed Citations and OvidMEDLINE Daily) (1946 to 3 Febru-
ary 2017), Embase (1980 to 2017 Week 5) and SPORTDiscus
(1949 to 20 April 2017). We also searched ClinicalTrials.gov and
the World Health Organization Clinical Trials Registry Platform
for ongoing and recently completed studies (to 6 February 2017).
In MEDLINE, we combined a subject-specific search with the
sensitivity-maximising version of the Cochrane Highly Sensitive
Search Strategy for identifying randomised trials (Lefebvre 2011).
The search strategies for MEDLINE, CENTRAL, Embase and
SPORTDiscus are shown in Appendix 1.
We applied no language restrictions.
Searching other resources
We contacted experts in the field (identified by the lead authors
in published studies) to find unpublished trials. We checked the
bibliographies of included studies and relevant reviews for further
references to relevant trials.
Data collection and analysis
Selection of studies
Two authors (MR and DR) independently screened the titles,
abstracts and descriptors of the studies retrieved from the searches.
Studies that appeared meet the inclusion criteria were selected
and the above two authors independently reviewed the full-text
articles. Any disagreements about study selection were resolved
by consultation with the third and fourth author (HS and JC).
If required, we contacted study authors for further information;
this, however, did not include contacting authors to checkwhether
DOMS had been measured where not stated in the trial reports.
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Data extraction and management
Two authors (MR and DR) independently extracted data using
a pre-piloted data extraction form. We resolved any discrepancies
that could not be settled by discussion by consultation with the
third and fourth authors (HS and JC). Where necessary, we con-
tacted primary authors of selected studies for additional informa-
tion and data.
Assessment of risk of bias in included studies
Two authors (MR and DR) independently assessed the risk of bias
in the included studies using the guidelines and criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).We assessed the included studies for selection bias
(random sequence generation and allocation concealment), per-
formance bias (blinding of participants and personnel), detection
bias (blinding of outcome assessment), attrition bias (incomplete
outcome data), reporting bias (selective reporting) and any other
sources of bias. We resolved any disagreement by discussion and,
where necessary, consultation with the third author and forth au-
thor (HS and JC).
Measures of treatment effect
We calculated mean differences with 95% confidence intervals for
continuous data.We calculated standardised mean differences and
95% confidence intervals when combining results from studies
using different ways of measuring a continuous outcome. Where
possible, we used follow-up scores in preference to change scores.
Should dichotomous data have been available, we planned to cal-
culate risk ratios with 95% confidence intervals.
Unit of analysis issues
The unit of randomisation in the included trials was the individual
participant. Some trials reported the same outcomes at more than
one time point (e.g. soreness measured immediately after exercise,
one day post-exercise, two days post-exercise, three days post-ex-
ercise and so on). As planned, we extracted and presented data for
the above listed time points up to seven days post-exercise. We
consulted a statistician to discuss the appropriate use and process-
ing of data from cross-over trials that were included in the review.
For these, we extracted data at each time point and analysed the
data as if a parallel design was employed (Deeks 2011). We judged
that there was an adequate washout period in each of the trials.
Dealing with missing data
Where there were missing data for an included study, we con-
tacted the primary study author via email. We ignored data miss-
ing at random and focused only on the available data. Where ap-
propriate, we conducted intention-to-treat analyses in which all
randomised participants are analysed in the groups to which they
were originally assigned. While planned, there were insufficient
data (oftenmissing denominators) to conduct worst-case and best-
case scenario sensitivity analyses to examine the potential effects of
dropouts and exclusions. We contacted authors for missing mean
and standard deviations. Where data were not available in the
manuscript and the authors did not respond we extracted data
from graphs using Graphclick 2010.
Assessment of heterogeneity
We visually evaluated heterogeneity between comparable trials us-
ing forest plots, and the Chi² test and I² statistic, with the level of
significance for the Chi² test being set at P = 0.1 (Deeks 2011).
Thus, we considered a P value for Chi² of < 0.1 to indicate statis-
tically significant heterogeneity between studies. We interpreted
values of I² as follows: 0% to 40% might not be important; 30%
to 60% may represent moderate heterogeneity; 50% to 90% may
represent substantial heterogeneity; and 75% to 100% may rep-
resent considerable heterogeneity.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publica-
tion bias and other reporting biases, we aimed to minimise their
potential impact by ensuring a comprehensive search for eligible
studies and by being alert for duplication of data. Where there
were 10 or more studies in an analysis, we planned to use a funnel
plot to explore the possibility of small-study effects (a tendency for
estimates of the intervention effect to be more beneficial in smaller
studies). (We restricted these to DOMS at 24 and 48 hours given
these were the time periods for which the majority of data were
available.)
Data synthesis
If considered appropriate, we pooled the results of comparable
groups of trials. Initially we used the fixed-effect model and 95%
confidence intervals but then selected the random-effects model,
again with 95% confidence intervals, because of the substantial
clinical and statistically significant heterogeneity.
Subgroup analysis and investigation of heterogeneity
As described inDifferences between protocol and review, wemod-
ified our list of planned subgroup analyses, which involved the
removal of one (antioxidant supplement versus antioxidant-en-
riched food) and the merging of two subgroups relating to type
of exercise (normal sporting activities versus laboratory-induced
DOMS; exercise that requires high oxygen consumption (e.g. run-
ning, cycling) versus exercise that requires low oxygen consump-
tion (e.g. eccentric exercise in one arm). We also added in a sub-
group analysis relating to source of funding.
Our revised list of planned subgroup analyses is as follows.
• Treatment intervention
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◦ Timing of administration (pre-exercise or post-
exercise)
• Type of exercise
◦ Mechanically induced damage (e.g. resistance exercise)
versus whole body aerobic exercise (e.g. running)
• Funding source
◦ Trials funded by food company or provider of
antioxidant supplements versus those not funded by food
company or provider of antioxidant supplements
To test whether subgroups were statistically significantly different
from one another, we used the test for subgroup differences avail-
able in the Review Manager 5 software (RevMan 2014).
Sensitivity analysis
Where sufficient datawere available, we performed sensitivity anal-
yses to investigate the effects of various aspects of trial and review
methodology.We performed limited sensitivity analyses to explore
the effects of inclusion of trials at high or unclear risk of selection
bias, principally from lack of or unclear allocation concealment,
the effects of including cross-over trials, and from the choice of
model for data synthesis (fixed-effect compared with random-ef-
fects). We did not conduct our other planned sensitivity analyses
to explore the effects of inclusion of trials at high risk of selection
bias specifically because of lack of allocation concealment, or for
which only abstracts were obtained, or the effects of missing data.
’Summary of findings’ table
We prepared a ’Summary of findings’ table for the main compar-
ison (antioxidant supplementation versus a placebo intervention)
(Schünemann 2011). We summarised the quality of evidence by
applying the principles of the GRADE framework and following
the recommendations and worksheets of the Cochrane Effective
Practice and Organisation of Care Group for creating ’Summary
of findings’ tables (EPOC 2013). We assessed the quality of the
evidence according to four levels (high, moderate, low and very
low). We selected muscle soreness up to 6 hours after exercise, 24,
48, 72 and 96 hours; subjective recovery and adverse events for
presentation in a ’Summary of findings’ table.
R E S U L T S
Description of studies
Results of the search
The search was completed in February 2017. We screened a total
of 1558 records from the following databases: Cochrane Bone,
Joint andMuscle Trauma Group Specialised Register (25 records),
CENTRAL (194), MEDLINE (302), Embase (476), SPORTDis-
cus (117), ClinicalTrials.gov (162) and the WHO International
Clinical Trials Registry Platform (282). We also identified 12 po-
tentially eligible studies from ongoing searches and through con-
tacting experts in the field.
The search resulted in the identification of 128 potentially eligi-
ble studies, for which we obtained full reports. Upon study selec-
tion, we included 50 (see Included studies) and excluded 77 (see
Excluded studies). One study is ongoing (NCT02281981). A flow
diagram summarising the study selection process is presented in
Figure 1.
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Figure 1. Study flow diagram
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Included studies
We included 50 studies with a total of 1089 participants of which
48 studies with 1043 participants were included in the quanti-
tative synthesis (meta-analysis) for muscle soreness. All the stud-
ies were reported in English in peer-reviewed journals, in articles
published between 1992 to 2016. Details of the individual studies
are provided in Characteristics of included studies.
We contacted the authors of 33 studies to request for raw data for
delayed onset muscle soreness (DOMS), maximal voluntary iso-
metric contraction (MVIC), range of motion (ROM) and perfor-
mance measures. Nineteen authors responded to our request (Bell
2015; Bell 2016; Bloomer 2004; Bloomer 2005; Bloomer 2007;
Close 2006; Cobley 2011; Drobnic 2014; He 2015; Howatson
2009; Kaminski 1992; Kerksick 2009; Laupheimer 2014; Nicol
2015; O’Fallon 2012; Tanabe 2015; Thompson 2004; Trombold
2010; Trombold 2011); and 14 did not (Arent 2010; Avery 2003;
Beaton 2002a; Bryer 2006; Connolly 2006; Connolly 2006a;
Goldfarb 2011; Herrlinger 2015; Krotkiewski 1994; McFarlin
2016; Michailidis 2013; Phillips 2003; Peschek 2014; Su 2008).
With the exception of Herrlinger 2015, we successfully extracted
data from graphs for the other 13 studies in the second category
using GraphClick, Arizona (version 3.0.2, 2010).
The two studies not included in the quantitative analyses for
DOMS were Herrlinger 2015 and McCormick 2016. This re-
sulted in the loss of 37 participants for whom DOMS data
were missing for Herrlinger 2015 and of nine participants for
McCormick 2016. We only included the data for McCormick
2016 in the qualitative analysis because the exercise paradigm was
completely different to all the other studies included in this review.
The other studies used an exercise paradigm where mechanical or
whole body aerobic exercise was used to cause muscle damage and
then a range of outcomes such as muscle soreness, muscle func-
tion, range of motion and performance were measured at various
time points up to several days after exercise. However, participants
in McCormick 2016 had a fixed daily training regimen for five
continuous days performance, with outcomes being measured at
the start and then throughout the trial. Thus the severity of muscle
damage caused by the daily training regimen was not controlled.
Design
All 50 studies were randomised controlled trials; no quasi-ran-
domised controlled trials met the inclusion criteria. Thirty-eight
trials (with a total of 901 participants) employed a parallel design.
The other 12 trials (with a total of 188 participants) employed a
cross-over design (Arent 2010; Connolly 2006a; Kaminski 1992;
McCormick 2016; McLeay 2012; Michailidis 2013; Nicol 2015;
Peschek 2014; Tanabe 2015; Thompson 2001; Trombold 2010;
Trombold 2011). The time between intervention arms in the cross-
over trials was five days in Arent 2010; 14 days in Connolly 2006a,
Nicol 2015, Thompson 2001, Trombold 2010 and Trombold
2011; 21 days in Kaminski 1992 and Peschek 2014; 28 days in
Tanabe 2015; 30 days in McLeay 2012; 35 days in McCormick
2016 and 42 days in Michailidis 2013.
Three studies had three groups: Herrlinger 2015 compared low-
dose phenolic blend (12 participants) versus high-dose phenolic
blend (12 participants) versus placebo (13 participants); Kerksick
2009 compared epigallocatechin gallate supplementation (10 par-
ticipants) versus N-acetyl cysteine supplementation (10 partici-
pants) versus placebo (10 participants); and Silva 2008 compared
N-acetyl cysteine (nine participants) versus N-acetyl cysteine plus
placebo (eight participants) versus placebo (eight participants).
Sample sizes
The 50 trials included a total of 1089 participants with 901 par-
ticipants in the parallel-group trials (range 7 to 54) and 188 par-
ticipants in the cross-over trials (range 8 to 24).
Setting
Twenty-four studies were conducted in the USA (Arent 2010;
Avery 2003; Beaton 2002a; Bloomer 2004; Bloomer 2005;
Bloomer 2007; Bryer 2006; Connolly 2006; Connolly 2006a;
Goldfarb 2011; He 2015; Herrlinger 2015; Hutchinson 2016;
Kaminski 1992; Kerksick 2009; Kuehl 2010; McBride 1997;
McFarlin 2016; O’Connor 2013; O’Fallon 2012; Peschek 2014;
Phillips 2003; Trombold 2010; Trombold 2011); 12 studies
were carried out in the UK (Bailey 2011; Bell 2015; Bell 2016;
Close 2006; Cobley 2011; Howatson 2009; Laupheimer 2014;
Lynn 2015; Thompson 2001; Thompson 2001a; Thompson
2003; Thompson 2004); two studies were conducted in Australia
(McCormick 2016; Nicol 2015); two studies in Brazil (Silva 2008;
Silva 2010); two studies in China (Nie 2004; Su 2008); two stud-
ies in Greece (Michailidis 2013; Theodorou 2011); one study in
Iran (Meamarbashi 2011); one study in Ireland (Shafat 2004); one
study in Japan (Tanabe 2015); one study inNewZealand (McLeay
2012); one study in Poland (Krotkiewski 1994); and one study in
Spain (Drobnic 2014).
Seven trials were designed to produce DOMS under field-based
conditions (Bailey 2011; Cobley 2011; Howatson 2009; Kuehl
2010; Laupheimer 2014; Lynn 2015; McCormick 2016), and the
other 43 studies were designed to produce DOMS under labora-
tory-based conditions.
Funding source
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Details of the funding of individual studies are given in
Characteristics of included studies. In all, 21 studies were indus-
try funded either by a food company or a provider of antioxi-
dant supplements (Arent 2010; Bailey 2011; Beaton 2002a; Bell
2015; Bell 2016; Bloomer 2005; Bloomer 2007; Connolly 2006a;
Herrlinger 2015; Kerksick 2009; Kuehl 2010; McFarlin 2016;
O’Connor 2013; Peschek 2014; Phillips 2003; Tanabe 2015;
Thompson 2001; Thompson 2001a; Thompson 2003; Trombold
2010; Trombold 2011).Of the 28 other studies reporting on fund-
ing, 15 declared “none” in their report (Avery 2003; Bloomer
2004; Bryer 2006; Close 2006; Cobley 2011; Connolly 2006;
Drobnic 2014; Hutchinson 2016; Kaminski 1992; Laupheimer
2014; McBride 1997; Nie 2004; Shafat 2004; Theodorou 2011;
Thompson 2004); the other 13 referring to various sources of
university and public body research funding sources (Goldfarb
2011; He 2015; Howatson 2009; Krotkiewski 1994; Lynn 2015;
McCormick 2016;McLeay 2012;Meamarbashi 2011;Michailidis
2013; Nicol 2015; O’Fallon 2012; Silva 2008; Silva 2010). We
were unsuccessful in obtaining information on funding from the
only trial that did not report on this (Su 2008).
Participants
Of the 1089participants, 961 (88.2%)weremale and128 (11.8%)
were female. Two studies recruited females only (Bloomer 2004;
McLeay 2012). The age range of participants was between 16
(Nie 2004) and 55 years (Laupheimer 2014). The majority of
the studies recruited recreationally active or moderately trained
participants with the exception of seven studies (Bryer 2006;
Kerksick 2009; Meamarbashi 2011; O’Connor 2013; O’Fallon
2012; Phillips 2003; Tanabe 2015), which included a total of
193 sedentary participants. One study had a sample of 16 semi-
professional soccer players (Bell 2016) and one study (Laupheimer
2014) had seven well-trained distance runners. Only McCormick
2016 had participants (nine in all) who were classed as highly-
trained elite athletes.
Details of exercise
There was a range of different exercise models used to induce mus-
cle damage. Twenty-eight studies usedmechanically induced exer-
cise (i.e. resistance-based exercise) and 22 studies used whole body
aerobic exercise (i.e. running, cycling, bench stepping). The ma-
jority of the studies that used mechanically induced exercise em-
ployed some form of resistance training protocol using weights or
an isokinetic dynamometer to induce delayed onset muscle dam-
age and soreness with large variances on number of repetitions,
sets and percentage of load used. One study used a circuit train-
ing session where participants rotated round a circuit of cycling
and stepping exercises (Krotkiewski 1994). Two studies used a re-
peated maximal sprint protocol on a cycle ergometer (Arent 2010;
Bell 2016), one study used a repeated bench stepping protocol
(Meamarbashi 2011), and one study used a repeated squat jump
protocol using a weighted jacket (Nie 2004). Sixteen studies used a
running model: seven trials used a downhill running protocol on a
treadmill (Close 2006; Drobnic 2014; He 2015; Herrlinger 2015
Peschek 2014; Su 2008; Thompson 2004); four trials used the 90
minute Loughborough Intermittent Shuttle Running Test (LIST)
(Bailey 2011; Thompson 2001; Thompson 2001a; Thompson
2003); one study used the Yo-Yo IR 1 repeated sprint test (Cobley
2011), and three trials used a competitive running race to induce
damage. Howatson 2009 and Laupheimer 2014 used the London
marathon, one study used the ultra-endurance Hood Coast Relay,
which is based in the United States (Kuehl 2010), and one study
used a half marathon run (Lynn 2015).
The majority of the studies asked the participants to refrain from
strenuous exercise, refrain from taking any form of anti-inflamma-
tory medication or other supplements, and not use any other form
of analgesic activity that would reduce or relieve soreness, such as
an ice bath or massage, for the duration of the study. Participants
were typically excluded if they took any form of supplementation
regularly or had any type of chronic inflammatory condition.
Interventions
In all trials, an antioxidant supplement was compared with a
placebo. A summary of the antioxidant supplement regimens
tested in the individual trials is presented in Table 1.
In all, 13 trials used antioxidants from a whole natural food
source (Bell 2015; Bell 2016; Connolly 2006a; Howatson 2009;
Hutchinson 2016; Kuehl 2010; Lynn 2015; McCormick 2016;
McLeay 2012; O’Connor 2013; Peschek 2014; Trombold 2010;
Trombold 2011), 19 used an antioxidant extract or mixed an-
tioxidants (Arent 2010; Bailey 2011; Bloomer 2005; Cobley
2011; Drobnic 2014; Goldfarb 2011; Herrlinger 2015; Kerksick
2009; Krotkiewski 1994; Laupheimer 2014; McFarlin 2016;
Meamarbashi 2011; Michailidis 2013; Nicol 2015; O’Fallon
2012; Phillips 2003; Silva 2008; Su 2008; Tanabe 2015), and
18 provided either vitamin C or vitamin E or both together
(Avery 2003; Beaton 2002a; Bloomer 2004; Bloomer 2007; Bryer
2006; Close 2006; Connolly 2006; He 2015; Kaminski 1992;
McBride 1997; Nie 2004; Shafat 2004; Silva 2010; Theodorou
2011; Thompson 2001; Thompson 2001a; Thompson 2003;
Thompson 2004). All studies used a placebo either as a powder,
capsule or drink; however, three studies did not provide details
of what the placebo comprised (Arent 2010; McBride 1997; Nie
2004).
No trials compared high-dose versus low-dose antioxidant supple-
ments, where the low-dose supplementation is within normal or
recommended levels for the antioxidant involved.
Antioxidants used
Whole foods tested were:
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• Bilberry juice (n = 19) (Lynn 2015)
• Blackcurrant nectar (n = 16) (Hutchinson 2016)
• Blueberry smoothie (n =10) (McLeay 2012)
• Cherry (n = 127) (Bell 2015, n = 16; Bell 2016, n = 16;
Connolly 2006a, n = 16; Howatson 2009, n = 16; Kuehl 2010, n
= 54; McCormick 2016, n = 9)
• Cocoa (n = 8) (Peschek 2014)
• Mixed grape drink (n = 40) (O’Connor 2013)
• Pomegranate juice (n = 33) (Trombold 2010, n = 16;
Trombold 2011, n = 17)
Antioxidant extract or mixed or other antioxidants tested were:
• Allicin (n = 16) (Su 2008)
• Astaxanthin extract (n = 20) (Bloomer 2005)
• Black tea extract (n = 18) (Arent 2010)
• Curcumin (n = 79) (Drobnic 2014, n = 20; McFarlin 2016,
n = 28; Nicol 2015, n = 17; Tanabe 2015, n = 14)
• Fruit and vegetable powder (Juice Plus) (N = 44) (Goldfarb
2011)
• Green and black tea extract (n = 37) (Herrlinger 2015)
• Mixed antioxidants (vitamin C, E, B6, B9, B12 and zinc)
(n = 38) (Bailey 2011)
• Mixed flavanoid antioxidants (N = 40) (Phillips 2003)
• N-acetylcysteine (NAC) with epigallocatechin gallate
(EGCG) (n = 30) (Kerksick 2009)
• N-acetylcysteine (NAC) (n = 53) (Cobley 2011, n = 14;
Michailidis 2013, n = 10; Silva 2008, n = 29)
• Pollen extract (n = 50) (Krotkiewski 1994)
• Purslane extract (n = 20) (Meamarbashi 2011)
• Quercetin (n = 30) (O’Fallon 2012)
• Resveratrol (n = 7) (Laupheimer 2014)
Vitamin C or E or both combined were:
• Vitamin C (n = 158) (Bryer 2006, n = 18; Close 2006, n =
20; Connolly 2006, n = 24; Kaminski 1992, n = 25; Nie 2004, n
= 16; Thompson 2001, n = 9; Thompson 2001a, n = 16;
Thompson 2003, n = 16; Thompson 2004, n = 14)
• Vitamin C and E co-ingestion (n = 134) (Beaton 2002a, n
= 18; Bloomer 2004, n = 18; Bloomer 2007, n = 36; He 2015, n
= 22; Shafat 2004, n = 12; Theodorou 2011, n = 28)
• Vitamin E (n = 57) (Avery 2003, n =18; McBride 1997, n =
12; Silva 2010, n = 27)
There was a large variation across the studies regarding the dura-
tion of supplementation: the shortest period was under one day
(Tanabe 2015; Thompson 2001) and the longest period was 91
days (Herrlinger 2015). Although the formof supplementwas var-
ied, including capsules, powders and drinks, every study used an
antioxidant dosage higher than the recommended daily amount.
Every study required the participant to ingest the supplement
orally either once daily or up to three times per day.
Supplementation was taken before, the day of and after exercise for
up to several days in all the studies except for three studies where
supplements were post-exercise only (Michailidis 2013; Peschek
2014; Thompson 2003).
Outcomes
Primary outcomes
Muscle pain
All 50 trials included muscle soreness as an outcome measure,
the recording of which was an inclusion criterion of this review.
Details of the measurement of muscle soreness in the individual
trials are presented in Table 2.
Thirty-three trials measuredmuscle soreness using a 0 to 10 cm (or
0 to 100 mm) visual analogue scale (VAS). Of the 17 other trials,
seven measured soreness using a 1 to 10 cm scale (Bailey 2011;
Bryer 2006; Goldfarb 2011; Kaminski 1992; Michailidis 2013;
Thompson 2001; Thompson 2003); four trials used the 0 to 20
cm (or 0 to 200 mm) scale (Bell 2015; Bell 2016; Howatson 2009;
Lynn 2015); two studies (He 2015; Meamarbashi 2011) used a
0- to 6-point scale, Herrlinger 2015 used a 0 to 7 Likert scale,
Drobnic 2014 used a 0- to 4-point scale; Cobley 2011 used a 0 to
12 cm scale and Su 2008 used the Borg CR-10 scale (Borg 1998).
The Borg CR-10 scale ranges from 0 (no soreness) to 10 (maximal
soreness). In the included studies, participants were asked to rate
a muscle soreness on the soreness scales by either carrying out a
squat using body weight, self palpitation of muscle or based on
muscle soreness at rest.
There was considerable variation on the timing of the soreness
measurement after the damaging exercise occurred. Whilst all the
trials measured soreness at baseline, 18 studies measured muscle
soreness immediately after exercise, two studies measured sore-
ness two hours after exercise (Trombold 2010; Trombold 2011),
and one study measured soreness six hours after exercise (Kerksick
2009). Due to this variation, we grouped these studies into the ’up
to 6 hours post-exercise’ category. In addition to measuring sore-
ness immediately after exercise, a few trials also measured soreness
2, 4, 6 or 10 hours post-exercise although the earliest follow-up
time point to immediately post-exercise was used. Forty-one trials
measured muscle soreness at 24 hours, 45 trials at 48 hours, 28
trials at 72 hours and 17 trials at 96 hours post-exercise. Only six
trials measured muscle soreness subsequently: four trials measured
soreness at 120 hours post-exercise (Krotkiewski 1994;Michailidis
2013; O’Fallon 2012; Theodorou 2011), one study at 144 hours
(Michailidis 2013), and three studies at 168 hours after exercise
(Michailidis 2013; Phillips 2003; Silva 2008).
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Subjective recovery
None of the 50 included trials measured the primary outcome of
subjective recovery.
Adverse effects
Only nine studies reported information on adverse effects, seven of
which reported no adverse effects of antioxidant supplementation
(Kerksick 2009; Laupheimer 2014; Lynn 2015; McLeay 2012;
Michailidis 2013; O’Connor 2013; Phillips 2003), and two which
reported specific adverse effects (Cobley 2011; Kuehl 2010). The
remaining 41 studies failed to report adverse effects.
Secondary outcomes
Muscle tenderness
Muscle tenderness (or pressure pain threshold, PPT) was mea-
sured in four trials using a handheld algometer where the cylin-
drical metal probe was placed on the belly of the muscle and the
investigator applied pressure gradually to the point where the par-
ticipant felt discomfort (Close 2006; Connolly 2006; Connolly
2006a; Peschek 2014).
Performance variables
Performance variablesweremeasured infive trials: Arent 2010 used
the 30-second Wingate to measure power output in Watts per kg
of bodyweight (W/kg); Bell 2015measured cycling efficiency; Bell
2016 used a battery of tests including the 20 m sprint, 505 Agility
test and counter-movement jump; Cobley 2011 used the 20 m
sprint and Yo-Yo test; and O’Connor 2013 examined the effects of
antioxidant supplementation on maximal oxygen consumption.
Muscle force
Muscle force production was measured in 30 trials using a dy-
namometer or an isokinetic dynamometer in the muscle where
damage was caused (Bailey 2011; Beaton 2002a; Bell 2015; Bell
2016; Bloomer 2004; Bloomer 2005; Bloomer 2007; Bryer 2006;
Close 2006; Cobley 2011; Connolly 2006; Connolly 2006a;
Goldfarb 2011; Herrlinger 2015; Howatson 2009; Kerksick
2009; McLeay 2012; Meamarbashi 2011; Michailidis 2013;
O’Connor 2013; O’Fallon 2012; Peschek 2014; Shafat 2004;
Tanabe 2015; Theodorou 2011; Thompson 2001; Thompson
2001a; Thompson 2003; Trombold 2010; Trombold 2011). The
main variable measured in these trials was peak isometric force.
Range of motion
Range of motion was assessed in 13 trials using a goniometer
and units were reported in degrees (Bailey 2011; Beaton 2002a;
Bloomer 2004; Bryer 2006; Connolly 2006; Goldfarb 2011;
Howatson 2009; McLeay 2012; Meamarbashi 2011; O’Connor
2013; O’Fallon 2012; Tanabe 2015; Theodorou 2011). Flexion
range was determined either in the elbow or the knee by using uni-
versal landmarks to ensure consistency on subsequent measures.
Excluded studies
We excluded 77 studies, 73 because delayed onset muscle soreness
was not measured (Characteristics of excluded studies). One study
was excluded because the supplement used is not classed as an
antioxidant (Kingsley 2006). We excluded one study because the
antioxidant supplement was co-ingested with a fish oil supplement
and therefore the effect of antioxidant-only supplementation was
not examined (Lenn 2002). We excluded one study because the
antioxidant was combined with a protein supplement (Romano-
Ely 2006), and we excluded one study because antioxidants were
combinedwith ibuprofen, coldwater immersion andwhey protein
at the same time (Al-Nawaiseh 2016).
Studies awaiting classification
There are no studies awaiting classification.
Ongoing trials
Details of one ongoing trial testing curcumin supplementa-
tion are available in the Characteristics of ongoing studies table
(NCT02281981).
Risk of bias in included studies
Details of the ’Risk of bias’ assessment, including methods of ran-
domisation, for individual trials are provided in Characteristics of
included studies and the assessments are summarised in Figure 2
and Figure 3.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
Allocation
Random sequence generation
We judged 30 studies, all of which gave details of random sequence
generation, at low risk of bias. We rated 15 studies at unclear risk
of bias because they did not specify how the random sequence
was generated and attempts obtain clarification from authors were
unsuccessful. Clarification received from the authors of Tanabe
2015 did not confirm effective random sequence generation and
so we judged this at unclear risk of bias too.
Four studies were at high risk of bias (Howatson 2009; Kerksick
2009; Su 2008; Theodorou 2011). Howatson 2009 matched
on sex and predicted finishing time. Participants were matched
in clusters according to age and body weight for assignment in
Kerksick 2009. Su 2008 randomly assigned participants into an
allicin or control group according to sex and sports participation
and in Theodorou 2011, participants were allocated based on age,
body mass index (BMI) andmaximum isometric torque into equal
groups then a computer generator was used for the assignment
into groups.
Concealment of treatment allocation
We deemed that 20 studies had a low risk of bias because al-
location concealment was very likely (Bailey 2011; Bell 2015;
Bell 2016; Bloomer 2004; Bloomer 2005; Bloomer 2007; Close
2006; Cobley 2011; He 2015; Herrlinger 2015; Kerksick 2009;
Laupheimer 2014; McCormick 2016; Meamarbashi 2011; Nicol
2015; O’Connor 2013; Peschek 2014; Silva 2008; Silva 2010;
Theodorou 2011).We rated 23 studies at unclear risk as therewere
no details specified in themanuscripts and authors did not respond
to our request for clarification. The authors of a further six studies
responded to our query but their response was unclear thus they
were assessed also at unclear risk of bias (Drobnic 2014; Howatson
2009; Lynn 2015; Nie 2004; Shafat 2004; Tanabe 2015).We con-
sidered McLeay 2012 at high risk of bias because safeguards to en-
sure allocation concealment were absent and the treatment for the
second stage of this cross-over trial would have been predictable.
Blinding
Overall, 36 studies were double-blind or blinding was reported
and therefore we assessed them at low risk of performance and
detection bias.
We assessed eight studies at high risk of performance bias because
of the lack of blinding of personnel (Drobnic 2014; Howatson
2009; Lynn 2015;McLeay 2012; Peschek 2014; Shafat 2004; Silva
2008; Tanabe 2015). We rated five studies at unclear risk of per-
formance bias as there were no details specified in the trial reports
and the authors did not respond to our request for clarification
(Bryer 2006; Connolly 2006a; Herrlinger 2015; McBride 1997;
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Su 2008).We assessed only one study at high risk of detection bias,
with a clear possibility of a lack of participant blinding (McLeay
2012). Of the nine six studies assessed at unclear risk of detec-
tion bias, six provided no details of whether there was blinding
(Bryer 2006; Connolly 2006a; Herrlinger 2015; McBride 1997;
Su 2008; Tanabe 2015), and there were reasons for some doubts
aboutwhether blindingwas assured in three others (Drobnic 2014;
Lynn 2015; Shafat 2004).
Incomplete outcome data
We judged 38 studies at low risk of attrition bias. We assessed one
study at unclear risk of attrition bias since there were no details
on participant flow and the authors did not reply to our request
for data (Krotkiewski 1994). We rated 11 studies at high risk of
attrition bias as dropouts ranged between 12.5% to 50% either
overall or in a trial arm (Arent 2010; Bloomer 2007; Connolly
2006a; Hutchinson 2016; Kaminski 1992; Lynn 2015; McFarlin
2016; Michailidis 2013; Phillips 2003; Silva 2008; Silva 2010).
In Arent 2010, out of the six participants who dropped out, five
withdrew of their own volition due to the inability to tolerate the
physical demands of the testing protocol. Six participants did not
complete all aspects of the study for personal reasons in Bloomer
2007. Two participants withdrew from another cross-over study
for personal reasons (Connolly 2006a). InHutchinson 2016, eight
participants withdrew due to illness and injury unrelated to the
study protocol. In Kaminski 1992, six participants withdrew for
a variety of reasons (loss of capsule integrity, failure to properly
maintain records, non-compliance with the experimental proto-
col), and one was removed for failure to develop DOMS in either
stage of the cross-over trial. In Lynn 2015, data were missing from
two participants of the intervention group; however, as this was
a cross-over trial, attrition was balanced across groups. McFarlin
2016 had a 30% attrition/non-compliance rate, probably with an
unevendropout rate between the twogroups.One cross-over study
stated in a published protocol that 20 individuals were enrolled
and 12 completed although the manuscript stated that 10 males
completed the study (Michailidis 2013). Phillips 2003 excluded
five participants due to complications with blood-drawing proce-
dures; however, it is unclear which group they were from. Four
participants withdrew from Silva 2008 and six participants from
Silva 2010 for personal reasons not associated with the exercise or
the supplementation; it was not specified to which group the loses
applied in either study.
Selective reporting
Three studies were registered with ClinicalTrials.gov and as all the
outcomeswere reported in the published studieswe initially judged
these at low risk of selective reporting (Kuehl 2010; Michailidis
2013; Theodorou 2011). However, Theodorou 2011 did not
record adverse effects and we thus judged it at unclear risk of
bias. We also judged all nine studies that reported on adverse ef-
fects from antioxidant supplementation, as well as fully report-
ing outcomes listed in their methods sections, at low risk of se-
lective reporting bias (Cobley 2011; Kerksick 2009; Kuehl 2010;
Laupheimer 2014; Lynn 2015; McLeay 2012; Michailidis 2013;
O’Connor 2013; Phillips 2003). We rated the remaining 40 stud-
ies at high risk of selective reporting. As well as the lack of report-
ing of adverse effects, this reflected the lack of response from the
authors of 16 studies to requests for mean and standard deviation
data. Three studies rated at high risk of selective reporting bias be-
cause of other deficiencies in reporting were Bell 2015, Bell 2016
and Thompson 2003: the first two studies did not report muscle
soreness data immediately post-exercise and Thompson 2003 did
not report data for all the time points.
Other potential sources of bias
We deemed 16 studies at unclear risk of other potential sources
of bias such as dietary control or avoiding medication or supple-
ments that could reduce muscle soreness. Of these, we judged
seven studies at unclear risk of other bias because no details re-
garding dietary control or instructing participants to avoid non-
steroidal anti-inflammatory drugs (NSAIDs) or other supplements
were provided in the trial report (Bailey 2011; Bloomer 2005;
McBride 1997; Nicol 2015; Shafat 2004; Silva 2008; Silva 2010).
The nine other studies controlled the participants’ diets but pro-
vided no details regarding dietary control or instructing partici-
pants to avoid NSAIDs or other supplements and we therefore
judged them at unclear risk of bias (Bell 2016; Krotkiewski 1994;
McCormick 2016; McLeay 2012; Michailidis 2013; Nie 2004;
Theodorou 2011; Thompson 2001; Thompson 2004). We rated
34 studies at low risk of other bias as diet, intake of supplements
and medication were controlled.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings: antioxidants versus placebo
Evidence from the 50 trials included in this review applied to
only one comparison: antioxidant supplements versus control
(placebo).
Antioxidant supplementation versus placebo or no
supplementation
All 50 included studies made this comparison. Muscle soreness
data were not available for pooling from one trial (Herrlinger
2015), and no data were pooled from McCormick 2016 because
of its protracted exercise regimen.
Primary outcomes
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Delayed onset muscle soreness (DOMS) (visual analogue
scale, various scales or scores; highest values = worst pain)
Forty-eight studies presented data on muscle soreness at various
different time points based on various visual analogue scale (VAS)
scores. Results are presented at eight follow-up times after exercise:
up to 6 hours, and at 24, 48, 73, 96, 120, 144 and 168 hours. As
there was considerable clinical heterogeneity we used the random-
effects model. Both Kerksick 2009 and Silva 2008 tested two an-
tioxidants: in the analyses, Kerksick 2009 appears twice for the
first four follow-up times and Silva 2008 appears twice at 48, 96
and 168 hours.
Antioxidant supplementation reducedmuscle soreness in compar-
ison with placebo intervention whenmeasured up to 6 hours post-
exercise (standardised mean difference (SMD) -0.30, 95% confi-
dence interval (CI) -0.56 to -0.04; participants = 525; studies =
21; I2 = 53%; low-quality evidence); Analysis 1.1); at 24 hours
after exercise (SMD -0.13, 95% CI -0.27 to 0.00; participants =
936; studies = 41; I2 = 5%; moderate-quality evidence; Analysis
1.2; Figure 4); at 48 hours after exercise (SMD -0.24, 95% CI -
0.42 to -0.07; participants = 1047; studies = 45; I2 = 47%; low-
quality evidence; Analysis 1.3; Figure 5) and at 72 hours after ex-
ercise (SMD -0.19, 95% CI -0.38 to -0.00; participants = 657;
studies = 28; I2 = 27%; moderate-quality evidence; Analysis 1.4).
(It is notable that the heterogeneity in this analysis is solely related
to the inclusion of Michailidis 2013). There was little effect of
antioxidants on muscle soreness at 96 hours after exercise (SMD
-0.05, 95% CI -0.29 to 0.19; participants = 436; studies = 17; I
2 = 31%; low-quality evidence; Analysis 1.5). Far fewer trials pro-
vided data at five days or subsequently. There was very low-qual-
ity evidence of little effect of antioxidants on muscle soreness at
120 hours (SMD 0.21, 95% CI -0.26 to 0.69; participants = 128;
studies = 4; I2 = 39%), at 144 hours (SMD -0.23, 95% CI -1.11
to 0.65; participants = 20; studies = 1) or at 168 hours (SMD -
0.04, 95% CI -0.48 to 0.41; participants = 80; studies = 4; I2 =
0%); Analysis 1.6).
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Figure 4. Forest plot of comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle
soreness (all studies), outcome: 1.2 Muscle soreness at 24 hours; random-effects model.
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Figure 5. Forest plot of comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle
soreness (all studies), outcome: 1.3 Muscle soreness at 48 hours; random-effects model.
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As there was considerable variation in the units used to measured
muscle soreness, we rescaled all trials to the 0 to 10 scale at the first
five time points in order to explore the actual difference between
groups on a standard scale. The results are as follows: up to 6 hours
(mean difference (MD) -0.52, 95%CI -0.95 to -0.08; participants
= 525; studies = 21; I2 = 66%; Analysis 1.7); at 24 hours (MD -
0.17, 95% CI -0.42 to 0.07; participants = 936; studies = 41; I2
= 29%; Analysis 1.8); at 48 hours (MD -0.41, 95% CI -0.69 to -
0.12; participants = 1047; studies = 45; I2 = 64%; Analysis 1.9); at
72 hours (MD -0.29, 95% CI -0.59 to 0.02; participants = 657;
studies = 28; I2 = 27%; Analysis 1.10); and at 96 hours (MD-0.03,
95% CI -0.43 to 0.37; participants = 436; studies = 17; I2 = 51%;
Analysis 1.11). This rescaling also allows us to examinewhether the
antioxidant supplement produces a clinically important difference.
For consistency with Bleakley 2012, we considered 1.4 cm as the
minimal important difference (MID) for pain reduction on a 10
cm visual analogue scale; this was based on an estimated MID
for musculoskeletal conditions of the shoulder by Tashjian 2009.
It is notable that all of the upper limits of the 95% CIs of these
five analyses are lower that this MID and hence all quantitative
differences do not appear to represent person-relevant differences
in muscle soreness.
Subgroup and sensitivity analyses
We performed only a few subgroup and sensitivity analyses. We
selected the 24 and 48 hours analyses for subgroup analyses given
that these were the categories with the largest number of trials. We
did not use the up to 6 hours time period because of the variation
in the timing of measurement: i.e. some studies measured this out-
come immediately after exercise whereas other studies measured
this up to 2 hours or up to 6 hours after exercise.
A sensitivity analysis exploring the use of the fixed-effect model
for all eight follow-up times produced similar results to that of
random-effects model (Table 3; analysis not shown).
A subgroup analysis could not be performed on timing of ad-
ministration (i.e. pre-exercise and post-exercise versus post-exer-
cise only) because there were very few trials (one or two studies
depending on the time of follow-up) in the post-exercise group.
We performed a subgroup analysis on the type of exercise, that is,
mechanically induced versus whole body aerobic exercise for the
24 and 48 hour follow-up times (see Analysis 1.12; Analysis 1.13).
There is no evidence of subgroup differences for muscle soreness
for type of exercise at 24 hours (Chi² = 0.44, df = 1; P = 0.51, I²
= 0%) or at 48 hours (Chi² = 0.88, df = 1; P = 0.35, I² = 0%).
Our second subgroup analysis was based on source of funding
where we compared studies that were funded by a food company
or provider of antioxidant supplements versus studies that there
were not (see Analysis 1.14; Analysis 1.15). There is no evidence
of subgroup differences for muscle soreness according to source of
funding at 24 hours (Chi² = 0.03, df = 1, P = 0.87, I² = 0%) or 48
hours (Chi² = 0.10, df = 1, P = 0.875 I² = 0%); no information
on funding was available for Su 2008.
We conducted a sensitivity analysis testing trials at unclear risk
of bias, relating to random sequence generation, allocation con-
cealment or both, which included 19 trials (Bailey 2011; Bell
2015; Bell 2016; Bloomer 2004; Bloomer 2005; Bloomer 2007;
Close 2006; Cobley 2011; He 2015; Herrlinger 2015; Howatson
2009; Laupheimer 2014; McCormick 2016; Meamarbashi 2011;
O’Connor 2013; Peschek 2014; Silva 2008; Silva 2010; Tanabe
2015). This analysis made little difference to the overall effect at
either 24 hours post-exercise (SMD -0.10, 95% CI -0.37 to 0.17;
participants = 280; studies = 14; I2 = 19%) or at 48 hours (SMD
-0.31, 95% CI -0.66 to 0.04; participants = 327; studies = 16; I2
= 57%).
Also presented are sensitivity analyses testing the effects of exclud-
ing cross-over studies; these provide reassurance that the inclusion
of such trials did not have an important effect on the results (Table
4).
Subjective recovery
No study measured subjective recovery (return to previous activi-
ties without signs or symptoms).
Adverse effects
Nine studies, reporting on a total of 216 participants, reported on
this outcome (very low-quality evidence). One study reported that
all six participants in theNAC(N-acetylcysteine) supplementation
grouphaddiarrhoea, whichwasmild infive participants and severe
diarrhoea in one (Cobley 2011). The same study reported mild
indigestion in four participants (67%) in the NAC group and one
of six participants in the placebo group. Another study reported
that tart cherry juice caused mild gastrointestinal distress in one of
26 participants taking the antioxidant supplement (Kuehl 2010).
Seven studies reported no adverse effects of taking the antioxidant
supplementation (Kerksick 2009; Laupheimer 2014; Lynn 2015;
McLeay 2012;Michailidis 2013; O’Connor 2013; Phillips 2003).
The remaining 41 studies failed to report adverse effects.
Secondary outcomes
Muscle tenderness
Only four studies measured muscle tenderness using a handheld
algometer (Close 2006; Connolly 2006; Connolly 2006a; Peschek
2014) (and Analysis 1.17). Two studies measured tenderness using
pressure algometry and reported the results in Newtons (Connolly
2006; Connolly 2006a), and two studies measured tenderness and
reported in kg (Close 2006; Peschek 2014). There was very low-
quality evidence of little difference between antioxidant supple-
mentation versus placebo in tenderness (a greater pressure exerted
means less tenderness) at the four time points (24, 48, 72 and
96 hours) for the pooled data from the two studies (52 partici-
pants) reporting the results in Newtons (Analysis 1.16); nor for
five time points (up to 6 hours, 24, 48, 72 and 96 hours) for the
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data from the two studies (36 participants) reporting the results
in kg (Analysis 1.17).
Performance variables
The quality of the evidence for all performance variables was very
low; each variable presented here being reported by only one of
the five studies reporting these outcomes (Arent 2010; Bell 2015;
Bell 2016; Cobley 2011; O’Connor 2013). Arent 2010 (18 partic-
ipants; cross-over trial) found no effect of antioxidant supplemen-
tation on the 30-second Wingate performed on a cycle ergome-
ter (the DOMS-provoking exercise) seven days after supplemen-
tation (MD 0.30 W/kg, 95% CI -2.74 to 3.34; Analysis 1.18).
Cobley 2011 (12 participants) found antioxidant supplementa-
tion (NAC) enhanced sprint time over 20 metres at three follow-
up times (lower values = better performance): 24 hours (MD -0.41
seconds, 95% CI -0.63 to -0.19), 48 hours (MD -0.30 seconds,
95% CI -0.52 to -0.08) and 120 hours (MD -0.30, 95% CI -
0.54 to -0.06; Analysis 1.19). O’Connor 2013 (40 participants)
found no improvements in maximal oxygen consumption when
measured after 42 days after antioxidant supplementation (higher
values = better performance) (MD 0.20 mL/kg/min, 95% CI -
5.66 to 6.06; Analysis 1.20). Bell 2016 (16 participants) found
no effect of antioxidant supplementation on agility (5-0-5 agility:
lower values = better performance) at any of the three time points
measured: 24 hours (MD 0.01 seconds, 95% CI -0.16 to 0.18),
48 hours (MD -0.05 seconds, 95% CI -0.19 to 0.09) or 72 hours
(MD -0.02 seconds, 95% CI -0.17 to 0.13) (Analysis 1.21). Bell
2015 (16 participants) found no effect of antioxidant supplemen-
tation on six-second sprint power (higher values = better perfor-
mance) at any of the three time points measured: 24 hours (MD
39.00 W, 95% CI -182.33 to 260.33), 48 hours (MD 50.00 W,
95% CI -195.44 to 295.44) or 72 hours (MD 53.00 W, 95% CI
-174.56 to 280.56) (Analysis 1.22).
Muscle force production (maximal voluntary contraction)
Thirty studies measured muscle function at various different time
points. Muscle force production was measured in different ways
and we pooled results only from studies using the same outcome
measure: 15 trials reported the percentage change in force produc-
tion from baseline; six reportedNewton metres, six reported New-
tons, two reportedNewtonmetres per kg of body mass and one re-
ported kg. We rated the quality of evidence as very low for all find-
ings. Whenmuscle force production was measured as a percentage
change from baseline, antioxidant supplementation appeared to
increase force production to a small extent (all under 6%) in com-
parison with placebo across the first five time points: up to 6 hours
after exercise (MD 5.86%, 95% CI 3.29 to 8.42; participants =
255; studies = 11; I2 = 3%), at 24 hours (MD2.51%, 95%CI 0.99
to 4.04; participants = 375; studies = 15; I2 = 75%), at 48 hours
(MD 4.46%, 95% CI 2.94 to 5.98; participants = 375; studies =
15; I2 = 59%), at 72 hours (MD 3.92%, 95% CI 0.88 to 6.96;
participants = 277; studies = 11; I2 = 51%), and at 96 hours after
exercise (MD5.29, 95%CI 3.65 to 6.92; participants = 252; stud-
ies = 9; I2 = 72%) (Analysis 1.23). (Although in the results for 168
hours after exercise, the antioxidant showed a harmful effect on
muscle force production, only two studies measured this outcome
at this time point and the results were statistically heterogeneous
(MD -7.96, 95% CI -15.96 to 0.05; participants = 36; studies =
2; I2 = 68%). Where data were pooled, for up to six studies for
force production measured in Newton metres, or for up to five
studies for force production measured in Newtons, there were no
differences found between the antioxidant supplementation and
placebo groups across all of the time points measured (see Analysis
1.24 and Analysis 1.25). For completeness, the non-pooled results
for the two trials reporting the strength in Newton metres per kg
of body mass are shown in Analysis 1.26 and those for the trial
reporting strength in kg in Analysis 1.27. The former are domi-
nated by those of Michailidis 2013, which favour antioxidants in
the first five follow-ups but placebo in the last two follow-ups.
Range of motion
There was very low-quality evidence that range of motion,
which was measured in 10 studies (Bailey 2011; Bloomer 2004;
Bryer 2006 Connolly 2006a; Goldfarb 2011; Meamarbashi 2011;
O’Connor 2013; Phillips 2003; Tanabe 2015; Theodorou 2011),
did not differ importantly between the two groups (antioxidant
versus placebo) at any of the follow-up times (see Analysis 1.28).
All differences (higher values = better range of motion) were small
and unlikely to relate to a clinically important difference at either
the elbow or knee. The first five follow-up time results are pre-
sented here: up to 6 hours after exercise (MD -0.25 degrees, 95%
CI -3.31 to 2.81; participants = 163; studies = 6; I2 = 0%), at 24
hours (MD 1.03 degrees, 95% CI -0.91 to 2.96; participants =
259; studies = 9; I2 = 0%), at 48 hours (MD 2.71 degrees, 95%
CI 0.39 to 5.04; participants = 259; studies = 9; I2 = 61%), at
72 hours (MD 2.93 degrees, 95% CI -0.02 to 5.87; participants
= 196; studies = 7; I2 = 0%) and at 96 hours (MD 0.79 degrees,
95% CI -1.26 to 2.84; participants = 158; studies = 6; I2 = 0%).
High-dose versus low-dose, where the low-dose
supplementation is within normal or recommended
levels for the antioxidant involved
None of the included studies made this comparison.
D I S C U S S I O N
Summary of main results
This review examined the effectiveness of antioxidants for prevent-
ing and treating muscle soreness after exercise. Fifty randomised
placebo-controlled studieswere included, 12ofwhich used a cross-
over design. The 50 studies involved a total of 1089 participants
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(961 male; 128 female; age range 16 to 55 years). The studies
were heterogeneous, including the timing (pre-exercise or post-
exercise), frequency, dose or duration, and type of antioxidant
supplementation, and the type of preceding delayed onset mus-
cle soreness (DOMS)-producing exercise. All studies used an an-
tioxidant dosage higher than the recommended daily amount. No
studies compared high-dose versus low-dose, where the low-dose
supplementation was within normal or recommended levels for
the antioxidant involved.
The included studies made only one comparison: antioxidant sup-
plements versus control (placebo). Our main outcomes were mus-
cle soreness (up to 6 hours post-exercise and at 24, 48, 72 and 96
hours), subjective recovery and adverse events.
Antioxidant supplementation versus placebo or no
supplementation
A summary of the evidence available for the main outcomes for
this comparison is presented in Summary of findings for the main
comparison. The assessment of the quality of the evidence varied
between moderate quality, where the effect is probably true but
there is a possibility that it could be substantially different, low
quality, where the effectmay be true but itmay also be substantially
different from what was found, and very low quality, where we are
very uncertain about the estimate.
Pooled standardised mean difference (SMD) results for muscle
soreness indicated a small difference in favour of antioxidant sup-
plementation after DOMS-inducing exercise at all main follow-
ups: up to 6 hours (525 participants; 21 studies; low-quality evi-
dence); at 24 hours (936 participants; 41 studies; moderate-qual-
ity evidence), at 48 hours (1047 participants; 45 studies; low-qual-
ity evidence); at 72 hours (657 participants; 28 studies; moder-
ate-quality evidence), and little difference at 96 hours (436 par-
ticipants; 17 studies; low-quality evidence). When, however, we
rescaled all the trial results to the 0 to 10 cm scale in order to com-
pare the actual difference between groups, we found that the 95%
confidence intervals (CIs) for all five follow-up timeswere all below
1.0 cm, and thus all below the minimal important difference of
1.4 cm that we used in this review. Thus, all statistical differences
in DOMS favouring antioxidant supplementation were unlikely
to equate to meaningful or important differences in practice. Nei-
ther of our subgroup analyses to examine for differences in effect
according to type of DOMS-inducing exercise (mechanical versus
whole body aerobic) or according to funding source confirmed
subgroup differences. Sensitivity analyses to test the selection of
the statistical model for pooling (fixed-effect instead of random-
effects) and the exclusion of cross-over studies all showed similar
results to the main analyses.
None of the 50 studies reported on subjective recovery (return to
previous activities without signs or symptoms).
Only nine studies (216 participants) reported on adverse effects,
with actual events reported in two studies. One study (12 partic-
ipants) reported that all six participants in the NAC (N-acetyl-
cysteine) supplementation group had diarrhoea, which was mild
in five participants and severe in one (Cobley 2011). The same
study reported mild indigestion in four participants (67%) in the
NAC group and one of six participants in the placebo group. It
should be noted that NAC supplementation is usually prescribed
and it has been found to cause uncomfortable side effects includ-
ing nausea and diarrhoea in other studies. Another study reported
that tart cherry juice caused mild gastrointestinal distress in one of
26 participants taking the antioxidant supplement (Kuehl 2010).
The other seven studies reported no adverse effects of taking the
antioxidant supplementation; this included 10 participants hav-
ing NAC supplementation in one study. Overall, the available ev-
idence for adverse events is very low-quality.
Overall completeness and applicability of
evidence
Data for muscle soreness, the primary outcome, were available
from48 of the 50 small placebo-controlled randomised trials, with
pooled data available at 24 hours after the exercise from 41 trials
(one of which tested two antioxidants), involving 936 participants
and from 45 (two of which tested two antioxidants), involving
1047 participants. In contrast there were no data for subjective
recovery and few data for adverse effects.
We consider the applicability of the evidence in terms of the pop-
ulation characteristics, the exercise used to induce muscle damage
and trial settings, the antioxidants used and outcomes. In partic-
ular, the 50 trials included in this review varied regarding dosages
of antioxidants, the muscle damage model and adequate control
of extraneous variables.
The majority of the 1089 participants included in this review were
male (961; 88.2%) and so arguably the findings of the review are
mainly applicable to males but there is no biological basis for why
antioxidants should have a different effect in the two sexes. These
sex differences are typical of what is observed in the athletic re-
covery literature (Bieuzen 2013; Bleakley 2012; Costello 2014).
More noteworthy is that no data from highly-trained elite athletes
were included in the analyses; the data pertaining to nine elite ath-
letes tested in McCormick 2016 were not included in the meta-
analyses because the exercise paradigm was completely different
to all the other studies included in this review. As the majority
of the participants were either college students or relatively young
and active, these findings cannot be generalised in the elite athlete
population who have a different physiological and training status.
Some reservations in terms of applicability also apply to older in-
dividuals due to their anatomical and physiological characteristics
as there were no older participants included in this review (age
range of participants: 16 to 55 years).
There were large variations regarding the mode of exercise used
to induce muscle damage in the studies, with some studies us-
ing exhaustive high-intensity exercise such as downhill running
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(i.e. whole body aerobic exercise) and other studies using a resis-
tance training protocol (i.e. mechanically induced exercise). Thus
the level of muscle damage experienced by the participants will
have varied. In addition, the intensity of the exercise used to illicit
muscle damage also varied greatly amongst studies: some studies
used an extremely demanding and intense exercise protocol such
as 10 sets of 10 repetitions knee extensions performed at 80% of
one repetition maximum or a marathon run, whereas others used
less exhaustive protocols such as a bench stepping exercise. The
amount of muscle damage and oxidative stress caused depends on
the type, intensity and duration of physical exercise performed
(Castrogiovanni 2012). Paulsen 2012 found exercise that has a
greater eccentric component that involves a greater range of mo-
tion and high force generation is more likely to cause greater levels
of damage. Moreover, Bleakley 2012 reported that resistance ex-
ercises performed under laboratory conditions are associated with
high levels of muscle damage and soreness, particularly in the un-
trained population. Our subgroup analysis that compared type of
exercise at 24 and 48 hours did not show subgroup differences
between whole body aerobic exercise and mechanically induced
exercise. Despite the variation, the key point for this review is that
the exercise protocols, whether in the laboratory or field setting,
were all sufficient to induce muscle damage that would result in
DOMS in people undergoing sport activities.
There was large variation in the dose and duration of the antioxi-
dants used, with three trials testing supplements started only after
exercise. The variation was too great to enable meaningful indi-
rect comparisons (subgroup analyses) and no trial compared high-
versus low-dose supplementation, where the low-dose supplemen-
tation was within normal or recommended levels for the antioxi-
dant involved. Nonetheless, all studies used an antioxidant dosage
higher than the recommended daily amount.
The timing for assessment of muscle soreness, with the majority
of evidence available for 24 and 48 hours after exercise, was ap-
propriate. However, the timing of measurement for up to 6 hours
varied greatly amongst the studies where some studies measured
muscle soreness immediately after exercise and some studies mea-
sured this several hours after exercise. There was considerable vari-
ation in themeasurement of muscle soreness, whichmeant that we
pooled SMDs for the main analyses. Exploratory analyses, where
all results were on a 10 cm scale, allowed an assessment of whether
the between-group differences were clinically relevant. Crucially,
the upper limits of the 95% CIs at all five time points were much
less than a typical minimal important difference (MID) for pain.
Quality of the evidence
We assessed the quality of evidence using the GRADE framework,
which com-
bines considerations of risk of bias,indirectness,inconsistency (het-
erogeneity),imprecision and publication bias. The findings for the
main outcomes are shown in Summary of findings for the main
comparison. We downgraded all outcomes one level for serious
risk of bias, due mainly to selective reporting bias (the majority of
the trials failed to report on adverse effects) and, to a lesser degree,
attrition biases. We did not downgrade for indirectness in relation
to muscle soreness. We downgraded two outcomes for serious in-
consistency reflecting heterogeneity that could not be traced to
the inclusion of just one outlier trial. Pooled evidence did not sup-
port downgrading for imprecision. Our tests for publication bias
did not reveal a serious concern (Figure 6; Figure 7), although all
were small studies. Thus, we did not downgrade for publication
bias. We concluded that the quality of the evidence ranged from
moderate to very low.
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Figure 6. Funnel plot of comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle
soreness (all studies), outcome: 1.2 Muscle soreness at 24 hours; random-effects model.
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Figure 7. Funnel plot of comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle
soreness (all studies), outcome: 1.3 Muscle soreness at 48 hours; random-effects model.
Potential biases in the review process
We used the standard methods described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). Al-
though our search was extensive, we cannot exclude the possibility
that we have missed relevant evidence. For studies where we re-
quired the rawdata, we contacted authors via email. The authors of
14 studies did not respond to several emails requesting mean and
standard deviation data (Avery 2003; Beaton 2002a; Bryer 2006;
Connolly 2006; Connolly 2006a; Goldfarb 2011; Krotkiewski
1994; McFarlin 2016; Michailidis 2013; Peschek 2014; Phillips
2003; Su 2008; Trombold 2010; Trombold 2011). We therefore
extracted these data from graphs using Graphclick 2010 Arizona
(version 3.0.2, 2010).Whilst this is not ideal, we tried tominimise
error by having two review authors (MR and DR) independently
extract the data, with any discrepancies resolved by consultation
with the third and fourth authors (HS and JC).
One potential source of bias is the post-hoc exclusion of trials not
reporting our primary outcomes (see Types of outcome measures).
However, none of the excluded studies were aimed at the preven-
tion, reduction or treatment of DOMS.
We set out “to assess the effects (benefits and harms) of antioxi-
dant supplements and antioxidant-enriched foods for preventing
and reducing the severity and duration of delayed onset muscle
soreness following exercise” (Objectives). To achieve this, we de-
cided to pool data from clearly heterogeneous trials; for instance
varying in their study design, populations, the exercise protocols,
the antioxidant dosage, start and length of supplementation, their
accounting for extraneous variables that could affect recovery and
to a lesser degree in their timing of measuring muscle soreness
(DOMS). In the light of this clinical heterogeneity, the statistical
heterogeneity was not extreme and sometimes the heterogeneity
could be sourced to a very few outliers (e.g. Michailidis 2013 for
muscle soreness at 72 hours (Analysis 1.4)). Subgroup analysis by
type of exercise proved reassuring. Keeping the focus on the main
characteristic of the intervention (i.e. oral antioxidant supplemen-
tation at dosage above the recommended daily dosage) appears
justified.
Publication bias is a threat to any systematic review or meta-analy-
sis and publication bias among nutrition-related scientific articles
remains a problem. Lesser 2007 investigated financial sponsorship
of scientific articles addressing the health effects of three commonly
consumed beverages to determine how sponsorship affects pub-
lished conclusions and found that industry funding of nutrition-
related studies may bias conclusions in favour of sponsors’ prod-
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ucts. However, funnel plots for the outcomes of muscle soreness
at 24 hours and 48 hours were not suggestive of publication bias
(Figure 6; Figure 7). Moreover, we performed a subgroup analy-
sis on studies that were funded by a food company or provider
of antioxidant supplements and compared them with studies that
were not funded by a food company or provider of antioxidant
supplements and we found no evidence of subgroup differences
and thus sponsorship bias (Analysis 1.14; Analysis 1.15).
Our inclusion of cross-over studies and our analysis of their data
as if from a parallel group trial, thus without adjustment for the
cross-over design, are other potential sources of bias. With one
exception, the cross-over studies included in this review used a
washout period of two to six weeks, which is sufficient to allow
the muscles to recover. The exception used a washout period of
only five days between treatments and therefore carries some risk
of a carry-over effect (Arent 2010); sensitivity analysis to check
on the effect of excluding the data from this trial did not result
in important changes. Further sensitivity analyses checking the
effects of excluding the cross-over trials from the muscle soreness
analyses showed that our inclusion and handling of the cross-over
studies did not have an important impact on the review results.
Agreements and disagreements with other
studies or reviews
Several narrative reviews have been written on antioxidant sup-
plementation and recovery (e.g. Gross 2011; Howatson 2008b;
McGinley 2009; Peternelj 2011). However, to our knowledge this
is the first systematic review that has examined the effects of an-
tioxidant supplements for preventing and reducing muscle sore-
ness after exercise. Our review also includes more recently pub-
lished evidence. For example, of the 45 trials contributing evidence
to the 48 hours muscle soreness analysis (Analysis 1.3), 14 were
published in 2012 or subsequently, and 14 more were published
between 2009 and 2011.
The observations by Howatson 2008b on the large variations in
type of, dosage used and duration of antioxidant and exercise
modality are consistent with our findings. McGinley 2009, which
reviewed the effects of vitamin C, vitamin E and both combined
on muscle damage and oxidative stress, also attributed the mixed
findings to variations in dosage, timing and duration of antioxi-
dant and exercise modality. McGinley 2009 suggested that there
was some evidence to show that both vitamin C and vitamin E an-
tioxidants can reduce oxidative stress but there was poor evidence
to show any positive effects on protecting against muscle damage
and soreness. It is also notable that there has been some indica-
tion that long-term antioxidant supplementation in high doses,
in particular vitamin E, may increase mortality (Bjelakovic 2007).
Peternelj 2011 concluded that antioxidant supplementation atten-
uates exercise-induced oxidative stress but had no effects on exer-
cise-inducedmuscle damage, soreness and performance. Although
Peternelj 2011 did not perform a meta-analysis, they suggested
that there is a growing body of evidence indicating that antioxidant
supplements may have a detrimental effect as they may interfere
with the beneficial effects of exercise training. Gross 2011 in their
narrative review on antioxidant supplementation and endurance
training noted that the use of antioxidants in sport by amateur and
professional athletes was common and that some studies had sug-
gested that these may actually be counterproductive (in particular
vitamin C and E supplements) as they may impair and weaken
some of the desired signalling roles played by free radicals during
training adaptations. The latter, however, was not investigated by
Gross 2011. Nonetheless, over the last few years there has been
an emergence of studies showing that chronic antioxidant sup-
plementation may actually be counterproductive, particularly in
interfering with exercise-induced cell-signalling in skeletal mus-
cle thus having an overall detrimental effect of exercise training
on both performance and health (Gomez-Cabrera 2008; Paulsen
2014; Ristow 2009). More specifically, several studies have shown
that antioxidant supplements promote exercise-induced oxidative
stress (Avery 2003; Bailey 2011; Beaton 2002; Childs 2001; Knez
2007; Lamprecht 2009; Malm 1996; Nieman 2004), hinder cell
adaptation to exercise-induced oxidative stress (Gomez-Cabrera
2008; Ristow 2009; Paulsen 2014), and delay healing and recov-
ery from exercise (Close 2006; Teixeira 2009), and long-term an-
tioxidant supplementation in high doses may increase mortality
(Bjelakovic 2014; Slatore 2008).
The risk of adverse effects is likely to be dependent of the type
of antioxidant. One of the two trials in the review reporting on
adverse effects was testing NAC supplementation and reported
that all six participants in the antioxidant group had diarrhoea
(Cobley 2011). As well as being a listed side effect of this prescrip-
tion drug, uncomfortable side effects such as nausea and diarrhoea
from NAC supplementation have also been reported elsewhere
(Ferreira 2011).
As well as random errors relating to small trials and bias, there
are numerous factors that can explain why there are differences
between trials and in the antioxidant literature on whether antiox-
idants are beneficial or not for recovery. The recovery process is
complex, and there are many extraneous variables that could inter-
fere or accelerate the recovery process. Factors such as differences
in antioxidant dosage, length of supplementation, and accounting
for extraneous variables that could affect recovery could explain
differences between trials (Close 2014). Second, there are large
variations in the type of participants with most studies recruiting
untrained, sedentary and relatively young and healthy individu-
als and far fewer studies recruiting well-trained athletes. Partici-
pants will vary in size, body weight, body composition and they
may respond differently to antioxidant supplementation due to
metabolic differences; these may also be some reasons that can
explain the differences in findings. Nonetheless, as argued above,
retaining the focus on the broad question asked in this review
has helped to us to examine and summarise the evidence for the
overall question of whether antioxidants prevent or reduce muscle
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soreness after exercise.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is moderate- to low-quality evidence that antioxidant sup-
plementation does not result in a clinically relevant reduction of
muscle soreness after exercise at any of the five follow-up times: up
to 6 hours and at 24, 48, 72 and 96 hours after exercise. There is
no evidence available on subjective recovery and only limited evi-
dence on adverse effects of taking antioxidant supplements. Some
antioxidant supplements such as N-acetylcysteine may cause un-
wanted side effects including gastrointestinal discomfort and di-
arrhoea.
Implications for research
The findings of, and messages from, this review provide an oppor-
tunity for researchers and other stakeholders to come together and
consider what are the priorities, and underlying justifications, for
future research in this area. Should there be a continuing focus on
antioxidants, in preference to other interventions used for reduc-
ingmuscle soreness, the areawould benefit from standardisation of
methods and antioxidant protocols. Future randomised controlled
trials should ensure that the rationale for the antioxidant protocol
is considered and specified, and attention given to dietary control
and other factors that may affect recovery as these are important
confounders when investigating the impact of antioxidant supple-
mentation on exercise performance and recovery. The rationale for
selection of populations different from those covered in the review
should also be given.We suggest that a case could be made for elite
athletes, not included in this review, as this particular group have
a different physiological and training status. As recently noted,
future studies should employ a parallel design with larger sample
sizes as when investigating muscle recovery cross-over trials may
have a risk regarding carry-over effects between treatment periods
(Bleakley 2012; Costello 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arent 2010
Methods Randomised controlled trial (cross-over design)
Separated by a 5-day washout
Participants Setting: laboratory; USA
n = 24 college-aged males with at least 1 year of weightlifting experience; mean age 21.
3 (SE 0.4) years
18 participants completed the study; 1 participant dropped out due to training conflicts
with his sport and the other 5 participants withdrew of their own volition due to the
inability to tolerate the physical demands of the testing protocol
Inclusion/exclusion criteria
This study was limited to males in order to control for fluctuations in cortisol that occur
during the menstrual cycle. At initial enrolment, all participants self-reported to be free
from current injuries limiting their ability to train and complete physiological testing
Interventions Intervention
Black tea extract: each 2-capsule serving contained 880 mg black tea extract and was
standardised for 350 mg theaflavin
4 capsules per day - 2 in the morning and 2 in the afternoon
Placebo
Not specified
Duration
Supplements were taken 9 days before and 2 days after exercise (11 days)
Outcomes PRIMARY
Muscle soreness was assessed using a 10 cm visual analogue scale (VAS). The anchor at
0 corresponds to “no soreness” and at 10 to “too sore to move muscles”. Participants
were asked to perform one squat with hands on hips and then draw a line on the scale
corresponding to their level of soreness
SECONDARY
Wingate 30-second sprint was performed on a Monark 894E Anaerobic Test Ergometer
(Monark Exercise AB, Sweden). The load was set according to each participant’s mass.
The test was 30 seconds of all out cycling followed by 5 minutes of rest and then 8 x 10-
second intervals of all out cycling. Each interval was separated by 2 minutes of rest. The
resistance for the Wingate and intervals was set at 0.10 kP/kg body mass
Exercise type 30-second Wingate with 5 minutes rest followed by 8 x 10-second maximal sprints with
2 minutes recovery
Sources of funding The study was funded by WellGen, Inc USA through an unrestricted research
Notes Author was contacted via email on 27May 2016 to request data for delayed onset muscle
soreness but did not respond
Risk of bias
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Arent 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details specified in manuscript
Author was contacted via email on 27 May
2016 but did not respond
Allocation concealment (selection bias) Unclear risk No details specified in manuscript
Author was contacted via email on 27 May
2016 but did not respond
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 participants withdrew from the study
Attrition rate = 25%
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study
Participants were also asked to keep food
records
Avery 2003
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 18 healthy men who were active in endurance sports but not resistance trained (9 in
each group)
Mean age vitamin group: 22.7 ± 4.1 years
Mean age placebo group: 22.3 ± 3.6 years
Inclusion/exclusion criteria
Participants were normally actively participating in endurance and sports activities but
not resistance training to ensure the whole-body resistance exercise protocol resulted
in detectable muscle soreness and muscle disruption. The participants had not lost or
gained weight in the previous year, were not adhering to special diets and were not regular
consumers of nutritional supplements including vitamin E. All participants were non-
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Avery 2003 (Continued)
smokers and not currently taking any medication known to affect any of the dependant
variables in the study
Interventions Intervention
Vitamin E supplementation 992 mg per day (1200 IU)
Number of capsules per day not specified
Placebo
Microcrystalline cellulose
Duration
31 days
Outcomes PRIMARY
Delayed onset muscle soreness of the shoulders, chest, quadriceps and hamstrings was
evaluated using a visual analogue scale (0 to 10 cm) where 0 is “no pain” and 10 is
“extreme pain” after performing shoulder abduction, shoulder horizontal adduction and
hip flexion (unloaded squat)
Exercise type Whole body resistance exercise training protocol; 3 sets of 10 repetitions of 30% to 60%
1 RM
Sources of funding None
Notes Authors were contacted on 25May 2016 to request data for delayed onsetmuscle soreness
with no reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were matched according to
physical characteristics and training history
and then randomly assigned using a com-
puter program
Allocation concealment (selection bias) Unclear risk No details in the manuscript
Authors were contacted on 25 May 2016
with no reply
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
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Avery 2003 (Continued)
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplement
were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study as well as any form of therapeutic in-
tervention such as massage and ice
Participants who were exposed to any form
of resistance training were also excluded
Bailey 2011
Methods Randomised controlled trial (parallel design)
Participants Setting: field and laboratory; UK
n = 38 healthy young men (18 in the antioxidant group and 20 in the placebo group);
mean age 22 (SD 1) years
Inclusion/exclusion criteria
All participants were non-smokers and habitually active in a variety of sports but were
unfamiliar with the specific exercise protocol involved in the study
Interventions Intervention
Mixed antioxidant supplement. 400 mg vitamin C, 268 mg vitamin E, 2 mg vitamin
B6, 200 µg vitamin B9, 5 µg zinc sulphate, 1 µg vitamin B12 capsules
1 capsule daily
Placebo
Lactose capsules
Duration
6 weeks
Outcomes PRIMARY
Delayed onset muscle soreness using a visual analogue scale 1 to 10 with anchor terms
ranging from 1 being “not sore” to 10 being “very very sore”
SECONDARY
Peak isometric torque of knee flexors
Range of motion at the knee
Exercise type 90-minute intermittent shuttle running
Sources of funding The study received financial support from Unilever R&D
Notes -
Risk of bias
45Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bailey 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a computer generator
Allocation concealment (selection bias) Low risk Identical capsules ingested twice daily with
meals
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk No details on whether participants were
asked to refrain from using other supple-
ments or anti-inflammatory medication
Beaton 2002a
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 18 healthy men, mean age 20.3 (SD 1.70) years
Inclusion/exclusion criteria
Non-smokers, not taking vitamin E supplements(or any other antioxidant or related
supplements) and had not participated in resistance training, or any other form of
structured exercise for at least 6 months
Interventions Intervention
1200 IU vitamin E supplementation
Placebo
Safflower oil
Duration
30 days
Outcomes PRIMARY
Muscle soreness was assessed using theDescriptor Differential Scale (DDS) at the quadri-
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Beaton 2002a (Continued)
ceps where 0 is “no pain” and 10 is “extreme pain”
SECONDARY
Peak isometric torque of knee flexors performed on the Biodex. Participants performed
3 maximal voluntary contraction repetitions each being of 5 seconds duration with 60
seconds rest in between
Exercise type 24 sets of 10 repetitions of eccentric knee flexion and extension contractions
Sources of funding The authors acknowledged Quest vitamins (Vancouver, BC) for the gracious donation
of the vitamin E used in the study. “This work was supported by NSERC (SMP). SMP
is the recipient of a PREA and gratefully acknowledges that source of support in aiding
in the completion of this research.”
Notes Supplements were given in the form of a capsule
Authors were contacted on numerous occasions to request data for delayed onset muscle
soreness, maximal voluntary isometric contraction and range of motion with the final
email sent 25 May 2016 with no reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in the manuscript
Authors were contacted on numerous oc-
casions with final email sent 25 May 2016
with no reply
Allocation concealment (selection bias) Unclear risk No details in the manuscript
Authors were contacted on numerous oc-
casions with final email sent 25 May 2016
with no reply
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
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Beaton 2002a (Continued)
Other bias Low risk Participants were non-resistance trained
and were asked to refrain from using other
supplements or anti-inflammatorymedica-
tion
Bell 2015
Methods Double-blind randomised controlled trial (parallel design)
Participants Setting: laboratory; England
n = 16 healthy men (8 in the experimental group; 8 in the placebo group)
Mean age 30 (SD 8) years
Inclusion/exclusion criteria
Exclusion criteria for the study included > 45 years of age, female, allergy to specific
fruit products, currently taking any nutritional supplements or medication, and history
of gastrointestinal, renal or cardiovascular disease
Interventions Intervention
Participants were instructed to consume 30 mL of the supplement twice per day (0800
and 1800 hours) for 8 consecutive days (4 days pretrial, on the day of, and 3 days post-
trial). Manuscript states “manufacturer’s specification (Cherry Active Ltd, Hanworth,
UK), each 30 mL dose of MC contained ~90-110 Montmorency tart cherries; indepen-
dent laboratory analysis shows the juice to provide 9.2 mg·mL−1 of anthocyanins and
669.4 mg·mL−1 of carbohydrate (Atlas Biosciences, Tuscon, Ariz., USA)”
Placebo
A commercially available mixed berry cordial (less than 5% fruit in concentrate form)
, mixed with 100 mL water and maltodextrin (MyProtein Ltd., Northwich, UK) until
matched for carbohydrate content
Duration
8 days
Outcomes PRIMARY
Muscle soreness was assessed using a 0 to 200 mm visual analogue scale where 0 is “no
pain” and200 is “pain/soreness as bad as it could be”. Participants rated their soreness after
completing a squat to approximately a 90° knee flexion before standing and immediately
marked upon the scale to indicate their level of soreness
SECONDARY
Maximum voluntary isometric contraction of the dominant knee extensors was deter-
mined using a strain gauge (MIE Medical Research Ltd., Leeds, UK). Participants were
seated on a platform and the strain gauge was attached to the dominant ankle at an in-
ternal joint angle of 80° (verified by a goniometer). Participants were given standardised
verbal encouragement for the duration of each of the 3 maximum 3-second contraction.
Each contraction was separated by 1 minute
Power: 6-second peak cycle power
Cycling efficiency
Exercise type A 109-minute cycling trial designed to replicate road race demands on an electromag-
netically braked, cycle ergometer (Velotron Racer-Mate, Seattle, Wash., USA)
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Bell 2015 (Continued)
Sources of funding Manuscript states: “The Cherry Marketing Institute (a not for profit organisation) pro-
vided financial support for the analysis of inflammatory indices”
Notes Authors were contacted on 3 February 2017 to request raw data for delayed onset muscle
soreness and maximal voluntary isometric contraction and responded on 3 February
2017
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in manuscript
Authors confirmed via email on 3 February
2017 that stratified randomisation based
on aerobic fitness and coin toss was em-
ployed
Allocation concealment (selection bias) Low risk No details in manuscript
Author confirmed via email on 3 February
2017 that opaque vessels used for all drink-
ing bottles and this was prepared by an in-
dependent member of the department
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk Delayed onset muscle soreness data im-
mediately post-exercise not recorded or re-
ported
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants did not complete any other ex-
ercise or take supplements/medication over
the course of the study
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Bell 2016
Methods Double-blind randomised controlled trial (parallel design)
Participants Setting: laboratory; England
n = 16 semi professional male soccer players (8 in the experimental group; 8 in the
placebo group)
Mean age 25 (SD 4) years
Inclusion/exclusion criteria
Inclusion criteria required participants to have trained in soccer consistently across the
preceding 3 years and be free of any lower limb injury for the preceding 6 months
Interventions Intervention
Participants were instructed to consume 30 mL of the supplement twice per day (0800
and 1800 hours) for 7 consecutive days (4 days pretrial and on each trial day). The sup-
plement was a commercially available Montmorency cherry concentrate (CherryActive,
Sunbury, UK); containing a total anthocyanin content of 73.5 mg·L-1 of cyanidin-3-
glucoside, a total phenolic content of 178.8 gallic acid equivalent·L-1 and an antioxidant
capacity (TEAC) of 0.58 trolox equivalents·L-1
Placebo
A commercially available, less than 5% fruit, cordial, mixed with water and maltodextrin
(MyProtein Ltd, Northwich, UK) until matched for energy content of the intervention
(102 kcal)
Duration
7 days
Outcomes PRIMARY
Muscle soreness was assessed using a 0 to 200 mm visual analogue scale where 0 is “no
pain” and 200 is “unbearably painful”. Participants rated their soreness after completing
a squat to approximately a 90° knee flexion before standing and immediately marked
upon the scale to indicate their level of soreness
SECONDARY
Maximum voluntary isometric contraction of the dominant knee extensors was deter-
mined using a strain gauge (MIE Medical Research Ltd., Leeds, UK). Participants were
given standardised verbal encouragement for the duration of each of the 3 maximum 3-
second contractions. Each contraction was separated by 1 minute
Sprint performance (20 m - infrared timing gates)
Agility: 5-0-5 agility test (infrared timing gates)
Power: counter movement jump (jump mat)
Exercise type 12 × 20 m run sprints, departing every 60 seconds followed by an adapted version of the
Loughborough Intermittent Shuttle Test (LIST) (6 x 15-minute sections)
Sources of funding TheCherryMarketing Institute (a not for profit organisation) provided financial support
for the analysis of inflammatory indices
Notes Authors were contacted on 3 February 2017 to request raw data for delayed onset muscle
soreness and maximal voluntary isometric contraction and responded on 3 February
2017
Risk of bias
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Bell 2016 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in manuscript
Authors confirmed via email on 3 February
2017 that stratified randomisation based
on aerobic fitness and coin toss was em-
ployed
Allocation concealment (selection bias) Low risk Manuscript states: “All supplements were
prepared by an independent member of the
department prepared in opaque bottles in
order to maintain the double blind design”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No details in manuscript
Authors confirmed via email on 3 Febru-
ary 2017 that all participants completed the
study
Selective reporting (reporting bias) High risk Delayed onset muscle soreness data im-
mediately post-exercise not recorded or re-
ported
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk Manuscript states that participants “were
also provided with a diet record diary and a
list of foods to avoid throughout the 4 days
prior to and during the trial period”
No information on NSAIDs or medication
Bloomer 2004
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 18 healthy women age range 19 to 31 years (9 in each group)
Inclusion/exclusion criteria
Participants provided amedical history and completed physical activity and diet and sup-
plementation questionnaires to determine eligibility. None had orthopaedic ormetabolic
conditions that could have affected the variables of measurement. All participants were
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Bloomer 2004 (Continued)
non-smokers, did not use oral contraceptives, anti-inflammatory drugs or dietary sup-
plements (i.e. antioxidants for at least the past 3 months), and all were classified as non-
resistance trained (i.e. had not performed resistance training in the past 12 months)
Interventions Intervention
268 mg vitamin E, 1 g vitamin C, 90 µg selenium
Placebo
Lactose placebo pill
3 capsules per day
Duration
18 days
Outcomes PRIMARY
Delayed onset muscle soreness in both arms using a visual analogue scale (0 to 10 cm)
where 0 is “no pain” and 10 is “unbearable pain”
Soreness was measured following active movement of elbow flexion or extension, as well
as following light palpitation by the investigators
SECONDARY
Maximum isometric force was performed on the Biodex isokinetic dynamometer (Biodex
Medical Systems, Ronkonkoma, NY). Participants were secured in the Biodex chair by
shoulder and lap belts. Participants were asked to perform 3maximal isometric unilateral
contractions with their elbow flexors each lasting 3 seconds with 60 seconds rest in
between each effort
Range of motion was measured both relaxed and flexed at the elbow. Range of motion
was calculated as relaxed minus flexed
Exercise type 4 sets of 12 repetitions of non-dominant elbow flexors at an angular velocity of 20°/
second
Sources of funding None
Notes Authors were contacted on 3 October 2013 to request raw data for delayed onset muscle
soreness and maximal voluntary isometric contraction and responded on 1 November
2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in manuscript
Authors were contacted on 24 May 2016;
response: “Likely via coin flip or random
number selection”
Allocation concealment (selection bias) Low risk Response: “Blinding code retained by per-
son not associated with research and/or
provided in sealed envelope”
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Bloomer 2004 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study with
100% compliance
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were non-resistance trained
and relatively inactive
Participants were asked to refrain from us-
ing other supplements or anti-inflamma-
tory medication and oral contraceptives
Bloomer 2005
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 20 weight-trained men (10 in the experimental group; 10 in the placebo group)
Antioxidant group: mean age 24 (SEM 1.1) years
Placebo group: mean age 26.2 (SEM 2.0) years
Inclusion/exclusion criteria
All participants had been weight training their lower body for a minimum of 12 months
prior to testing and demonstrated a minimum strength of 1.5 times their body weight
in the barbell back squat exercise. All participants were free of the orthopaedic and
metabolic conditions that would have affected the variables of measurement
Interventions Intervention
Astaxanthin - BioAstin; 1732 mg safflower oil; haematococcus algae extract (contains 4
mg astaxanthin and 480 mg lutein)
Placebo
1732 mg safflower oil
2 capsules per day
Duration
3 weeks before and 96 hours after
Outcomes PRIMARY
Delayed onset muscle soreness in the dominant leg during knee extension using a 10 cm
visual analogue scale where 0 is “no pain” and 10 is “unbearable pain”
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Bloomer 2005 (Continued)
SECONDARY
Muscle performance 1 RM concentric strength in the knee extension
Isometric knee extensor action was performed using the modified York barbell (York, P.
A. knee extension/flexion machine. The cable length was adjusted so that the knee was
at 90 degrees flexion
Mean dynamic force was determined in the knee extension exercise using a Body-Solid
knee extension machine interfaced with a Fitrodyne dynamometer (Fitronic, Bratislava,
Slovakia)
Exercise type York knee extension machine 10 sets of 10 repetitions at 85% of 1 RM
Sources of funding The studywas supported byCyanotechCorp.Kailua-Kona,HI, and IMAGINNutrition,
Inc. Laguna Niguel, CA
Notes Authors were contacted on 3 October 2013 to request raw data for delayed onset muscle
soreness and maximal voluntary isometric contraction and responded on 1 November
2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in manuscript
Authors were contacted on 24 May 2016;
response: “Likely via coin flip or random
number selection”
Allocation concealment (selection bias) Low risk No details in manuscript
Authors were contacted on 24 May 2016;
response: “Blinding code retained by per-
son not associated with research and/or
provided in sealed envelope”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants successfully completed
testing with 100% compliance
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
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Bloomer 2005 (Continued)
Other bias Unclear risk No details on whether participants were
asked to refrain from using other supple-
ments or anti-inflammatory medication
Bloomer 2007
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 36 men mean age 25 (SD 5) years
18 participants had prior exercise and 18 had no prior exercise; only the results for the
second group were included in this review
“6 participants did not complete the study due to personal reasons (e.g. lack of time,
problems with blood donation, injury resulting from accident not to the study”
Participants withdrew from the following groups: 1 participant from no prior exercise
placebo; 2 participants from no prior exercise antioxidant group; 2 participants from
prior exercise placebo group; 1 participant from prior exercise antioxidant group
Inclusion/exclusion criteria
No participant was vegetarian or a smoker, nor did they use tobacco products, anti-
inflammatory drugs, or antioxidant supplements before (for a minimum of 6 months) or
during the study period. Eligible participants were those capable of concentrically bench
pressing a load greater or equal to their body mass, who performed resistance training
using dynamic (concentric/eccentric) muscle actions for a minimum of 1 year before
study participation (with no layoffs during this time period), and who performed upper-
body resistance exercises at least once per week the previous year
Interventions Intervention
Mixed antioxidant 1000 mg of vitamin C + 378 mg mixed tocopherols - 41 mg alpha,
3 mg beta, 84 mg delta, 250 mg gamma; and 39.5 mg mixed tocotrienols - 11 mg
alpha, 1.5 mg beta, 5 mg delta, 22 mg gamma
Placebo
Soft gel (soybean oil) and powder (cellulose) placebos were identical in appearance to
the antioxidants
2 capsules per day
Duration
14 days
Outcomes PRIMARY
Delayed onset muscle soreness, visual analogue scale (0 to 10 cm) following performance
of 2 (concentric-eccentric) repetitions of the barbell bench press exercise using a standard
20 kg barbell. 0 represents “no pain” and 10 represents “intense pain”
SECONDARY
Maximal isometric force in a bench press position measured using a customised force
plate and power rack design. The upper arm was fixed parallel to the floor with a 90
degree angle about the elbow joint and the bar was in line with the mid-sternum
Exercise type Barbell bench press 10 sets, 10 reps of 70% 1 RM
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Bloomer 2007 (Continued)
Sources of funding Supported in part by Jarrow Formulas and The National Strength and Conditioning
Association Graduate Student Research Grant
Notes Authors were contacted on 3 October 2013 to request raw data for delayed onset muscle
soreness and maximal voluntary isometric contraction and responded on 1 November
2013
In our review, only the data from the no prior exercise group were used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in manuscript
Authors were contacted on 24 May 2016;
response: “Likely via coin flip or random
number selection”
Allocation concealment (selection bias) Low risk No details in manuscript
Authors were contacted on 24 May 2016;
response: “Blinding code retained by per-
son not associated with research and/or
provided in sealed envelope”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 participants did not complete all aspects
of the study for personal reasons
Attrition rate: 17%
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study
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Bryer 2006
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory, USA
n = 18 young, untrained males who did not weight train for 6 months, mean age 24.4
(SEM 1.7) years
Inclusion/exclusion criteria
All participants were prescreened, in good health, abstained from vitamin or herbal
supplements for at least 6 months and were free of any muscular injuries
Interventions Intervention
Vitamin C supplementation (3 g per day)
Placebo
Starch pills
3 capsules per day and participants were asked to keep food records
Duration
Supplementation given 2 weeks prior and 4 days after exercise
Outcomes PRIMARY
Delayed onset muscle soreness was assessed by means of a linear scale from 1 to 10 in a
rested position and in response to palpation on the arms of the muscle where 1 is “no
pain” and 10 is “extreme pain”
SECONDARY
Isometric force was conducted on an isokinetic dynamometer (Biodex System 3 Isoki-
netic Dynamometer, Biodex Medical Systems, Shirely, NY). Participants performed 3
concentric maximum voluntary contractions (MVC) and the forces were recorded for
both the dominant and non-dominant arms through a full range of motion at a speed
of 1.75 rad/second. The highest force obtained with no movement of the lever arm was
accepted as the maximum isometric force
Range of motion was assessed on both arms using a goniometer placed on markings from
the medial aspect of th elbow of the humerus
Exercise type 70 eccentric actions using the elbow flexors
Sources of funding None
Notes Authors were contacted via email on 25 November 2013 to request data for delayed
onset muscle soreness, maximal voluntary isometric contraction and range of motion,
but did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in manuscript
Authors were contacted via email on 25
November 2013 but no information was
provided
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Bryer 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Participants were given numbered contain-
ers for the 3 capsules per day
Authors were contacted via email on 25
November 2013 but no information was
provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details provided in the manuscript
Authors were contacted via email on 25
November 2013 but no information was
provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study with
no adverse outcomes
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from us-
ing any supplements; medication and diet
was controlled in both groups
Close 2006
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; UK
n = 20 physically active males naive to downhill running
Placebo group mean age 22.1 (SEM 0.4) years (n = 10)
Vitamin C group mean age 24.2 (SEM 1.5) years (n = 10)
Inclusion/exclusion criteria
All participants were non-smokers and free from any known illness as ascertained by
questionnaire Participants taking any form of vitamin supplementation were excluded
Interventions Intervention
1 g of vitamin C supplementation
Placebo
Lactose placebo
Duration
14 days
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Close 2006 (Continued)
Outcomes PRIMARY
Delayed onset muscle soreness was measured at the gastrocnemius, anterior tibialis,
hamstrings, quadriceps, gluteals (both sides) and lower back muscles using a 10-point
visual analogue scale where 0 is “no pain” and 10 is “extreme pain”
SECONDARY
Muscle functionwas performed an isokinetic dynamometer. The test involved concentric
quadriceps muscle torque assessment at 1.06 and 5.20 rad/second as well as eccentric
quadriceps assessment at 2.6 rad/second
Muscle tenderness was measurement using pressure algometry at the gastrocnemius,
anterior tibialis, hamstrings, quadriceps, gluteals (both sides) and lower back muscles
Exercise type 30 minutes of downhill running on a treadmill at a grade of -15% at 60% VO2max
Sources of funding None
Notes No details on whether supplement was administered as a drink or a capsule or a powder
Authors were contacted to request raw data for PPT, delayed onset muscle soreness
and maximal voluntary isometric contraction on 3 October 2013 and responded on 3
December 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in manuscript
Authors were contacted via email 17 May
2016
Author response: “A random number gen-
erator to allocate into groups and from
memory they were block randomised ac-
cording to their VO2max”
Allocation concealment (selection bias) Low risk No details in manuscript
Authors were contacted via email 17 May
2016
Author response: “All supplements were
given in visually identical capsules double
blind”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study with
no adverse effects
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Close 2006 (Continued)
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study as well as any form of therapeutic in-
tervention such as massage and ice
Cobley 2011
Methods Randomised controlled trial (parallel design)
Participants Setting: Laboratory and Field; UK
n = 14 recreationally trained males mean age 24.7 (SD 4.2) years (6 in each group)
2 participants dropped out for personal reasons
Inclusion/exclusion criteria
Recreationally trained was defined as participating in physical activity of an intermittent
nature at least 3 times per week for at least 12 months. Prospective participants were
excluded if they smoked or engaged in any course of supplementation or medication (e.
g. antioxidant supplementation) that may have interfered with the study’s results
Interventions Intervention
N-acetylcysteine supplementation 50 mg/kg
Placebo
Water and cordial
Duration
6 days
Outcomes PRIMARY
Delayed onset muscle soreness was assessed by a 12-point visual analogue scale where 0
is “no pain” and 12 is “intolerable pain”. Participants were required to mark a point on
the VAS that corresponded to their perception of total muscle soreness after performing
a 90 degree squat
SECONDARY
Absolute muscle torque was determined in the dominant limb concentric quadriceps
using a Isokinetic Dynamomter (Biodex Medical Systems, Shirely, NY). Concentric
quadriceps torque was determined at 60, 180 and 300 rad/second. 3 maximal repetitions
were performed at each speed with the greatest value attained being recorded
Yo-Yo Intermittent Recovery Test Level 1. Involves the performance of consecutive 2 x
20 m shuttles separated by 10 seconds recovery intervals. Running velocity is dictated by
audio beeps and increased by 0.5 km/hour throughout the test until volitional exhaustion
ensues
Loughborough intermittent Shuttle Test was completed in a well-ventilated indoor run-
way. This consists of successive cycles of cruising at 95% VO2max (60 m), jogging at
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Cobley 2011 (Continued)
55% VO2max (60 m), walking (60 m) and maximally sprinting (20 m) between 2 pairs
of timing lights placed 20 m apart in time with audio beeps for 15 minutes
Side effects on a scale of 0 to 10
Exercise type Loughborough intermittent Shuttle Test and Yo-Yo Intermittent Recovery Test Level 1
Sources of funding None
Notes N-acetylcysteine and placebo supplementation mixed in water
Authors were contacted to request raw data for delayed onset muscle soreness, maxi-
mal voluntary isometric contraction and performance data on 3 December 2013 and
responded on 5 December 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pair-matched based on performance on the
baseline test
Allocation concealment (selection bias) Low risk Not specified in manuscript
Authors were contacted on 21 February
2017 and replied “treatment allocation was
done in sealed opaque containers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants dropped out for personal rea-
sons
Attrition rate: 14.3%
Selective reporting (reporting bias) Low risk No published protocol available
All outcomes reported at all time points
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study as well as any form of therapeutic in-
tervention such as massage and ice
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Connolly 2006
Methods Randomised controlled trial (parallel design)
Participants Setting: 2006, USA
n = 24 healthy college males and females mean age 22 (SD 4) years
Inclusion/exclusion criteria
Without upper extremity injury, or previous known history of injury. Potential partic-
ipants who indicated arm discomfort during any baseline assessments were excluded.
Participants who reported habitually participating in a strenuous resistance-training pro-
gramme involving elbow flexors, or unusual upper extremity activity were also excluded
Interventions Intervention
Vitamin C supplementation 1000 mg 3 times per day
Placebo
3 x 50 mg per day of glucose
Duration
Supplements given 3 days before and 5 days after damaging exercise
Outcomes PRIMARY
Delayed onset muscle soreness assessed at the quadriceps by a 0 to 10 visual analogue
scale where 0 is “no discomfort whatsoever” and 10 is “indicated extreme pain and
discomfort”
SECONDARY
Maximal isometric strength
Muscle tenderness scores were assessed using a standard manual muscle myometer.Mea-
surements were made just proximal to the distal tendon of the biceps. Force was applied
via the probe through a 1 cm diameter head until the participant indicated pain or dis-
comfort
Exercise type 40 maximal eccentric contractions of the elbow flexors (2 x 20)
Sources of funding None
Notes Authors were contacted on 30 October 2013 to request data for delayed onset muscle
soreness and maximal voluntary isometric contraction but did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned (no details specified in
the manuscript)
Authors have been contacted with no re-
sponse (19 May 2016)
Allocation concealment (selection bias) Unclear risk No details specified in manuscript
Authors have been contacted with no re-
sponse (19 May 2016)
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Connolly 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study as well as any form of therapeutic in-
tervention such as massage and ice. Partici-
pants who were exposed to any form of re-
sistance training were also excluded
Connolly 2006a
Methods Randomised controlled trial (cross-over design)
Separated by a 14-day washout
Participants Setting: laboratory; USA
n = 16 men (training status not specified)
Mean age vitamin C group 22.3 (SD 3.90) years
Mean age placebo group 22.6 (SD 4.6) years
Inclusion/exclusion criteria
Not specified
Authors were contacted via email on 30 October 2013 and again on 26 May 2016
Interventions Intervention
Freshly prepared tart cherry juice with commercially available apple juice. One 12 oz
bottle of juice provided at least 600 mg phenolic compounds and at least 40 mg of
anthocyanins. Each bottle contained approximately 50 to 60 cherries. 2 x 12 oz bottles
consumed daily
Placebo
Unsweetened black cherry Kool-Aid with added sugar
Duration
8 days with a 2-week washout
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Connolly 2006a (Continued)
Outcomes PRIMARY
Pain scores were obtained by asking participants to verbally rate their overall discomfort
during active elbow flexion and extension with activities of daily living on a scale of 0 to
10 where 0 is “no discomfort whatsoever” and 10 is “extreme pain and discomfort”
SECONDARY
Maximal isometric strength was tested on a modified seated arm curl bench (preacher)
with the upper arm supported by a padded bench in about 45 degrees shoulder flexion.
Isometric strength was tested at 3 different elbow flexion angles: 130, 90 and 30 degrees
Muscle tenderness scores were assessed using a standard manual muscle myometer.Mea-
surements were made just proximal to the distal tendon of the biceps. Force was applied
via the probe through a 1 cm diameter head until the participant indicated pain or dis-
comfort
Exercise type 40 (2 x 20) maximal eccentric contraction of the elbow flexors using a modified preacher
curl
Sources of funding The study was funded by Cherrypharm Inc (West Hartford, Connecticut, USA)
The authors of the study each have 2.5% equity in Cherrypharm Inc
Notes Authors were contacted on 30 October 2013 to request data for delayed onset muscle
soreness and maximal voluntary isometric contraction but did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details specified in the manuscript
Authorswere contacted via email on30Oc-
tober 2013 and again on 26 May 2016
Allocation concealment (selection bias) Unclear risk No details specified in the manuscript
Authorswere contacted via email on30Oc-
tober 2013 and again on 26 May 2016
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details specified in the manuscript
Authorswere contacted via email on30Oc-
tober 2013 and again on 26 May 2016
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
High risk 2participantswithdrewbefore completion;
unclear which group they were in
Attrition rate: 12.5%
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
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Connolly 2006a (Continued)
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study as well as any form of therapeutic in-
tervention such as massage and ice. Partici-
pants who were exposed to any form of re-
sistance training were also excluded
Drobnic 2014
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory, Spain
n = 20 male, healthy, moderately exercising (regular aerobic exercise for at least 4 hours
per week), non-smoking with no injury
Mean age 38.1 (SD 11.1) years in placebo group (n = 10)
Mean age 32.7 (SD 12.3) years in curcumin group (n = 9)
Interventions Intervention
Curcumin given as the Phytosome delivery system (Meriva) 1 g twice daily corresponding
to 200 mg curcumin twice daily
Placebo
Matched capsules
Duration
5 days - supplements taken 2 days prior to running
Outcomes PRIMARY
Delayed onset muscle soreness lower limbs when descending and climbing stairs (4-
point visual analogue scale: 0 is “no pain” and 4 is “disabling pain”). Scores were a sum
of 8 sites (anterior right thigh, posterior right thigh, anterior right leg, posterior right
leg, anterior left thigh, posterior left thigh, anterior left leg, posterior left leg)
Exercise type Downhill running test on a treadmill at grade -10% at a constant speed (anaerobic
threshold) for 45 minutes
Sources of funding Authors Stefano Togni and Fedrico are employees of Indena SpA the manufacturer of
Meriva, Giovanni Appendino is a consultant to Indena SpA
Statistical analysis assistance was funded by Indena
Notes Authors were contacted to request raw data for delayed onset muscle soreness on 18
February 2016 and responded on 18 February 2016
Risk of bias
Bias Authors’ judgement Support for judgement
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Drobnic 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised used computer software
Allocation concealment (selection bias) Unclear risk Nodetails of safeguards. Although placebo-
controlled, the sports medicine physicians
performing the exercise test beforehand
were not blinded
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Study subjects and physicians perform-
ing the radiologic and laboratory assess-
ments were blinded to treatment, whereas
the sports medicine physicians involved in
exercise testing were not.”
It is not explained why the lattermost were
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Study subjects and physicians perform-
ing the radiologic and laboratory assess-
ments were blinded to treatment, whereas
the sports medicine physicians involved in
exercise testing were not.”
It is likely that the participants reporting
DOMSwere blinded but some uncertainty
remains
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 dropout by personal decision; 5%
dropout rate
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study
Participants were familiarised with the pro-
tocol and diet was standardised
Goldfarb 2011
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 44 healthy college aged men age range 18 to 35 years
Mean age in the antioxidant group 23.8 (SEM 3.6) years (n = 21)
Mean age in the placebo group 22.8 (SEM 0.7) years (n = 20)
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Goldfarb 2011 (Continued)
Inclusion/exclusion criteria
All participants completed a medical history, diet, supplement and fitness questionnaire
to determine eligibility. Participants were non-smokers, were not on anti-inflammatory
drugs or on dietary supplements for at least 3months and refrained from these substances
throughout the study
Interventions Intervention
Fruit, vegetable and berry juice powder (7.5 mg beta-carotene, 276 mg vitamin C and
108 IU of vitamin E) (Juice Plus+, NSA, LLC, Collierville, TN)
Placebo
Microcrystalline cellulose capsules
Participants were given a sealed container and were asked to take 6 capsules per day, 3
in the morning and 3 in the afternoon
Duration
28 days
Outcomes PRIMARY
Delayed onset muscle soreness was measured at the elbow flexor with the arm rested
using a visual linear scale ranging from 1 to 10 where 1 is “no pain” and 10 is “extreme
pain”
SECONDARY
Maximal isometric strength was measured on a Biodex isokinetic dynamometer. Each
participant performed 3 maximal isometric force contractions with their non-dominant
and dominant arm elbow flexors each lasting 3 seconds with 60 seconds rest in between
each effort
Range of motion was assessed using a goniometer assessing the elbow flexors on both
arms by asking participants to flex and extend their arms at the elbows
Exercise type 4 sets of 12 repetitions of eccentric actions of the elbow flexors
Sources of funding The research study was partially supported by theNSA LLC and the University of North
Carolina Greensboro
Notes Authors were contacted on 25 November 2013 to request data for delayed onset muscle
soreness, maximal voluntary isometric contraction and range of motion but did not
respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised but no de-
tails provided in the manuscript on how
this was done
Authors were contacted on 25 November
2013 with no reply
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Goldfarb 2011 (Continued)
Allocation concealment (selection bias) Unclear risk No details in the manuscript
Authors were contacted on 25 November
2013 via email with no reply
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants did not complete the study:
2 participants were from the placebo group
and 1 participant was from the supplemen-
tation group
Attrition rate: 6.8%
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study as well as any form of therapeutic in-
tervention such as massage and ice. Partici-
pants who were exposed to any form of re-
sistance training were also excluded
He 2015
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory, USA
n = 22 moderately trained males age range 18 to 25 years
Mean age supplement group 20.5 (SD 2.3) years n = 11
Mean age placebo group 21.3 (SD 4.0) years n = 11
Inclusion/exclusion criteria
Exclusion criteria included people who smoke, take any medication that would alter
cardiovascular or metabolic function, have musculoskeletal limitations or use anti-in-
flammatory drugs. People who supplemented with vitamin C and vitamin E or other
antioxidants within 3 months prior to the study were excluded
Interventions Intervention
Capsules 100 mg vitamin C and 400 IU vitamin E ingested daily for 2 weeks
Placebo
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He 2015 (Continued)
Maltodextrin capsules identical to supplement group
Duration
17 days to 14 days before and 2 days after the downhill run
Outcomes PRIMARY
Delayed onset muscle soreness of the quadriceps, hamstrings, gluteus, gastrocnemius
and tibialis anterior using a visual analogue scale of 0 “no pain” to 6 “unbearable pain”
Exercise type 40 minutes downhill running -10% grade at 65% to 70% VO2max
Sources of funding Funded by Wastl Human Performance Laboratory, Donald L. Corrigan Professional
Development Grant and Purdue Bilsland Strategic Initiative Fellowship
Notes Compliance with supplementation was 99.4% as assessed by random capsule count
Authors were contacted to request raw data for delayed onset muscle soreness on 24
February 2016 and responded on 25 February 2016
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generator
Allocation concealment (selection bias) Low risk Double-blind
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements
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Herrlinger 2015
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 37 men between the ages of 18 and 35 years who were recreationally active
High-dose (n = 12) mean age 24.33 (SEM 1.54) years
Low-dose (n = 12) mean age 21.67 (SEM 1.12) years
Placebo (n = 13) mean age 22.69 (SEM 1) years
Inclusion/exclusion criteria
Men who were recreationally active in both resistance and cardiovascular training yet not
exercising for more that 6 hours per week were included. The training criteria required
that participants be actively performing aerobic exercise and partaking in resistance
training at least twice per week for a minimum of 3 months
Participants were excludedwhowere actively engaged in eccentricmuscle training, down-
hill running, running more that 15 miles per week or presented with certain diseases
or conditions such as HIV, hepatitis B and C, uncontrolled cardiovascular arrhythmias,
chronic obstructive pulmonary disease, emphysema, diabetes, or unresolved orthopaedic
concerns. Additional exclusion criteria included a body mass index of < 18 or > 30 kg/m
2, use of tobacco products within the previous 12 months, and regular consumption of
medications or over-the-counter therapies that might affect inflammation such as: green
or black tea, green or black tea supplements, cherry juice, vitamin E, vitamin C, aspirin,
corticosteroids, anabolic steroids or NSAIDs
Interventions Intervention
A blend of water-extracted black and green tea (Camellia sinensis) containing a minimum
of 40% total polyphenols, 1.3% theaflavins, 5% to 8% epigallocatechin-3-gallate, 7%
to 13% caffeine, and 600 ppm manganese. There were 3 groups in this study:
Group 1: high-dose (2000 mg per day polyphenolic blend) n = 12
Group 2: low-dose (1000 mg per day polyphenolic blend) n = 12
Group 3: placebo n = 13
2 capsules twice per day were consumed
Placebo
4 capsules per day of 500 mg microcrystalline cellulose excipient as 2 capsules twice per
day were consumed
Duration
13 weeks
Outcomes Primary
Muscle soreness was assessed using a 7-point Likert scale questionnaire for a variety of
muscle groups including the gastrocnemius, hamstrings, quadriceps, gluteus maximus,
lower back, abdominals and the whole body where 1 is “no pain” and 7 is “severe pain”
Secondary
Muscle strength
All muscle strength tests were performed on a Biodex System 3 dynamometer (Biodex
Medical Systems, Shirley, NY, USA). Participants performed 3 sets of quadriceps leg
extensions on their dominant leg for 12 repetitions at 120 degrees per second
Exercise type Downhill running on a treadmill consisted of running at a 10% decline for 40 minutes
at a speed associated with 65% of VO2max
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Herrlinger 2015 (Continued)
Sources of funding Source of funding for the study was Kemin Foods, L.C. All authors were employed by the
sponsor company and manufacturer of the polyphenol blend at the time of the clinical
trial
Notes The authors of Herrlinger 2015 were contacted on 3 February 2017 and again on 18
February 2017 for missing data (delayed onset muscle soreness and maximal voluntary
isometric contraction maximal voluntary isometric contraction) as these were not avail-
able in themanuscript and could not be extracted from graphs. No response was received
and this study was therefore included in the qualitative analysis but not the quantitative
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors indicate random assignment to
one of 3 groups (placebo, low-dose, high-
dose), however methods to achieve ran-
domisation were not indicated in the
manuscript
Authors contacted 3 February 2017 but no
response was received
Allocation concealment (selection bias) Low risk No details in manuscript
Authors contacted 3 February 2017 via
email but no response was received
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details in manuscript
Authors contacted 3 February 2017 via
email but no response was received
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk From 39 participants randomised 37 com-
pleted the intervention (12 each for low
and high; 13 for placebo); 1 participant was
withdrawn due to elevated creatine kinase
during follow-up testing (high-dose group)
and 1 participant was excluded due to <
80% compliance (low-dose group)
Selective reporting (reporting bias) High risk All outcomes reported at all time points
Manuscripts states that participants were
“contacted on a weekly basis by phone or
email to ask about any adverse events...” al-
though adverse effects of antioxidant sup-
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Herrlinger 2015 (Continued)
plementation were not reported
Other bias Low risk Diet diaries performed prior to and during
baseline testing, however diet was notmon-
itored during or post-intervention. Pre-test
meals not standardised for all participants
however advice provided
Howatson 2009
Methods Randomised controlled trial (parallel design)
Participants Setting: Field; UK
n = 20 moderately trained male (13) and female (7) runners
Mean age cherry juice group 37 (SD 13) years
Mean age placebo group 38 (SD 5) years
Inclusion/exclusion criteria
18 of the participants were accepted for, and completed, the 2008 LondonMarathon. All
participants completed a health screening questionnaire and a written informed consent
Interventions Intervention
Tart cherry juice blend; 2 x 8 fl oz bottles per day. One bottle of the juice contained
the equivalent of 50 to 60 cherries and provided at least 600 mg phenolic compounds,
expressed as gallic acid equivalents, 32 g of carbohydrate and at least 40 mg of antho-
cyanins. One bottle in the morning and one in the afternoon
Placebo
Fruit flavoured concentrate mixed with 8 fl oz of water
Duration
5 days before and 2 days after
Outcomes PRIMARY
Delayed onset muscle soreness was determined using a 200 mm visual analogue scale
where 0 is “no soreness” and 200 is “unbearably painful.” The participant stood with the
hands on hips and feet approximately shoulder width apart. The participant was then
asked to squat down to 90 degrees (internal joint angle) rise to the start position and
then indicate on the visual analogue scale the soreness felt in the lower limbs
SECONDARY
Maximum voluntary isometric contraction of the non-dominant knee extensors was
determined using a strain gauge (MIE Medical Research Ltd, Leeds, UK). Participants
were seated on a platform and the non-dominant ankle was attached to the strain gauge
at an internal joint angle of 80 degrees (verified by a goniometer). Participants were given
3 submaximal trials, each separated by 1 minute. Each contraction lasted approximately
3 seconds and all participants were given standardised verbal encouragement throughout
Exercise type Participants completed the 2008 London marathon. The environmental conditions on
the day were barometric pressure: 758 mmHg; temperature: 7 degrees Celsius; wind
speed: 4 km/h; relative humidity: 56%; there were intermittent showers throughout the
day
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Howatson 2009 (Continued)
2 volunteers completed themarathon distance on similar terrain 14 days after the London
Marathon
Sources of funding The authors thanked Dr Marco Cardinale from the British Olympic Association for
procuring technical support and St Mary’s University College Scholarship and Research
Support Fund for financial support of the project
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Pseudo-randomised based onpredicted fin-
ishing time. “We also attempted to balance
the number ofmale and female participants
in each group to account for possible sex
differences”
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors were contacted via email on 27
May 2016
Author reply: “allocation was based on sex
and predicted finish time. So randomised,
but stratified. ABBA style and treatments
were given in identical containers”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not specified in manuscript
Authors were contacted via email on 27
May 2016
Author reply: “Single blind”; thus the per-
sonnel were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded for participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to keep a food diary
and to refrain from taking supplements or
taking part in strenuous exercise other than
the marathon
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Hutchinson 2016
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 16 college students (24 were originally recruited)
Mean age blackcurrant group (n = 9, 7 female) 19.5 (SEM 0.3) years
Mean age placebo group (n = 8, 6 female) 20.9 (SEM 0.9) years
Inclusion/exclusion criteria
Inclusion criteria included being untrained, moderately active, between the ages of 18
and 40 years. Exclusion criteria included a recent history of ankle, knee, hip or back pain
that precluded squatting exercises, and the use of anti-inflammatory or analgesic drugs
that would reduce pain
Interventions Intervention
Commercially available blackcurrant nectar (CurrantC) was provided by CorpPharms
(Staatsburg, NY). Each 16 oz bottle contained approximately 100 g of fruit, malvidin
glucosides 193.25 mg, cyanidin glucosides 175.69 mg
Placebo
The placebo drink was produced by mixing black cherry Kool-Aid powder (Kraft,
Ryrerbrook, NY, USA) with water
Duration
8 days
Outcomes Primary
Muscle soreness was assessed during a full range squat with no external weight using a 0
to 10 scale where 0 is “no soreness” and 10 is “extreme discomfort”
Exercise type Eccentric squatting session consisted of 3 sets of 10 repetitions of eccentric contractions
using a bar weighted with 115% of the respective 1 repetition maximum
Sources of funding None
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent 3rd party completed ran-
domisation using random number genera-
tion in Excel
Allocation concealment (selection bias) Unclear risk Not indicated in the manuscript
Authors contacted on 3 February 2017 but
no response was received
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind; labels removed frombottles;
neither personnel nor participants aware of
contents
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Hutchinson 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 24 recruited, 16 completed the study (4 ill-
ness; 3 injury; 1 removed due to undertak-
ing resistance training prior to study)
Selective reporting (reporting bias) High risk All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Diet not standardised during the trial
however participants advised to maintain
normal diet and avoid anti-inflammatory
foods and drugs
Kaminski 1992
Methods Randomised controlled trial (cross-over design)
Participants Setting: laboratory; USA
n = 25 healthy college students and college employees. Of the 25 original participants, 2
dropped out of the experiment, 3 were excluded for a variety of reasons (loss of capsule
integrity, failure to properly maintain records, non-compliance with the experimental
protocol), and 1 was removed for failure to develop delayed onset muscle soreness in
either trial. Left with 19 participants (6 women and 13 men). Age rage 24 to 48 years
Inclusion/exclusion criteria
Participantswere excluded from the study if theywere older than50 years, had a sensitivity
to lactose, took analgesic or anti-inflammatory agents during the trials, participated in
rigorous athletic training, had a current musculoskeletal ailment in the legs, or took
ascorbic acid or riboflavin supplements within 3 weeks of the study
Interventions Intervention
Vitamin C 1000 mg as 3 capsules per day
Placebo
Lactose capsules
Duration
Vitamin C taken 3 days before and 7 days after exercise with a 3-week washout period
Outcomes PRIMARY
Delayed onsetmuscle soreness wasmonitored by self-reporting using a 10 cm continuous
unmarked line as a visual analogue scale anchored with 1 “have no soreness” at one end
and 10 “my soreness could not be any worse” at the other
Exercise type Strenuous eccentric work of the plantar flexors of the calf
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Kaminski 1992 (Continued)
Sources of funding None
Notes Participants were asked to refrain from using anti-inflammatory medication and other
supplements for the duration of the study
Authors were contacted to request raw data for delayed onset muscle soreness on 3
December 2013 and responded on 9 December 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a computer program
Allocation concealment (selection bias) Unclear risk No details provided in manuscript
Authors were contacted via email on 14
May 2016 with no response
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 participants dropped out and were ex-
cluded for a variety of reasons
Attrition rate: 24%
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication and
other supplements for the duration of the
study
Kerksick 2009
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 30 healthy non-resistance trained men mean age 20 (SD 1.8) years
Inclusion/exclusion criteria
Non-resistance trained men defined as less than 1 workout per month over the last 6
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Kerksick 2009 (Continued)
months. All participants were classified as low risk for cardiovascular disease with no
contraindications to exercise according to the American College of Sports Medicine. No
nutritional supplements (including multivitamins) were consumed at least 3 months
prior to the study
Interventions Interventions
1. 1800 mg N-acetyl-cysteine (NAC)
2. 1800 mg epigallocatechin gallate (EGCG)
Placebo
1000 mg glucomannan
Supplements were taken in the morning on an empty stomach and compliance was
monitored by making phone calls and participants bringing back empty bottles during
next visit
Duration
14 days
Outcomes PRIMARY
Delayed onset muscle soreness was assessed at the quadriceps along a 10 cm visual
analogue scale where 0 is “no soreness” and 10 is “extreme soreness”
SECONDARY
Peak isometric torque was assessed using a Biodex System-3 isokinetic dynamometer 9
Biodex Medical Systems, Inc, NY, USA). Prior to testing participants warmed up on
a cycle ergometer for 10 minutes. Changes in dynamic strength of the knee extensors
was assessed by having participants complete 10 maximal repetitions in a concentric and
eccentric fashion
Peak dynamic torque was measured in the dominant knee extensors, a total of 3 maximal
voluntary contractions over 5 seconds duration were completed with 60 seconds rest
in between each repetition. Participants were verbally encouraged to produce maximal
effort throughout the entire 5-second period. The peak torque exerted throughout all 3
repetitions was regarded as peak isometric torque. All isometric repetitions were com-
pleted at an angle of 90 degrees flexion
Exercise type 10 sets of 10 repetitions at an isokinetic dynamometer; 1 minute rest between sets
Sources of funding Partial funding for the study was provided by the National Strength and Condition-
ing Association through GNC Nutritional Research Grant, a Baylor University Faculty
Research Award for Darryn Willoughby, PhD and HHPR a graduate student research
award and indirect costs provided by grants awarded to Richard Kreider, PhD through
the Exercise and Sports Nutrition Laboratory while at Baylor university
Notes Authorswere contacted on2November 2013 to request rawdata for delayed onsetmuscle
soreness and maximal voluntary isometric contraction and responded on 3 December
2013
Risk of bias
Bias Authors’ judgement Support for judgement
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Kerksick 2009 (Continued)
Random sequence generation (selection
bias)
High risk Participants were matched in clusters ac-
cording to age and body weight for assign-
ment
Allocation concealment (selection bias) Low risk Clear capsules provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk A total of 3 participants did not complete
the study; 2 participants withdrew from the
study and 1 was excluded due to non-com-
pliance
Attrition rate: 10%
Selective reporting (reporting bias) Low risk No published protocol available
All outcomes reported at all time points
“No adverse outcomes were reported to the
supplementation protocol”
Other bias Low risk Food records were obtained, participants
were instructed to minimise foods high in
quercetin and were asked to refrain from
taking any other supplements or anti-in-
flammatory medication or to engage in any
other modality that could enhance recov-
ery
Krotkiewski 1994
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; Poland
n = 50 male volunteers recruited from local paper
36 to the pollen group; mean age pollen extract group 35.1 (SEM 2.62) years
14 to the placebo group; mean age placebo group 35.1 (SEM 2.62) years
Inclusion/exclusion criteria
Inclusion criteria were absence of hypertension, diabetes, cardiovascular disease, organic
brain disease, alcohol or drug dependence and any other deviation from good health, no
physical training or permanent or intensive basis and the lack of any ongoing medication
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Krotkiewski 1994 (Continued)
Interventions Intervention
Pollen extract; superoxide dismutase activity of approximately 30,000 units per gram/
Polbax (Allegon, Sweden)
Placebo
Placebo not specified
Duration
4 weeks
Outcomes PRIMARY
Delayed onset muscle soreness, visual analogue scale (0 to 10 cm) where 0 is “no pain
and discomfort” and 10 is “intense pain and discomfort.”
Exercise type A circuit exercise test which consisted of 10 minutes on the step up test, 30 minutes
cycling at 70% VO2max followed by 10 minutes on the step test. 30 minutes of cycling
at 60% VO2max followed by 10 minutes on the step test repeated twice
Sources of funding The study was supported by the Swedish Sports Council and Askers Foundation
Notes All the authors were contacted several times via email with no response. Maximal volun-
tary strength data were not reported in the manuscript either in a graph or a table and
delayed onset muscle soreness data were reported as a difference between the starting
values therefore data could not be extracted
Authors were contacted on 3 November 2016 to request data for delayed onset muscle
soreness but did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in manuscript
36 participants in experimental group and
14 in the placebo
Authors contacted several times but did not
respond
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors contacted several times but did not
respond
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Manuscript states: “tablets were given in a
double blind manner”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
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Krotkiewski 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details in manuscript
It appears as if all participants completed
the study
Authors contacted several times but did not
respond.
Selective reporting (reporting bias) High risk No protocol available
All data reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk Manuscript states: “All participants explic-
itly asked to follow their habitual style of
life, particularly with regards to diet and
physical activity”, but nodetails onwhether
participants were asked to refrain from
NSAIDs or any other supplements
Kuehl 2010
Methods Randomised controlled trial (parallel design)
Participants Setting: field; USA
n = 54 male (36) and female (18) runners participating in the Hood Coast Relay; mean
age 35.8 (SD 9.6) years; 25 participant in the placebo group and 26 participants in the
Cherry group
Inclusion/exclusion criteria
Inclusion criteria included an ability and willingness to abstain from anti-inflammatory
or pain relieving drugs, and willingness to refrain from seeking any other treatment for
symptoms of muscle damage until the competition of the study
Exclusion criteria included recent use of painmanagement methods (including acupunc-
ture, transcutaneous electrical nerve stimulation, topical medications/aesthetics, muscle
relaxants, injections or systematic steroids). Women capable of becoming pregnant com-
pleted a pregnancy test to rule out pregnancy prior to participation
Interventions Intervention
Cherry juice 10.5 oz: 600 mg phenolic compounds, 40 mg anthocyanins, 40 to 50
cherries
Placebo
Unsweetened fruit punch with added sugar to match the cherry juice
Duration
7 days before the race and 8 days during the race; total 15 days
Outcomes PRIMARY
Delayed onsetmuscle sorenesswas assessed using a standard 100mmvisual analogue scale
where 0 is “no pain” and 100 is “most severe pain.” After finishing the race, participants
completed the pain VAS for general soreness
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Kuehl 2010 (Continued)
Exercise type Hood Coast Relay - 315 km. Each participant completed 3 running segments during
the race with individual segments ranging from 5.6 (SD 2.5) km and an average total
running distance of 26.3 (SD 2.5) km
Sources of funding No external funding was provided for this study. Cherrish Corporation (Seattle. WA)
provided the cherry juice in the study
Notes 2 x 335 bottles daily prior to race
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in manuscript
Authors were contacted via email on 27
May 2016
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors were contacted via email on 27
May 2016
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants dropped out (2 from exper-
imental group and 1 from placebo due to
NSAID use)
Attrition rate: 6%
Selective reporting (reporting bias) Low risk Study protocol published in ClincalTrials.
gov (NCT00733395)
All outcomes published in study protocol
were reported in the actual study
All outcomes reported at all time points
Tart cherry juice caused mild gastrointesti-
nal distress in 1 participant
Other bias Low risk Participants were asked to refrain from
using anti-inflammatory medication, any
other supplements or seek any modality to
reduce muscle soreness
81Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Laupheimer 2014
Methods Randomised controlled trial (parallel design)
Participants Setting: field; UK
n = 7 (experimental group of 3, placebo group of 4) well trained distance runners, age
range 40 to 55 years
Originally 8 (all males) were recruited but 1 participant in the experimental group was
excluded because of a viral infection during the study
Inclusion/exclusion criteria
Inclusion criteria were male gender and age 20 to 55 years. The male gender and age
were chosen to ensure a homogenous cohort and to optimise the safety of the use of
resveratrol
Exclusion criteria included a past medical history of chronic inflammatory medical con-
ditions, muscle disorders or heart conditions, and a drug history of immune suppressants
or anti-inflammatories
Interventions Intervention
600 mg of resveratrol daily for 7 days and immediately before the marathon
2 x 100 mg tablets were taken 3 times daily
Placebo
Not specified
Duration
9 days
Outcomes PRIMARY
General soreness on both legs; delayed onset muscle soreness, 10-point visual analogue
scale: 0 “complete absence of pain” to 10 “indicating extreme soreness with noticeable
pain and stiffness at all times”
Exercise type Running the London marathon race in 2010
Sources of funding None declared
Notes Participants were asked not to alter their diet in any way and were not given any nutrition
or hydration advice prior to the race
Authors were contacted to request raw data for delayed onset muscle soreness on 18
February 2016 and responded on 18 February 2016
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer block randomisation
Allocation concealment (selection bias) Low risk Double-blind
Before randomisation 2 different sets of en-
velopes had been prepared by an indepen-
dent person not associated with the study
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Laupheimer 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported at all time points
Selective reporting (reporting bias) Low risk All outcomes reported at all time points
“None of the seven participants reported
any adverse effects during the study period
or during the marathon itself ”
Other bias Low risk Participants were asked not to alter their
diet in any way and were not given any
nutrition or hydration advice prior to the
race
Participants were instructed to avoid anti-
inflammatory medication
Lynn 2015
Methods Randomised controlled trial (single-blind, parallel design)
Participants Setting: field; UK
n = 21 (experimental group of 11, placebo group of 10; 2 participants were excluded
from the bilberry group as they failed to report to the lab to provide follow-up data),
recreationally trained runners, age range 18 to 55 years
Inclusion/exclusion criteria
Individuals with cardiovascular disease, diabetes, hypertension, gastrointestinal prob-
lems, renal disease, musculoskeletal problems, regular antioxidant or NSAIDs use, and
any food allergies were excluded from the study
Interventions Intervention
2 x 200 mL of bilberry juice daily for 5 days before completing the Sheffield Half
Marathon, on race day and for 2 days post-race
Total phenol content per 200 mL serving was 744.14 ± 81.75 mg (n = 3). and 80.04 ±
3.51 mg (n = 3) of total anthocyanins
Placebo
Energy matched control drink
Duration
8 days
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Lynn 2015 (Continued)
Outcomes PRIMARY
Delayed onset muscle soreness, 200 mm visual analogue scale, rated after a squat to a
90 angle and returning to a standing position: 0 “complete absence of pain” to 200
“indicating extreme soreness with noticeable pain and stiffness at all times”
Exercise type Sheffield half marathon
Sources of funding The study was funded by Sheffield Hallam University
Notes 2 x 200 mL of bilberry juice was consumed 5 days before the race, on the day of, and
up to 48 hours post race
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in published abstract
Authors confirmed via email on 3 February
2017 that a “random numbers generator”
was employed
Allocation concealment (selection bias) Unclear risk No details in published abstract
Authors described via email on 3 February
2017 that the “Study was single blind so in-
vestigators knew which drink each partic-
ipant got” and “drinks were given in non-
labelled container”
Adequate safeguards not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details in published abstract
Authors described via email on 3 February
2017 that the “Study was single blind so in-
vestigators knew which drink each partic-
ipant got” and “drinks were given in non-
labelled container”
Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Participants may have remained blinded
but this is not confirmed
Incomplete outcome data (attrition bias)
All outcomes
High risk No details in published abstract
Authors confirmed via email on 3 Febru-
ary 2017 that “Of the 21 participants, we
missed getting data from 2, one missed the
post race sample, and on the last day one
other person was missed - both were in the
bilberry group”
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Lynn 2015 (Continued)
Selective reporting (reporting bias) Low risk No published protocol
All data available at all time points
Personal communication: “None of the
participants reported any adverse effects
from consuming the Bilberry juice or the
placebo”
Other bias Low risk Participants were asked to complete a food
diary and were asked to refrain from using
anti-inflammatory drugs or other supple-
ments that could reduce soreness
McBride 1997
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 12 males who were recreationally weight trained for at least 1 year
Mean age placebo group 22.0 (SEM) 0.85 (n = 6)
Mean age vitamin E group 21.17 (SEM) 0.65 (n = 6)
Inclusion/exclusion criteria
All participants were required to be recreationally weight trained with resistance training
experience of at least 1 year. Participants had no medical problems (e.g. orthopaedic,
endocrine, cardiovascular) that would confound the results of this investigation
Interventions Intervention
992 mg per day of vitamin E (1200 IU)
Placebo
Identical looking cellulose capsule - no detail on contents
Duration
2 weeks
Outcomes PRIMARY
Delayed onset muscle soreness, visual analogue scale (0 to 10 cm) where 0 is “no soreness”
and 10 is “extremely sore”
Exercise type Heavy resistance exercise protocol
Sources of funding None
Notes 1 capsule taken daily
Risk of bias
Bias Authors’ judgement Support for judgement
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McBride 1997 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details in the manuscript
Authors were contacted via email on 14
May 2016 but no response
Allocation concealment (selection bias) Unclear risk No details in the manuscript
Authors were contacted via email on 14
May 2016 but no response
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details in the manuscript
Authors were contacted via email on 14
May 2016 but no response
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk Diet was controlled using food records,
however no details on whether participants
were asked to refrain from using anti-in-
flammatory medication, any other supple-
ments or seeking any modality to reduce
muscle soreness
McCormick 2016
Methods Randomised, double-blind (cross-over design)
5-week washout period
Participants Setting: field/laboratory; Australia
n = 9 highly-trained (elite) male water polo players from theWestern Australian Institute
of Sport
Mean age 18.6 (SD 1.4)
Inclusion/exclusion criteria
Not specified - authors contacted on 4 February 2017 and a reply received 8 February
2017: “Participants had to be a part of theWest Australian Institute of Sport Men’s High
Performance Water polo squad that attend daily training sessions. Participants were not
taking any vitamin supplements (as per WAIS supplements policy). Maintained daily
contact with the research group to ensure consumption of the prescribed supplement.”
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McCormick 2016 (Continued)
Interventions Intervention
90 mL daily for 6 days of tart Montmorency Cherry Juice (Prunus cerasus) concentrate
(Cherry Active, Sunbury, UK) diluted with water, such that each 30 mL serving was
made up into a 200 mL beverage. Both the cherry juice and placebo were consumed in
2 doses each day; 200 mL before morning training, and 400 mL in the evening post
training
Placebo
3 different ’off the shelf ’ cordials: lime (Woolworths select lime cordial, Australia), cran-
berry (Bickford’s cranberry juice cordial, Australia) and raspberry (Cottee’s raspberry
flavoured cordial, Australia). Cordials were mixed with food colouring and 480 mL of
water in order to closely imitate the taste, colour and carbohydrate content
Duration
6 days
Outcomes Primary
Delayed onset muscle soreness (delayed onset muscle soreness) was measured on a 0 to
10 scale in the upper body, upper legs, lower legs and overall body encompassing the
anchor points of 0 (normal; without pain or stiffness) to 10 (very painful)
Total quality of recovery was also recorded on a 6- to 20-point scale for the upper body,
upper legs, lower legs and overall body, which encompassed the anchor points 6 (very,
very poor recovery) to 20 (very, very good recovery)
Secondary
Swimming-based tests comprised of the in-water vertical jump test, 10 m sprint test, a
repeat sprint test and the Water Polo Intermittent Shuttle Test
Exercise type A fixed training regimen for 6 days. All training (technical skill, weights, and swimming)
performed during the 7-day trials was identical, and took place in the controlled envi-
ronment of the indoor Water Polo pool or gymnasium
Sources of funding Manuscript states: “Funds received from the Australian Institute of Sport and the Aus-
tralian Sports Commission”
Notes This study was only included in the qualitative analysis because the exercise paradigm
was completely different to all the other studies included in this review. The other studies
used an exercise paradigm where mechanical or whole body aerobic exercise was used
to cause muscle damage and then a range of outcomes such as muscle soreness, muscle
function, range of motion and performance were measured at various time points up to
several days after exercise. However, participants in this study had a fixed daily training
regimen for 5 continuous days performance, with outcomes being measured at the start
and then throughout the trial. Thus the severity of muscle damage caused by the daily
training regimen was not controlled
Risk of bias
Bias Authors’ judgement Support for judgement
87Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCormick 2016 (Continued)
Random sequence generation (selection
bias)
Low risk Manuscript states: “randomised, double-
blind, repeated measures, crossover de-
sign”. No specific details provided on how
randomisation was completed
Authors contacted on 4 February 2017 and
response was received on 8 February 2017:
“Each participant was assigned a partici-
pant number and randomised by a number
generator into two separate groups.”
Allocation concealment (selection bias) Low risk No specific details provided on how ran-
domisation was completed
Authors contacted on 4 February 2017
and a response was received on 8 February
2017: “Fluids were prepared (by an inde-
pendent researcher) in the absence of the
athletes and researchers involved in the per-
formance testing. PLA was made to look
and taste the same as the CJ (specific prod-
uct details within the manuscript). Bottles
were then labelled with athlete names to
ensure no mix-up.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Manuscript states: “randomised, double-
blind, repeated measures, crossover design”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No details in the manuscript
Authors contacted on 4 February 2017
and a response was received on 8 February
2017: “Initial sample size was n=11 how-
ever, two participants withdrew during the
study due to injury. These participantswere
not included in the manuscript, leaving us
with n=9.”
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk Manuscript states: “A limitation of this in-
vestigation is that the anthocyanin concen-
tration of both the commercial and placebo
supplement used was not confirmed”
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McFarlin 2016
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 28 participants (40 in all)
Mean age curcumin group (n = 16, 11 females) 20 (SD 1) years
Mean age placebo group (n = 12, 7 females) 19 (SD 2) years
“We experienced a 30% attrition/non-compliance”; it was not specified which group
these participants withdrew from
Inclusion/exclusion criteria
Exclusion criteria included regular resistance training in the previous 6 months, leg mus-
cle or orthopaedic condition, arthritis or other chronic inflammatory injury in the lower
extremity, regular ingestion of curcumin containing foods, regular anti-inflammatory
use, intake of curcumin supplementation in the pas 6 months and any other condition
that would prohibit the completion of the lower body resistance exercise protocol
Interventions Intervention
Curcumin supplementation (Longvida; Verdure Sciences Corp, Noblesville, IN) 400 mg
per dose; total study dose 2400 mg
Placebo
400 mg rice flour
Duration
2 days prior to exercise, the day of and 3 days after exercise, total duration of 6 days
Outcomes PRIMARY
Soreness was measured using a 10 cm visual analogue scale from 0 at one end “no pain”
to 10 “severe pain” at the other end. Measures of soreness were made on the thigh (i.
e. quadriceps). A gauge was applied using standard fore (20 to 30 N) over the distal,
middle and proximal thigh in a seated position with the knee fully extended and relaxed
The 3 ratings for each quadricep were added together
Exercise type 6 sets of 10 repetition of the leg press exercise with a start load set at 110% of the
estimated 1 repetition maximum
Sources of funding The study was partially funded by a grant from Verdure Sciences Corp (PI: McFarlin)
and the National Strength and Conditioning Association to the University of North
Texas
Notes Authors contacted on 4 February 2017 to request data for delayed onset muscle soreness
but no reply was received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Manuscript states: “Stratified randomiza-
tion (based on gender and initial strength)
was used to assign participants to the treat-
ment conditions to ensure similar numbers
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McFarlin 2016 (Continued)
of men and women and a balance based on
initial muscle strength between conditions”
Allocation concealment (selection bias) Unclear risk No specific details provided on how ran-
domisation was completed
Authors contacted on 4 February 2017 but
no reply was received
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Manuscript states: “Subjects were pro-
vided supplements using a double-blind
approach”. However, no specific details
were provided
Authors contacted on 4 February 2017 but
no reply was received
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Manuscript states: “we enrolled 20 subjects
per group” and “In the case of the present
study, no subjects asked to drop (sic), thus
the key source of attrition was associated
with lack of adherence to the study protocol
or sample collection.” This equates to 30%
data loss and there was an uneven dropout
rate between groups
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Manuscript states: “Exclusion criteria in-
cluded: regular resistance training in the
previous 6 months, leg muscle or ortho-
pedic condition, arthritis or other chronic
inflammatory injury in the lower extrem-
ity, regular ingestion (N2 times per week)
of curcumin containing foods, regular
NSAID use (at least 3 of 7 days), intake
of a curcumin supplement (within the past
6 months), and any other condition that
would prohibit completion of the lower
body resistance exercise protocol”
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McLeay 2012
Methods Randomised controlled trial (balanced randomised cross-over design)
30 day washout
Participants Setting: laboratory; New Zealand
n = 10 healthy active females mean age 22 (SD 1) years
Inclusion/exclusion criteria
All participants were physically active and participated in this study. All participants
were physically active and participated in recreational level resistance and aerobic-based
exercise at least twice per week. All participants had at least 1 years’ experience in training
in this manner. Participants completed a Health Screening Questionnaire to exclude
those who were at risk physically, culturally or religiously in following the protocol.
Those who passed the questionnaire were asked to provide written consent
Interventions Intervention
Blueberry smoothie 200 g blueberries 50 g banana + 200 mL apple juice. Per 100 mL,
total phenolics 168 mg/gallic acid equ.; anthocyanins 96.6 mg; phenolic acid 26 mg,
flavonoids 10.2 mg; vitamin C 45 mg; vitamin E 3 mg
Placebo
Smoothie 25 g dextrose 50 g banana + 200 mL apple juice
Duration
4 days
Outcomes PRIMARY
Delayed onset muscle soreness was recorded using a subjective 10-point scale where 0 is
“no soreness” and 10 is “very, very painful.” Participants were asked to step up (concentric
muscle action) onto a 40 cm box then step down (eccentric muscular contraction) and
the soreness was rated
SECONDARY
Muscle function was tested using an isokinetic dynamometer (Biodex Medical Systems
Inc. 2004). Range of motion of the leg was set at 60 degrees for concentric and eccentric
contractions and at 75 degrees for isometric contractions. The participants performed
5 maximal contractions of each type with each set separated by 2 minutes of recovery.
Concentric and eccentric torque was measured at an angular velocity of 30 degrees per
second
Exercise type 3 sets of 100 eccentric repetitions of the quadriceps
Sources of funding Funded by an Institute of Food, Nutrition and Human Health Postgraduate Research
Award, and the New Zealand Ministry of Science and Innovation, contract C06X0807
awarded to Plant and Food research Ltd
Notes Drinks consumed on day of exercise the again at 12 hours and 36 hours post-exercise
Risk of bias
Bias Authors’ judgement Support for judgement
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McLeay 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Author response: “A table with vertically
numbered cells 1-10 had either ‘blueber-
ries’ or ‘no blueberries’ (4 of each) next to
them.Names were then simply pulled from
a hat and typed into these cells in drawn or-
der. A simple method, yet allowed for ran-
domised allocation of treatment.”
Allocation concealment (selection bias) High risk No details in manuscript
Authors were contacted on 27 May 2016
via email
Author response: “Due to the form the
treatment was given as (smoothie), we were
unable to blind the study. Both control and
blueberry smoothies were isocaloric how-
ever. The study was a cross-over design and
both treatment and leg of damage was ran-
domised.”
Adequate safeguards not reported for the
first phase; the second phase was pre-
dictable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study with
no adverse effects
Selective reporting (reporting bias) Low risk No published protocol available
All outcomes reported at all time points
Manuscript states: “there were no reported
adverse effects from the dietary interven-
tion”
Other bias Unclear risk Participants were asked to complete a food
diary but no detail on whether partici-
pants were asked to refrain from using anti-
inflammatory drugs or other supplements
that could reduce soreness
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Meamarbashi 2011
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory, Iran
n = 20 male non-athletic university students mean age 18.2 (SD 0.4) years
Inclusion/exclusion criteria
Participants were selected based on fitness and health screening tests and recruited in
a double-blind trial. Participants with history of any type of muscle injury, chronic
inflammation, coagulation disorders, immune system impairment and cardiovascular
problems were excluded. Participants were also excluded if they regularly participated in
vigorous exercise in the previous 3 months
Interventions Intervention
Purslane extract 1200 mg given as 2 x 600 mg capsules per day
Placebo
Lactose powder placebo capsules
Duration
5 days
Outcomes PRIMARY
A general rating of muscle soreness was assessed using a 0- to 6-point scale where 0
corresponded to “no pain” and 6 to “unbearably painful”. Participants were requested
to rate the discomfort in only the quadriceps and calf regions of the right leg
SECONDARY
Knee range of motion - participants laid prone on an examination table with both knees
fully extended. The knee joint angle was determined by using a goniometer and universal
landmarks to ensure alignment. Knee flexion range was determined when the participant
maximally and voluntary flexed the knee
Maximal knee extension isometric force was evaluated using a computerised dynamome-
ter attached to an adjustable steel chain. Participant was seated on a special chair with
knee flexed at an angle of 90 degrees then the ankle was fixed by a special belt connected
to a force transducer. During a 5-second test, force-time data were recorded on amemory
card
Exercise type 7 sets of 5 minutes of continuous bench stepping exercise with 1 minute rest; 50 cm
bench height
Sources of funding Financial support was received from the university postgraduate grant (no 11-4-899).
University of Mohaghegh Ardabil, Iran
Notes 2 capsules daily
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in the manuscript
Authors were contacted by email on 25
May 2016
Response: “two groups had selection crite-
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Meamarbashi 2011 (Continued)
ria’s and randomly selected by online pro-
gram from a bigger group of volunteers”
Allocation concealment (selection bias) Low risk No details in the manuscript
Authors were contacted by email on 25
May 2016
Response: “placebo and purslane were cap-
sulated”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from us-
ing any supplements and anti-inflamma-
tory drugs or other treatment that could re-
duce soreness. Diet not controlled
Michailidis 2013
Methods Randomised, double-blind (cross-over design)
6 weeks washout period
Participants Setting: laboratory, Greece
n = 10 male recreationally active
Mean age 23.5 (SD 2.5) years
Inclusion/exclusion criteria
Participants were recreationally trained, as evidenced by their maximal oxygen consump-
tion (O2max) level (> 45 mL · kg-1 · min-1); had been engaged in systematic exercise
≥ 3 times/week for ≥ 12 months, and were non-smokers. Participants abstained from
any vigorous physical activity and the consumption of caffeine, alcohol or performance-
enhancing or antioxidant supplements and medications before (6 months) and during
the exercise trials
Exclusion criteria included a known NAC intolerance or allergy, a recent febrile illness
and history of muscle lesion and lower limb trauma
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Michailidis 2013 (Continued)
Interventions Intervention
20 mg NAC/kg per day was administered orally (Uni-Pharma) in 3 daily dosages. NAC
was dissolved in a 500 mL drink that contained water (375 mL), a sugar-free cordial
(125 mL) and a 2 g low-calorie glucose/dextrose powder to improve palatability
Placebo
Placebo solution was formulated to be identical to the NAC solution, except for the
NAC content
Duration
Supplement consumed immediately after muscle-damaging exercise and for 8 days post-
exercise
Outcomes PRIMARY
Delayed onset of muscle soreness (delayed onset muscle soreness) was determined by
palpation of the muscle belly and the distal region of the vastus medialis, vastus lateralis
and rectus femoris after a squat. Perceived soreness was rated on a scale ranging from 1
(normal) to 10 (very, very sore)
SECONDARY
Maximal knee extensor eccentric peak torque at 60°/second on an isokinetic dynamome-
ter (Isoforce)
Exercise type 300 eccentric unilateral repetitions (20 sets, 15 repetitions/set, 30-second rest between
sets) with the quadriceps muscle group at a speed of 30°/second on an Isoforce (TUR
Gmbh) isokinetic dynamometer
Sources of funding Manuscript states: “Supported by departmental funding, a grant received by Bodosakis
Foundation (Greece) for instrument purchase, and grant funding (CE-80739). APR was
supported by a National Health and Medical Research Council Career Development
Award, Australia.”
Notes Authors were contacted on 7 February 2017 to request data for delayed onset muscle
soreness and maximal voluntary isometric contraction but did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in manuscript
Authors were contacted on 7 February
2017 but did not respond
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors were contacted on 7 February
2017 but did not respond
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Manuscript states the design was double-
blind
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Michailidis 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Protocol states 20 individuals were enrolled
and 12 completed. Manuscript states that
10 males completed the study
Selective reporting (reporting bias) Low risk Published protocol available (ClinicalTri-
als.gov identifier: NCT01778309)
All data reported at all time points
Manuscript states: “Participants reported
no adverse side effects attributed to NAC
consumption”
Other bias Unclear risk 5-day diet recalls (1 recall/day) were com-
pleted before each trial and standardised
between trials
No information on NSAIDs
Nicol 2015
Methods Randomised controlled trial (cross-over design)
14-day washout
Participants Setting: laboratory; Australia
n = 17 healthy men aged between 18 and 39 years
2 withdrew from the study following acceptance due to the inability to attend testing
commitments
Inclusion/exclusion criteria
Participants were undertaking light tomoderate regular physical activity including sports
training but not doing lower limb resisted exercise
Interventions Intervention
2.5 g of curcumin
Placebo
2.5 g Avicel 105, an inert plant cellulose
5 capsules taken twice daily
Duration
5 capsules were taken twice daily for 2.5 days prior to exercise, then 5 capsules twice
daily for 2.5 days after exercise
Outcomes Primary
Muscle soreness using a 0 to 10 cm visual analogue scale where 0 is ”no pain“ and 10 is
”severe pain“. Pain was rated for a single leg squat, walking downstairs, passive strength
of the gluteals and a single leg vertical jump
Muscle tenderness was assessed using a Somedic pressure algometer (Somedic, Sollen-
tuna, Sweden) at 4 standardised points
96Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nicol 2015 (Continued)
Secondary
Jump performance was measured by a single leg vertical squat jump. The jump and reach
method using Vertec (Vertec, Vertec Sports Imports, Hilliard, OH)
Exercise type Eccentric exercise protocol consisted of 7 sets of 1- eccentric single leg press repetitions
on a leg press machine
Sources of funding Manuscript states: ”Funding from the Australian Institute of Sport“
Notes Authors were contacted on 15 March 2016 to request raw data for delayed onset muscle
soreness and counter-movement jump and they responded on 15 March 2016
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Manuscript states that the ”randomiza-
tion sequence was generated using a ran-
dom numbers table (http://www.ramdom-
izer.org)“. Secondly: ”Randomization was
applied to both the order of treatment or
placebo and to the sequence of right or left
leg use within the unilateral crossover“. It
is known that the repeated bout effects can
be observed in the non-exercised limb
Allocation concealment (selection bias) Low risk Manuscript states: ”Allocation was con-
cealed using sequentially numbered medi-
cation. Investigators and participants were
blinded by provision of the medications by
AIS nursing staff according to the random-
ization protocol.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Manuscript states: ”Investigators and par-
ticipants were blinded by provision of the
medications by AIS nursing staff according
to the randomization protocol“ and that
”the participants reported that they could
not distinguish between the treatment and
placebo“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Manuscript states” “Two withdrew from
the study following acceptance due to the
inability to attend testing commitments,
and no replacements were added due to re-
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Nicol 2015 (Continued)
source constraints.” This equates to 11%
attrition
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk No information in the manuscript regard-
ing food or using anti-inflammatory drugs
or other supplements during the trial
Nie 2004
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; China
n = 16 male junior basketball players (8 in each group)
Mean age vitamin C group 16.7 (SD 0.3) years
Mean age placebo group 16.5 (SD 0.2) years
Inclusion/exclusion criteria
Participants completed 4 to 5 training sessions a week with an average weekly training
of 12.3 (SD 1.3) hours
Interventions Intervention
800 mg of vitamin C
Placebo
No details provided other than it was identical in appearance
Duration
Vitamin C taken 3 hours before exercise and 31 hours after exercise and outcomes
measured for up to 2 days post-exercise
Outcomes PRIMARY
Delayed onset muscle soreness was evaluated in the leg extensors using a 10 cm visual
analogue scale where 0 is “complete absence of pain” and 10 is “extremely sore with
noticeable pain and stiffness at all times and the muscle and leg are difficult to use”.
Perceived soreness was done during quadriceps extension
Exercise type 10 sets of 15 full-squat jumps with 10 kg weight imposed at the waist
Sources of funding None
Notes No detail on how the supplements were administered or whether it was a drink or capsule
Risk of bias
Bias Authors’ judgement Support for judgement
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Nie 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details in manuscript
Authors were contacted via email on 26
May 2016 and responded on 27May 2016:
“distribute subjects by lot”
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors were contacted via email on 26
May 2016 and responded on 27May 2016
but did not understand the query
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No details in manuscript
Authors were contacted via email on 26
May 2016 and responded to say that all
participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk Diet was controlled 2 days before test-
ing, however no details were provided on
whether participants were instructed to
avoid other supplements or anti-inflamma-
tory drugs during the study
O’Connor 2013
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 40 untrained men (20) and women (20); age range 18 to 39
Placebo group (n = 20; 10 women) Antioxidant group (n = 2; 9 women)
Inclusion/exclusion criteria
Excluded were pregnant women, individuals engaged in vigorous activities on a regular
basis (more than once per week on average during the prior month), those with con-
traindications to exercise, those taking pain or prescription drugs (except for oral con-
traceptives), and high consumers of 55 fruits, vegetables, drinks or chocolate products
known to contain polyphenols (> 1 serving per day during the prior month)
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O’Connor 2013 (Continued)
Interventions Intervention
Grape beverage - stilbenes (resveratrol = 1.75 mg/kg), catechins (catechin = 19.7 mg/kg,
epicatechin = 12.6 mg/kg), anthocyanins (peonidin = 31.7 mg/kg, cyanidin = 125 mg/
kg, malvidin = 145.2 mg/kg) and flavanols (quercetin = 32.6 mg/kg, kaempferol = 5.6
mg/kg, isorhamnetin = 6.8 mg/kg)
Placebo
A combination of starch, sugars, cellulose, acids, dipotassium phosphate, potassium
citrate, grape flavouring and food dyes was used to create a placebo powder that matched
the composition and caloric content of the grape powder as closely as possible but without
any polyphenolic compounds
Duration
45 days
Outcomes PRIMARY
Delayed onset muscle soreness in the arm was rated in response to isometric strength
measurement trials using a 100 mm visual analogue scale where 0 is “no pain” and 100
is “extreme pain”
SECONDARY
Range of motion
Isometric strength of the elbow flexors at 90 degrees
Maximal oxygen consumption performed on a treadmill
Exercise type 3 sets of 6 repetitions were performed using the non-dominant elbow flexors with a
weight of 120% of concentric 1 RM
Sources of funding Financial support for the study was provided by the California table Grape Commission
Notes One serving of powder daily mixed with 236 mL of water
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk One investigator generated an allocation
sequence using an online random number
generator that created blocks of 2 with an
allocation ratio of 1:1 to the conditions.
A different investigator randomly assigned
participants in blocks to their groups
Allocation concealment (selection bias) Low risk Opaque containers and a clip was placed
on the nose
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind: participants as well as re-
searchers administering the intervention,
assessing the outcomes and conducting the
statistical analyses were blinded
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O’Connor 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study with
no adverse effects
Selective reporting (reporting bias) Low risk No published protocol available
All outcomes reported at all time points
Manuscript states: “No adverse events oc-
curred in response to beverage consump-
tion”
Other bias Low risk Participants were asked to record food fre-
quency and were asked to refrain from us-
ing anti-inflammatory drugs or other sup-
plements that could reduce soreness
O’Fallon 2012
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory, USA
n = 30 sedentary adults (15 men and 15 women), age range 18 to 25 years
Mean age placebo group men (n = 8) 19.5 (SD 1.1) years, mean age placebo group
women (n = 7) 19.6 (SD 1.3) years
Mean age supplement group men (n = 7) 20.9 (SD 1.8) years, mean age placebo group
women (n = 8) 20.6 (SD 1.1) years
Inclusion/exclusion criteria
Participants were sedentary to recreationally active, naive to resistance training and resis-
tance-type activities of the upper extremities for 6 months before participation, negative
(by self-report) for family history of and current musculoskeletal or metabolic impair-
ments, and not taking any dietary supplements
Interventions Intervention
First Strike Nutrition (Natick Soldier Centre, Natick MA) Bars with 1000 mg of
Quercitin (Merck, SA Brazil)
Placebo
Placebo First Strike Nutrition Bar (Natick Soldier Centre, Natick MA)
Duration
7 days
Outcomes PRIMARY
Delayed onset muscle soreness was assessed using a 100 mm visual analogue scale where
0 is “no soreness” and 100 is “unbearable pain”
Elbow flexor
SECONDARY
Resting arm angle
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O’Fallon 2012 (Continued)
Upper arm swelling
Isometric peak torque
Exercise type 24 eccentric contractions of the elbow flexors
Sources of funding Funded by the US Army contract # W911QY-07-C-0001
Notes 1 bar twice daily for 7 days
Authors were contacted to request raw data for delayed onset muscle soreness, range
of motion and maximal voluntary isometric contraction on 3 November 2013 and
responded on 3 December 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned in a permuted block
design
Allocation concealment (selection bias) Unclear risk No details in the manuscript
Authors were contacted but no reply re-
ceived
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study with-
out any adverse effects
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Food records were obtained, participants
were instructed to minimise foods high in
quercetin and were asked to refrain from
taking any other supplements, anti-inflam-
matory medication or engage in any other
modality that could enhance recovery
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Peschek 2014
Methods Randomised controlled trial (cross-over design)
Separated by a 21-day washout
Participants Setting: laboratory, USA
n = 8 well-trained male runners and triathletes age range 18 to 44 years
Inclusion/exclusion criteria
Inclusion criteria - currently training for at least 6 or more hours per week
Exclusion criteria - lower body extremity injury in the past 6 months and/or were cur-
rently taking chronic or daily doses of anti-inflammatory medication or nutritional sup-
plements. Participants who had a history of a recent illness were also excluded from the
study
Interventions Intervention
240 mL serving of carbohydrate protein beverage plus natural cocoa (350 mg flavanols)
Placebo
Placebo cocoa-based (processed with alkali) carbohydrate protein beverage (0 mg of
flavanols)
Duration
Beverage consumed 1 and 2 hours into recovery after downhill running and primary and
secondary outcomes measured for up to 2 days after exercise
Outcomes PRIMARY
Delayed onset muscle soreness at the legs (10-point visual analogue scale: 0 is “no pain
at all” and 10 is “unbearable pain”)
SECONDARY
Muscle tenderness using a force algometer (Wagner Pain Test Model FPK Algometer)
Muscle function - Quadricep Extension
Performance - 5 km running time trial
Exercise type Downhill running protocol at a -10% grade for 30 minutes at a speed equal to 70% of
VO2 max
Sources of funding Chocolate milk was provided by Darigold Co.
Notes Drinks were 240 mL per serving and consumed 1 hour post-exercise and 2 hours post-
exercise
Authors were contacted on 18 February 2016 to request data for delayed onset muscle
soreness, maximal voluntary isometric contraction and 5 km time trial but did not
respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a computer program
Allocation concealment (selection bias) Low risk Unmarked bottles
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Peschek 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind design thus personnel were
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study with-
out any adverse effects
Selective reporting (reporting bias) High risk All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were instructed to consume a
similar diet during the period of testing
and replicate diet during both trials. Partic-
ipants were instructed to refrain from tak-
ing anti-inflammatory medication
Phillips 2003
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; USA
n = 40 healthy, untrained, non-smoking males who were regularly involved with weight
training mean; age 22.1 (SEM 3.9) years (16 in the antioxidant group and 19 in the
placebo group)
Inclusion/exclusion criteria
During the screening process an extensive interview to clarify the extent and nature of
each individual’s exercise habits was conducted, specifically to ascertain whether or not
a regular weight-training programme was a component thereof. Those participants not
involved with a regular weight-training programme and with no prior history of injury
to the biceps brachii or elbow region were included in the study
Interventions Intervention
Mixed antioxidant supplement (300 mg tocopherols, 800 mg docosahexaenoate, 300
mg flavonoids, of which was 100 mg hesperetin and 200 mg quercetin)
Placebo
Sunflower oil and rice powder capsules
Duration
2 weeks of supplementation
Outcomes PRIMARY
Muscle soreness was measured using a visual analogue scale (0 to 10 cm) where 0 is “no
pain” and 10 is “extreme pain”. Soreness measures were subjectively evaluated through
palpitation for oedema at the elbow and were performed by the same researcher through-
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Phillips 2003 (Continued)
out the study
SECONDARY
Range of motion was measured as active arm flexion from full extension using standard
goniometry. Each range ofmotion value was obtained from an average of 3measurements
Exercise type 3 sets of 10 repetitions at 80% of 1 RM of elbow flexor
Sources of funding This research was supported with funding from Galileo Laboratories, Inc
Notes Supplementswere taken in the formof capsules (number of capsules per day not specified)
Authors were contacted via email on 2 November 2013 and again on 3 December
2013 to request data for delayed onset muscle soreness and maximal voluntary isometric
contraction but they did not respond
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; however, no details in the
manuscript on how this was done
Authors were contacted via email on 2
November 2013 and again on 3 December
2013 with no reply
Allocation concealment (selection bias) Unclear risk No details in the manuscript
Authors were contacted via email on 2
November 2013 and again on 3 December
2013 with no reply
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 5participantswere excluded from the study
due to complications with the blood-draw-
ing procedures, however it is unclear which
group they were from
Attrition rate = 12.5%
Selective reporting (reporting bias) Low risk No published protocol available
All outcomes reported at all time points
Manuscript states: “During the period of
supplementation, there were no reported
adverse events by any of the research sub-
jects...”
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Phillips 2003 (Continued)
Other bias Low risk Participants were asked to refrain from us-
ing any other supplements and medication
for the duration of the study
Shafat 2004
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; Ireland
n = 12 moderately fit, active, non-smoking men
Mean age vitamin C group 25 (SD 7.5) years
Mean age placebo group 20.6 (SD 1.1) years
Inclusion/exclusion criteria
All volunteers were moderately active non-smokers who had not participated in any form
of resistance training exercise in the previous 6 months. Volunteers who were currently
taking supplements in the past 6 months were excluded from the study
Interventions Intervention
500 mg vitamin C and 1200 IU vitamin E; 2 x 250 mg tablets of vitamin C + 3 tablets
400 IU each vitamin E
Placebo
Glucose
Duration
37 days
Outcomes PRIMARY
Delayed onset muscle soreness was evaluated using a questionnaire employing a visual
analogue scale for a total of 8 sites (6 sites on the anterior muscle of the upper leg and 2
sites on the posterior muscles of the upper leg). The participants were asked to palpate
the relaxed muscle and rate soreness on a scale of 1 “normal” to 10 “very very sore”.
Results were summed for the 8 sites so that no soreness is indicated by a score of 8 and
maximal muscle soreness by a score of 80
SECONDARY
Maximal voluntary concentric torque for the knee extensors was measured at an angular
velocity of 0.5 rad/s 3minutes to and 3minutes following the eccentric contraction bout
on the Con-Trex dynamometer
Isometric maximum voluntary contraction force (MVC) and electrically simulated force
of the knee extensors were measured using a custom made isometric test rig. Volunteers
were seated in the upright position with their leg connected to a pre-calibrated load cell
(Novatech, Hastings, UK). Analogue signals from the strain gauge were converted to
digital information using an A:D convertor (Powerlab 1400, ADInstruments, Oxford-
shire, UK) and were recorded on a PC. The chair was adjusted to allow attachment of
the strain gauge above the ankle with the knee at an angle of 1.57 rad (90 degrees).
For MVC, volunteers were instructed to contract maximally for 3 seconds and verbally
encouraged during their effort. 3 repetitions were performed, separated by 1 minute.
The highest peak force value of the 3 repetitions was recorded as the MVC
Exercise type 30 sets of 10 eccentric knee extensions at a velocity of 0.52 rad·s−1
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Shafat 2004 (Continued)
Sources of funding None
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in manuscript
Authors were contacted via email on 26
May 2016 and responded on 5 June 2016:
“Numbers were drawn out of a hat to de-
termine a set allocation order which was
balanced in numbers for treatment and
placebo. As participants were recruited to
the study, they were allocated to a group
according to that random allocation order.
”
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors were contacted via email on 26
May 2016 and responded on 5 June 2016:
“All volunteers were informed that they
were being supplemented. All were sup-
plied with identical labelled dispensers,
containing capsules. However, the capsules
were not identical in colour or size. We
checked, informally, at the end of the test-
ing to see if volunteers thought they were
supplemented or controlled and they really
had no idea which was which”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-identical capsules; the personnel were
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Non-identical capsules; some risk of un-
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
107Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Shafat 2004 (Continued)
Other bias Unclear risk Participants that took supplements or
smoked were excluded
No details on whether participants were
asked to refrain from using anti-inflamma-
tory drugs or other treatment modalities
that could reduce soreness
Silva 2008
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; Brazil
n = 29 healthy, male university students mean age 21.3 (SD 4) years
Inclusion/exclusion criteria
Participants were non-smokers, did not take NAC or related supplements, had not
participated in resistance training or any other form of structured exercise for at least 6
months, did not have a history of muscle lesion, and were not carriers of any disease that
might compromise the results or be aggravated by physical exercise
Interventions Intervention
N-acetylcysteine (NAC) 10 mg/kg of body mass in 3 groups as follows:
Group 1: 21 days of N-acetylcysteine (NAC) 10 mg/kg of body mass n = 8
Group 2: 14 days of N-acetylcysteine (NAC) 10 mg/kg of body mass + placebo (14 days
of NAC + 7 days of placebo) n = 8
Group 3: 21 days of placebo n = 9
Placebo
Starch capsules
Duration
21 days
Outcomes PRIMARY
Delayed onset muscle soreness at the elbow flexor using a visual analogue scale (0 to 10
cm). Participants marked their subjective rating from 0 “without pain” to 10 “extreme
pain”
Exercise type Elbow flexion and extension on the Scott bench at 80% 1 RM until exhaustion
Sources of funding The study was supported by grants from UNESC, CNPq and CAPES (Brazil)
Notes 1 capsule per day for 14 days before the exercise protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in the manuscript
Authors were contacted via email on 24
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Silva 2008 (Continued)
May 2016
Author response: “We selected the individ-
ual using a random number table. The par-
ticipants were selected and they received a
number. According with the random num-
ber tables all individuals were included in
the experimental or control groups.”
Allocation concealment (selection bias) Low risk No details in the manuscript
Authors were contacted via email on 24
May 2016
Author response: “Allocation concealment
was ensured by the use of sequentially num-
bered, dark and sealed envelopes. An inde-
pendent colleague, blinded to the allocated
treatment, did the selection and carried out
the composition of groups.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single-blind; participants were blinded but
the researchers were not
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 4 participants withdrew for personal rea-
sons
Attrition rate: 14%
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk Participants were non-smokers, did not
take any other supplements and had not
participated in resistance training or any
form of structured exercise for 6 months
Nodetails onwhether the participants used
anti-inflammatory drugs for the duration
of the study
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Silva 2010
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; Brazil
n = 27 male university students mean age 25.5 (SD 4) years
Inclusion/exclusion criteria
All participants were non-smokers, were not taking vitamin E or any other antioxidant
or related supplements, had not participated in resistance training or any other form of
structured exercise for at least 6 months, did not have a history of muscular lesions, and
were not carriers of any disease that might compromise the results or be aggravated by
physical exercise
Interventions Intervention
800 IU per day of D-a-tocopherol acetate (vitamin E); 1 capsule per day
Placebo
Starch capsules
Duration
14 days before and 7 days after (total 21 days)
Outcomes PRIMARY
Muscle soreness of the biceps muscle was assessed using a 10 cm visual analogue scale
where 0 is “no muscular soreness” and 10 is “maximum muscular soreness”
Exercise type Elbow flexion and extension on the Scott bench at an intensity of 80% of 1 RM; 3 sets
to exhaustion with 2 minutes recovery
Sources of funding The research was supported by grants fromCNPq/MCT (Brazil), CAPES/MEC (Brazil)
and USESC (Brazil)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No details in manuscript
Authors were contacted on 26 May 2016
via email
Author response: “We selected the individ-
ual using a random number table. The par-
ticipants were selected and they received a
number. According with the random num-
ber tables all individuals were included in
the experimental or control groups.”
Allocation concealment (selection bias) Low risk No details in manuscript
Authors were contacted on 26 May 2016
via email
Author response: “Allocation concealment
was ensured by the use of sequentially num-
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Silva 2010 (Continued)
bered, dark and sealed envelopes. An inde-
pendent colleague, blinded to the allocated
treatment, did the selection and carried out
the composition of groups.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 participants withdrew from the study for
personal reasons
Attrition rate: 22%
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk No data on food records reported
Participants were instructed to refrain from
taking supplements for the duration of the
study but no details on anti-inflammatory
medication
Su 2008
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; China
n = 16 athletes aged 18 to 20 years (8 males and 8 females)
Mean age 18.9 (SD 0.8) years
Inclusion/exclusion criteria
A medical exam, including measurement of height, weight, blood pressure and electro-
cardiogram was performed for each participant before the start of the study. No partici-
pants had infectious diseases or were currently taking anti-inflammatory and anti-fatigue
medicine during the study period
Interventions Intervention
80 mg of allicin supplementation
Placebo
80 mg maltodextrin
Duration
2 weeks before and 2 days after running
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Su 2008 (Continued)
Outcomes PRIMARY
Muscle soreness was assessed using the Borg CR-10 Scale where 0 is “no pain” and 10
is “maximal pain”. At the beginning of the exercise test, participants were instructed to
give CR-10 values
Exercise type Downhill running on a treadmill at a grade of -10%
Sources of funding No information in the manuscript
Authors were contacted on 2 November 2013 and 3 December 2013 via email with no
response
Notes Supplements taken as capsules daily
Authors were contacted on 2 November 2013 and 3 December 2013 via email to request
data for delayed onset muscle soreness with no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were randomly assigned into
an allicin or control group by sex and sports
participation
Allocation concealment (selection bias) Unclear risk Not specified in the manuscript
Authors were contacted on 2 November
2013 and 3 December 2013 via email with
no response
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not specified in the manuscript
Authors were contacted on 2 November
2013 and 3 December 2013 via email with
no response
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to maintain their
normal dietary habits and avoid any form
of antioxidant supplementation
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Tanabe 2015
Methods Randomised controlled trial (cross-over design)
4-week washout period
Participants Setting: laboratory; Japan
n = 14 untrained young men mean age 23.5 (SD 2.4) years
Inclusion/exclusion criteria
Participants had not been involved in any regular resistance exercise training for the past
year
Interventions Intervention
150 mg of curcumin in 6 capsules of 25 mg each
Placebo
150 mg of starch in 6 capsules of 25 mg each
Duration
1 hour before exercise and 12 hours after exercise separated by a 4-week washout
Outcomes Primary
Muscle soreness was measured using a 100 mm visual analogue scale where 0 is “no pain”
and 100 is “extremely sore.” Soreness was measured upon palpitation of the upper arm
and passively extending the elbow joint
Secondary
Range ofmotionwasmeasured by actively extending the elbow jointmaximally (extended
elbow joint) and touching the shoulder of the same side with the hand (flexed elbow
joint angle). The range of motion was defined by the difference between the 2 elbow
joints. Each angle was measured by a goniometer 3 times and the mean of the 3 measures
was used
Maximum voluntary contraction of the exercised elbow flexors was measured using the
isokinetic dynamometer in the same positioning as the eccentric exercise and the elbow
joint angle was set at 90 degrees. 3 maximal isometric contractions were performed with
a 30-second rest
Exercise type 2 bouts of eccentric exercise of the elbow flexors on a Biodex dynamometer (Biodex
System 3, USA) using 1 arm for each bout separated by 4 weeks. Each exercise bout
consisted of 50 maximal eccentric contractions of the elbow flexors at a velocity of 120
degrees per second
Sources of funding The study was supported by Theravalues Corporation, Japan
Notes Authors were contacted to request raw data for delayed onset muscle soreness, range
of motion and maximal voluntary isometric contraction on 8 December 2017 and
responded on 9 December 2017
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Manuscript states: “randomised, single-
blinded” designwas used; no additional de-
tails in the manuscript
113Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tanabe 2015 (Continued)
Authors were contacted via email on 5
February 2017 and responded on 8 Febru-
ary 2017: “One investigator (YT) assigned
and managed the order of dominant-non-
dominant and active-placebo to be coun-
terbalanced as described in manuscript.”
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors were contacted via email on 5
February 2017 and responded on 8 Febru-
ary 2017: “The subjects were allocated be-
fore the authors got any subject informa-
tion (e.g., height, weight, day of birth etc)
.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was a single-blinded design
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Authors were contacted via email on 5
February 2017 and responded on 8 Febru-
ary 2017: “all participants completed the
study”
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Manuscript states: “Subjects maintained
their normal food intake and lifestyle
habits, but abstained from strenuous phys-
ical activities, and did not take anti-inflam-
matory drugs during the study period.”
Theodorou 2011
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; Greece
n = 28 healthy, recreationally trained men
Mean age placebo group 25.6 (SEM 1.2)
Mean age vitamin C group 26.2 (SEM 1.5)
Inclusion/exclusion criteria
Men were recruited after advertising the study in the local media
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Theodorou 2011 (Continued)
Interventions Intervention
1g of vitamin C and 400 IU vitamin E
Placebo
Lactose
Duration
11 weeks
Outcomes PRIMARY
Delayed onset muscle soreness was assessed using a squat using body weight with a 0 to
10 scale where 0 is “normal” and 10 is “very sore”
SECONDARY
Range of motion
Isometric peak torque using an isokinetic dynamometer. Isometric knee extensor peak
torque at 90 degrees knee flexion was measured. The average of the 3 best maximal
voluntary contractions with the dominant leg was recorded
Exercise type Knee extensions on an isokinetic dynamometer
Sources of funding None: the authors had no personal or financial conflicts of interest
Notes 1 capsule per day
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were allocated based on age,
BMI and maximum isometric torque into
equal groups then a computer generator
was used for the assignment into groups
Allocation concealment (selection bias) Low risk No details in manuscript
Authors were emailed in 25 May 2016 via
email to request this information
Author response: “We used an independent
person and a sealed opaque envelope for the
allocation concealment.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
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Theodorou 2011 (Continued)
Selective reporting (reporting bias) Unclear risk Study protocol published (ClinicalTrials.
gov: NCT01290458)
All the outcomes published in the study
protocol were measured in the actual study
All outcomes reported at all time points
However, adverse effects of antioxidant
supplementation were not reported
Other bias Unclear risk Participants were asked to keep food
records for 3 days before testing, however
no details on whether participants were
asked to refrain from using other supple-
ments and anti-inflammatory medication
Thompson 2001
Methods Randomised controlled trial (cross-over design)
Separated by 14-day washout
Participants Setting: laboratory, UK
n = 9 male, habitually active, male university students
Mean age 28.4 (SEM 1.3) years
Inclusion/exclusion criteria
Participants who smoked or took vitamin supplements were excluded from the study
Interventions Intervention
1 g of vitamin C 2 hours before exercise
Placebo
Carbohydrate sports drink
Duration
Supplement consumed on day of test 2 hours before exercise with a 14-day washout
Outcomes PRIMARY
Delayed onset muscle soreness at the quadriceps using a 10-point (1 to 10 cm) visual
analogue scale where 0 is “not sore” and 10 is “very very sore”
SECONDARY
Isometric flexion and extension
Exercise type Loughborough Intermittent Shuttle Running Test - 90 minutes variable intensity run-
ning over 20 m distance
Sources of funding The authors acknowledged the financial support of SmithKline Beecham
Notes Supplements were ingested in a drink
Risk of bias
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Thompson 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Details not in the manuscript therefore au-
thors were contacted (19 May 2016)
“A third party independent from the in-
vestigators generated a randomisation plan
and held the sequence for allocation”
Allocation concealment (selection bias) Unclear risk Not reported in manuscript therefore au-
thors were contacted (19 May 2016)
No response received
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants complete the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk Vitamin C intake through diet was
screened through weighed food records
No detail on whether participants were
asked to refrain from using supplements or
anti-inflammatory medication
Thompson 2001a
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; UK
n = 16 physically active males (8 in the placebo group and 8 in the vitamin C group)
Mean age vitamin C group 25 (SEM 2) years
Mean age placebo group 23 (SEM 2) years
Inclusion/exclusion criteria
Participants who had smoked or took vitamin supplements were excluded from the study.
All participants regularly took part in a variety of activities but were unfamiliar with the
exercise protocol
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Thompson 2001a (Continued)
Interventions Intervention
Vitamin C supplementation; 1 g of vitamin C on day 1 followed by 400 mg/day divided
into 2 doses for 12 days
Placebo
Lactose capsules
Duration
13 days
Outcomes PRIMARY
Delayed onset muscle soreness at the quadriceps using a 10-point (0 to 10 cm) visual
analogue scale where 0 is “not sore” and 10 is “very very sore”
SECONDARY
Isometric quadriceps muscle contraction. Muscle function was assessed in the flexors and
extensors of both legs on an isokinetic dynamometer (CYBEX model 770, LUMEX,
USA)
Exercise type Loughborough Intermittent Shuttle Running Test - 90 minutes variable intensity run-
ning over 20 m distance
Sources of funding The study was financially supported by SmithKline Beecham UK
Notes 1 g given in a solution followed by 400 mg/day doses in capsule form
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Details not in the manuscript therefore au-
thors were contacted (19 May 2016)
“A third party independent from the in-
vestigators generated a randomisation plan
and held the sequence for allocation”
Allocation concealment (selection bias) Unclear risk Not reported in the manuscript therefore
authors were contacted (19 May 2016)
No response received
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the participants completed the study
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Thompson 2001a (Continued)
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants who smoked or took vitamin
supplements were excluded. No detail on
whether participants kept food records or
were instructed to refrain from taking sup-
plements for the duration of the study and
no details on avoiding anti-inflammatory
medication
Thompson 2003
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; UK
n = 16 male university students (8 participants in each group)
Mean age vitamin C group 23.6 (± SEM 1.4) years
Mean age placebo group 24.3 (± SEM 1.7) years
Inclusion/exclusion criteria
Participants who smoked or took vitamin supplements were excluded from the investi-
gation. All participants were habitually active in a variety of sports, although none were
familiar with the exercise protocol used in the present study
Interventions Intervention
200 mg vitamin C
Placebo
Carbohydrate sports drink
Duration
3 days
Outcomes PRIMARY
Delayed onset muscle soreness was rated on a 10-point scale ranging from 1 “not sore”
to 10 “very very sore.” Soreness was assessed whilst the participants actively contracted
the quadriceps
SECONDARY
Isometric quadriceps muscle contraction. Muscle function was assessed in the flexors and
extensors of both legs on an isokinetic dynamometer (CYBEX model 770, LUMEX,
USA)
Exercise type Loughborough Intermittent Shuttle Running Test - 90 minutes variable intensity run-
ning over 20 m distance
Sources of funding The authors acknowledged the financial support of SmithKline Beecham, UK
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Thompson 2003 (Continued)
Notes Supplements were ingested in a drink daily
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Details not in the manuscript therefore au-
thors were contacted (19 May 2016)
“A third party independent from the in-
vestigators generated a randomisation plan
and held the sequence for allocation”
Allocation concealment (selection bias) Unclear risk Not reported in the manuscript therefore
authors were contacted (19 May 2016)
No response received
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the participants completed the study
Selective reporting (reporting bias) High risk No published protocol
Data not reported for all outcomes
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to record food fre-
quency and to refrain from using anti-in-
flammatory drugs or other supplements
that could reduce soreness
Thompson 2004
Methods Randomised controlled trial (parallel design)
Participants Setting: laboratory; UK
n = 14 male university students
Mean age vitamin C group 25.3 (SEM 1.4) years
Mean age placebo group 22.6 (SEM 1.7) years
Inclusion/exclusion criteria
Participants who smoked or took vitamin supplements were excluded from the study.
All participants regularly took part in a variety of activities but were unfamiliar with the
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Thompson 2004 (Continued)
exercise protocol used in the study
Interventions Intervention
200 mg vitamin C
Placebo
200 mg lactose
Duration
14 days
Outcomes PRIMARY
Muscle soreness was assessed in the quadriceps using a 0 to 100 mm scale where 0 is
“normal” and 100 is “very very sore”. In order to activate the sensation of soreness, par-
ticipants assessed soreness whilst actively contracting the leg extensors against resistance
equivalent to 75% of each individual’s one repetition maximum
Exercise type 30 minutes downhill running at -18% gradient
Sources of funding None
Notes No details on how many capsules were consumed per day
Authors were contacted to request raw data for delayed onset muscle soreness on 3
November 2013 and responded on 4 November 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Details not in the manuscript therefore au-
thors were contacted (19 May 2016)
“A third party independent from the in-
vestigators generated a randomisation plan
and held the sequence for allocation”
Allocation concealment (selection bias) Unclear risk Not reported in manuscript therefore au-
thors were contacted (19 May 2016)
No response received
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All the participants completed the study
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Thompson 2004 (Continued)
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Unclear risk Vitamin C intake through diet was
screened through weighed food records
No detail on whether participants were
asked to refrain from using supplements or
anti-inflammatory medication
Trombold 2010
Methods Randomised controlled trial (cross-over design)
Separated by a 14-day washout
Participants Setting: laboratory; USA
n = 16 healthy, non-smoking, recreationally active males, mean age 24 (SD 1.4) years
Inclusion/exclusion criteria
Participants were disqualified if they had participated in resistance exercise training of any
kind in the previous 3 months, were currently participating in a formalised endurance
training programme or had previous history of upper body injury. Other exclusion
criteria included a recent weight change of more than 5 kg, history of hypertension, use
of anti-inflammatory drugs, angiotensin converting enzyme inhibitors lipid-lowering
medications or selective serotonin reuptake inhibitors
Interventions Intervention
Pomegranate juice POMWonderful 500mL twice daily, 650mg polyphenols, consisting
of 95.5% ellagitannins, 3.5% ellagic acid and 1% anthocyanins
Placebo
35 g carbohydrate + colouring and flavouring to match the pomegranate juice
Duration
2 doses per day separated by 12 hours; 2 x 9-day treatment periods separated by a 14-
day washout
Outcomes PRIMARY
Delayed onset muscle soreness of the elbow flexor muscles was determined before each
isometric strength test using a 0 to 10 visual analogue scale where 0 is “no soreness” and
10 is “unbearable soreness”. The rating was obtained before the measurement of strength
while performing unloaded elbow flexion of the tested arm
SECONDARY
Maximal isometric strength in elbow extensors was performed on a modified preacher
curl bench. Force was recorded using a load cell (LC101-500; Omega Engineering,
Stamford, CT) secured to the ground using a galvanised steel cable and a strap secured to
the waist of the participant. The participant performed 4 trials, 2 at both 150 degrees and
135 degrees of complete elbow extension, with a 180-second rest in between each trial.
Strength was reported as the average of the peak values at angles 150 and 135 degrees of
elbow flexion
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Trombold 2010 (Continued)
Exercise type 2 sets of 20 maximal eccentric elbow flexion exercises
Sources of funding The study was supported by a grant from POMWonderful, L.L.C
Notes 2 doses of 480 mL of the drink consumed daily separated by 12 hours. Participants were
reminded to take the products verbally and via email communication to consume the
experimental supplements at the required times
Authors were contacted to request raw data for delayed onset muscle soreness and maxi-
mal voluntary isometric contraction on 2 November 2013 and responded on 5 Decem-
ber 2013
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details in manuscript
Authors were contacted on 26 May 2016
via email with no response
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors were contacted on 26 May 2016
via email with no response
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from us-
ing anti-inflammatory drugs or other sup-
plements that could reduce soreness
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Trombold 2011
Methods Randomised controlled trial (cross-over design)
Separated by a 14-day washout
Participants Setting: laboratory; USA
n = 17 healthy, non-smoking, resistance-trained males; mean age 21.9 (SD 2.4) years
Inclusion/exclusion criteria
The participants were required to have been weight training for at least the last 3 months,
exercising both their upper and lower body, at least twice per week. Criteria for exclusion
were a recent weight change of > 5 kg; history of hypertension; the prescience of major
orthopaedic injury; use of anti-inflammatory drugs; over-the-counter pain medicine,
vitamin or mineral supplements, angiotensin-converting enzyme inhibitors
Interventions Intervention
Pomegranate juice 250 mL POM Wonderful (LA, USA). Each bottle contained ap-
proximately 1979 mg/L of tannins, 384 mg/L anthocyanins and 121 mg/L of ellagic
derivatives
Placebo
35 g carbohydrate + colouring and flavouring to match the pomegranate juice
Duration
44 days; 15 days of supplementation with a 14-day washout
Outcomes PRIMARY
Delayed onset muscle soreness of the elbow flexor and knee extensor muscles was deter-
mined before each isometric strength test using a 0- to 10-point visual analogue scale
where 0 is “no soreness” and 10 is “unbearable soreness”. The rating was obtained before
the measurement of strength while performing unloaded elbow flexion and knee exten-
sion on the tested arm and leg
SECONDARY
Maximal isometric strength in elbows and knee extensors was performed on a modified
preacher curl bench and modified knee extension machine respectively. The participant
performed 4 trials at both 30 and 45 degrees above elbow extension and 45 and 90 degree
below knee extension with 180-second rest in between each trial. Strength for both tests
was reported as the average peak value of each joint angle
Exercise type 3 sets of 20 maximal eccentric elbow extensions on an isokinetic dynamometer
Sources of funding The study was funded by POMWonderful, L.L.C.
Notes Supplement taken as 250 mL bottle twice daily separated by 12 hours. Participants were
reminded to take the products verbally and via email communication to consume the
experimental supplements at the required times
Authors were contacted to request raw data for delayed onset muscle soreness and maxi-
mal voluntary isometric contraction on 2 November 2013 and responded on 5 Decem-
ber 2013
Risk of bias
Bias Authors’ judgement Support for judgement
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Trombold 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details in manuscript
Authors were contacted on 26 May 2016
via email with no response
Allocation concealment (selection bias) Unclear risk No details in manuscript
Authors were contacted on 26 May 2016
via email with no response
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) High risk No published protocol available
All outcomes reported at all time points
Adverse effects of antioxidant supplemen-
tation were not reported
Other bias Low risk Participants were asked to refrain from us-
ing anti-inflammatory drugs or other sup-
plements that could reduce soreness
BMI: body mass index
EGCG: epigallocatechin gallate
IU: international units
NAC: N-acetyl-cysteine
NSAID: non-steroidal anti-inflammatory drug
PPT: pressure pain threshold
RM: repetition maximum
SD: standard deviation
SE: standard error
SEM: standard error of the mean
VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aalizadeh 2016 Although delayed onset muscle soreness is in the title, it was not measured
Authors were contacted on 4 February 2017 to confirm
Al-Nawaiseh 2016 Examined antioxidants, ibuprofen, coldwater immersion andwhey protein at the same time compared
to a placebo
Ammar 2016 Non-randomised study design
Arent 2010a Delayed onset muscle soreness not measured
Askari 2012 Delayed onset muscle soreness not measured
Askari 2013 Delayed onset muscle soreness not measured
Babaei 2009 Delayed onset muscle soreness not measured
Bell 2014 Delayed onset muscle soreness not measured
Bloomer 2006 Delayed onset muscle soreness not measured
Bowtell 2011 Delayed onset muscle soreness not measured
Tenderness was measured using a handheld algometer
Braakhuis 2014 Delayed onset muscle soreness not measured
Bunpo 2016 Delayed onset muscle soreness not measured
Carvalho-Peixoto 2015 Delayed onset muscle soreness not measured
Cavas 2004 Delayed onset muscle soreness not measured
Childs 2001a Delayed onset muscle soreness not measured
Clifford 2017 Delayed onset muscle soreness not measured
Daneshvar 2013 Delayed onset muscle soreness not measured
Dawson 2002 Delayed onset muscle soreness not measured.
Eichenberger 2010 Delayed onset muscle soreness not measured
Fuster-Munoz 2016 Delayed onset muscle soreness not measured
Gaeini 2006 Delayed onset muscle soreness not measured
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(Continued)
Gomez-Cabrera 2003 Delayed onset muscle soreness not measured
Hillman 2017 Tart cherry juice with whey protein
No tart cherry juice only group
Itoh 2000 Delayed onset muscle soreness not measured.
Jakeman 1993 Delayed onset muscle soreness not measured
Jowko 2011 Delayed onset muscle soreness not measured
Jowko 2012 Delayed onset muscle soreness not measured
Jowko 2015 Delayed onset muscle soreness not measured
Kaikkonen 1998 Delayed onset muscle soreness not measured
Keong 2006 Delayed onset muscle soreness not measured
Kim 2013 Delayed onset muscle soreness not measured
Kingsley 2006 Supplementation used was not classed as an antioxidant
Kizaki 2015 Delayed onset muscle soreness not measured
Kon 2008 Delayed onset muscle soreness not measured
Kraemer 2007 Delayed onset muscle soreness not measured
Lafay 2009 Delayed onset muscle soreness not measured
Lamprecht 2009a Delayed onset muscle soreness not measured
Leelarungrayub 2011 Delayed onset muscle soreness not measured
Lenn 2002 Antioxidant supplement was mixed with fish oils and antioxidant supplement alone not investigated
Levers 2015 Delayed onset muscle soreness not measured
Tenderness was measured using a handheld algometer
Levers 2016 Delayed onset muscle soreness not measured
Tenderness was measured using a handheld algometer
Louis 2010 Delayed onset muscle soreness not measured
Margaritis 2003 Delayed onset muscle soreness not measured
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(Continued)
Mastaloudis 2006 Delayed onset muscle soreness not measured
Matsumoto 2005 Delayed onset muscle soreness not measured
McKenna 2006 Delayed onset muscle soreness not measured
Meamarbashi 2014 Delayed onset muscle soreness not measured
Meamarbashi 2016 Delayed onset muscle soreness not measured
Medved 2004 Delayed onset muscle soreness not measured
Meydani 1993 Delayed onset muscle soreness not measured
Mizuno 1997 Delayed onset muscle soreness not measured
Morillas-Ruiz 2005 Delayed onset muscle soreness not measured
NCT01555775 Antioxidant supplement compared to another dietary supplement (protein-carbohydrate supplement)
Nieman 2010 Delayed onset muscle soreness not measured
Olesen 2013 Delayed onset muscle soreness not measured
Ostman 2012 Delayed onset muscle soreness not measured
Panza 2016 Delayed onset muscle soreness not measured
Passerieux 2015 Delayed onset muscle soreness not measured
Paulsen 2014a Delayed onset muscle soreness not measured
Petersen 2001 Delayed onset muscle soreness not measured
Pilaczynska-Szczesniak 2005 Delayed onset muscle soreness not measured
Roengrit 2014 Delayed onset muscle soreness not measured
Tenderness was measured using a handheld algometer
Roengrit 2015 Delayed onset muscle soreness not measured
Tenderness was measured using a handheld algometer
Romano-Ely 2006 Intervention was antioxidants and protein versus carbohydrate only
Protein can reduce muscle soreness
Sacheck 2003 Delayed onset muscle soreness not measured
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(Continued)
Sanchis-Gomar 2015 Delayed onset muscle soreness not measured
Santos 2016 Delayed onset muscle soreness not measured
Skarpanska-Stejnborn 2008 Delayed onset muscle soreness not measured.
Suzuki 2015 Delayed onset muscle soreness not measured
Taub 2015 Delayed onset muscle soreness not measured
Teixeira 2009a Delayed onset muscle soreness not measured
Toscano 2015 Delayed onset muscle soreness not measured
Yarahmadi 2014 Delayed onset muscle soreness not measured
Yarahmadi 2014a Delayed onset muscle soreness not measured
Yfanti 2010 Delayed onset muscle soreness not measured
Yfanti 2012 Delayed onset muscle soreness not measured
Zoppi 2006 Delayed onset muscle soreness not measured
Characteristics of ongoing studies [ordered by study ID]
NCT02281981
Trial name or title The effects of repeated bouts of downhill running and curcumin supplementation on arterial stiffness during
recovery
Methods Randomised controlled trial (double-blind)
Participants Setting: laboratory; USA
n = 17 healthy, non-smoking, resistance-trained males; mean age 21.9 (SD 2.4) years
Inclusion/exclusion criteria
The participants were required to have been weight training for at least the last 3 months, exercising both
their upper and lower body, at least twice per week. Criteria for exclusion were a recent weight change of >
5 kg; history of hypertension; the prescience of major orthopaedic injury; use of anti-inflammatory drugs;
over-the-counter pain medicine, vitamin or mineral supplements, angiotensin-converting enzyme inhibitors
Interventions Experimental
Curcumin supplement 200 mg, curcuminoids, 7 days of supplementation in capsular form
Placebo
Sucrose, capsular
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NCT02281981 (Continued)
Outcomes PRIMARY
Delayed onset muscle soreness (every 24 hours up to 72 hours post baseline); subjective analogue scale
SECONDARY
N/A
Starting date November 2014
Contact information Dr Jamie Burr, Assistant Professor, University of Prince Edward Island
Notes ClinicalTrials.gov identifier: NCT02281981
N/A: not applicable
SD: standard deviation
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D A T A A N D A N A L Y S E S
Comparison 1. Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Muscle soreness up to 6 hours;
random-effects model
21 525 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.56, -0.04]
2 Muscle soreness at 24 hours;
random-effects model
41 936 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.27, 0.00]
3 Muscle soreness at 48 hours;
random-effects model
45 1047 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.42, -0.07]
4 Muscle soreness at 72 hours;
random-effects model
28 657 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.38, -0.00]
5 Muscle soreness at 96 hours;
random-effects model
17 436 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.29, 0.19]
6 Muscle soreness (follow-ups:
120, 144 and 168 hours);
random-effects model
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 at 120 hours 4 128 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.26, 0.69]
6.2 at 144 hours 1 20 Std. Mean Difference (IV, Random, 95% CI) -0.23 [-1.11, 0.65]
6.3 at 168 hours 4 80 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.48, 0.41]
7 Muscle soreness up to 6 hours -
all at same scale (0 to 10; worst
pain)
21 525 Mean Difference (IV, Random, 95% CI) -0.52 [-0.95, -0.08]
8 Muscle soreness at 24 hours - all
at same scale (0 to 10; worst
pain)
41 936 Mean Difference (IV, Random, 95% CI) -0.17 [-0.42, 0.07]
9 Muscle soreness at 48 hours - all
at same scale (0 to 10; worst
pain)
45 1047 Mean Difference (IV, Random, 95% CI) -0.41 [-0.69, -0.12]
10 Muscle soreness at 72 hours -
all at same scale (0 to 10; worst
pain)
28 657 Mean Difference (IV, Random, 95% CI) -0.29 [-0.59, 0.02]
11 Muscle soreness at 96 hours -
all at same scale (0 to 10; worst
pain)
17 436 Mean Difference (IV, Random, 95% CI) -0.03 [-0.43, 0.37]
12 Muscle soreness at 24 hours.
Subgroup analysis by type of
exercise (whole body aerobic vs.
mechanically induced)
41 936 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.27, 0.00]
12.1 Whole body aerobic
exercise
17 338 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.33, 0.18]
12.2 Mechanically induced 24 598 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.34, -0.01]
13 Muscle soreness at 48 hours.
Subgroup analysis by type of
exercise (whole body aerobic vs.
mechanically induced)
45 1047 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.42, -0.07]
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13.1 Whole body aerobic
exercise
17 349 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.47, 0.23]
13.2 Mechanically induced 28 698 Std. Mean Difference (IV, Random, 95% CI) -0.31 [-0.50, -0.12]
14 Muscle soreness at 24 hours.
Subgroup analysis by funding
sources (funded by food
company or provider of
antioxidant supplements vs.
not funded by food company
or provider of antioxidant
supplements)
40 920 Std. Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.26, 0.01]
14.1 Company funding 17 427 Std. Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.31, 0.08]
14.2 Other funding 23 493 Std. Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.32, 0.05]
15 Muscle soreness at 48 hours.
Subgroup analysis by funding
sources (funded by food
company or provider of
antioxidant supplements vs.
not funded by food company
or provider of antioxidant
supplements)
44 1031 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.34, -0.09]
15.1 Company funding 18 443 Std. Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.38, 0.00]
15.2 Other funding 26 588 Std. Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.40, -0.06]
16 Muscle tenderness measured in
Newtons (all follow-up times)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
16.1 at 24 hours 2 52 Mean Difference (IV, Fixed, 95% CI) -1.60 [-7.64, 4.45]
16.2 at 48 hours 2 52 Mean Difference (IV, Fixed, 95% CI) -2.14 [-9.48, 5.19]
16.3 at 72 hours 2 52 Mean Difference (IV, Fixed, 95% CI) -0.34 [-6.55, 5.86]
16.4 at 96 hours 2 52 Mean Difference (IV, Fixed, 95% CI) -2.32 [-9.62, 4.99]
17 Muscle tenderness measured in
kg (all follow-up times)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Up to 6 hours 1 20 Mean Difference (IV, Fixed, 95% CI) -0.61 [-14.10, 12.
88]
17.2 at 24 hours 2 36 Mean Difference (IV, Fixed, 95% CI) 0.53 [-0.95, 2.01]
17.3 at 48 hours 2 36 Mean Difference (IV, Fixed, 95% CI) 0.52 [-1.08, 2.13]
17.4 at 72 hours 1 20 Mean Difference (IV, Fixed, 95% CI) -1.03 [-13.01, 10.
95]
17.5 at 96 hours 1 20 Mean Difference (IV, Fixed, 95% CI) -1.39 [-15.12, 12.
33]
18 30-second Wingate average
peak power output (W/kg)
(post 7 days of intervention)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19 20 m Sprint time (s) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19.1 at 24 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.2 at 48 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.3 at 120 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Maximal oxygen consumption
(mL/kg/min) (post 42 days of
supplementation)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
21 Agility (seconds) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
21.1 at 24 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.2 at 48 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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21.3 at 72 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 6 second sprint maximal power
(Watts) (all follow-up times)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 at 24 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.2 at 48 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.3 at 72 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Maximal voluntary isometric
contraction measured as
percentage change from
baseline
15 Mean Difference (IV, Fixed, 95% CI) Subtotals only
23.1 Up to 6 hours 11 255 Mean Difference (IV, Fixed, 95% CI) 5.86 [3.29, 8.42]
23.2 at 24 hours 15 375 Mean Difference (IV, Fixed, 95% CI) 2.51 [0.99, 4.04]
23.3 at 48 hours 15 375 Mean Difference (IV, Fixed, 95% CI) 4.46 [2.94, 5.98]
23.4 at 72 hours 11 277 Mean Difference (IV, Fixed, 95% CI) 3.92 [0.88, 6.96]
23.5 at 96 hours 9 252 Mean Difference (IV, Fixed, 95% CI) 5.29 [3.65, 6.92]
23.6 at 168 hours 2 36 Mean Difference (IV, Fixed, 95% CI) -7.96 [-15.96, 0.05]
24 Maximal voluntary isometric
contraction measured in
Newton metres
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
24.1 Up to 6 hours 3 84 Mean Difference (IV, Fixed, 95% CI) -1.50 [-4.77, 1.76]
24.2 at 24 hours 6 148 Mean Difference (IV, Fixed, 95% CI) -0.63 [-6.27, 5.01]
24.3 at 48 hours 6 148 Mean Difference (IV, Fixed, 95% CI) 0.80 [-5.46, 7.06]
24.4 at 72 hours 4 94 Mean Difference (IV, Fixed, 95% CI) -3.62 [-11.91, 4.67]
24.5 at 96 hours 3 96 Mean Difference (IV, Fixed, 95% CI) -4.65 [-16.21, 6.92]
24.6 at 120 hours 2 58 Mean Difference (IV, Fixed, 95% CI) -5.89 [-19.14, 7.36]
24.7 at 168 hours 1 38 Mean Difference (IV, Fixed, 95% CI) 58.0 [13.57, 102.43]
25 Maximal voluntary isometric
contraction measured in
Newtons
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
25.1 Up to 6 hours 4 73 Mean Difference (IV, Fixed, 95% CI) 6.50 [-55.11, 68.10]
25.2 at 24 hours 5 87 Mean Difference (IV, Fixed, 95% CI) 23.03 [-23.18, 69.
24]
25.3 at 48 hours 5 87 Mean Difference (IV, Fixed, 95% CI) 34.87 [-17.80, 87.
55]
25.4 at 72 hours 4 70 Mean Difference (IV, Fixed, 95% CI) -5.11 [-73.42, 63.
19]
25.5 at 96 hours 1 20 Mean Difference (IV, Fixed, 95% CI) -112.0 [-265.08, 41.
08]
25.6 at 168 hours 1 18 Mean Difference (IV, Fixed, 95% CI) -225.0 [-534.90, 84.
90]
26 Maximal voluntary isometric
contraction measured in
Newton metres per kg of body
mass
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
26.1 Up to 6 hours 2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.2 at 24 hours 2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.3 at 48 hours 2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.4 at 72 hours 2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.5 at 96 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.6 at 120 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.7 at 144 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.8 at 168 hours 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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27 Maximal voluntary isometric
contraction measured in kg
1 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
27.1 at 24 hours 1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.2 at 48 hours 1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
28 Range of motion (all follow-up
times)
10 Mean Difference (IV, Fixed, 95% CI) Subtotals only
28.1 Up to 6 hours 6 163 Mean Difference (IV, Fixed, 95% CI) -0.25 [-3.31, 2.81]
28.2 at 24 hours 9 259 Mean Difference (IV, Fixed, 95% CI) 1.03 [-0.91, 2.96]
28.3 at 48 hours 9 259 Mean Difference (IV, Fixed, 95% CI) 2.71 [0.39, 5.04]
28.4 at 72 hours 7 196 Mean Difference (IV, Fixed, 95% CI) 2.93 [-0.02, 5.87]
28.5 at 96 hours 6 158 Mean Difference (IV, Fixed, 95% CI) 0.79 [-1.26, 2.84]
28.6 at 120 hours 2 63 Mean Difference (IV, Fixed, 95% CI) -0.34 [-2.43, 1.76]
28.7 at 168 hours 1 38 Mean Difference (IV, Fixed, 95% CI) 5.0 [2.77, 7.23]
Analysis 1.1. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 1 Muscle soreness up to 6 hours; random-effects model.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 1 Muscle soreness up to 6 hours; random-effects model
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bloomer 2004 9 1.43 (0.9) 9 2.12 (0.84) 4.1 % -0.75 [ -1.72, 0.21 ]
Bloomer 2005 10 5.6 (3.7947) 10 4.2 (0.9487) 4.4 % 0.48 [ -0.41, 1.38 ]
Bloomer 2007 7 4.35 (2.4605) 8 3.78 (2.2345) 3.8 % 0.23 [ -0.79, 1.25 ]
Bryer 2006 10 1.8 (3.1623) 8 4.5 (3.1113) 4.0 % -0.82 [ -1.80, 0.16 ]
Close 2006 10 2.23 (2.98) 10 2.82 (0.89) 4.5 % -0.26 [ -1.14, 0.62 ]
Cobley 2011 6 2.8 (1.3) 6 2.6 (1.1) 3.4 % 0.15 [ -0.98, 1.29 ]
Goldfarb 2011 21 1.7 (1.833) 20 1.1 (1.3416) 6.0 % 0.36 [ -0.25, 0.98 ]
He 2015 (1) 11 1.36 (0.92) 11 2.18 (1.25) 4.5 % -0.72 [ -1.59, 0.15 ]
Howatson 2009 10 115 (52) 10 115 (60) 4.5 % 0.0 [ -0.88, 0.88 ]
Kaminski 1992 (2) 19 5 (2.7) 19 6.7 (2) 5.7 % -0.70 [ -1.36, -0.04 ]
Kerksick 2009 (3) 10 0.53 (0.88) 5 0.31 (0.56) 3.6 % 0.26 [ -0.82, 1.34 ]
Kerksick 2009 (4) 10 0.33 (0.6) 5 0.31 (0.56) 3.6 % 0.03 [ -1.04, 1.11 ]
Kuehl 2010 26 22.6 (12.6) 25 45.3 (20.5) 6.0 % -1.32 [ -1.93, -0.71 ]
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Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lynn 2015 10 27.89 (26.32) 10 81.6 (46.17) 3.9 % -1.37 [ -2.37, -0.37 ]
Meamarbashi 2011 10 1.5 (1.5) 10 2.5 (1.9) 4.4 % -0.56 [ -1.46, 0.34 ]
Michailidis 2013 10 8.1 (0.8) 10 8.3 (0.6) 4.5 % -0.27 [ -1.15, 0.61 ]
Nicol 2015 (5) 17 2 (1) 17 1 (1.15) 5.4 % 0.91 [ 0.20, 1.62 ]
Nie 2004 8 2.5 (1.1) 8 2.7 (1.6) 4.0 % -0.14 [ -1.12, 0.84 ]
Su 2008 8 2.7 (3.1113) 8 5.1 (0.8485) 3.7 % -1.00 [ -2.05, 0.06 ]
Tanabe 2015 14 1.3 (1.4) 14 1.4 (1.5) 5.2 % -0.07 [ -0.81, 0.67 ]
Trombold 2010 16 3.7 (1.8) 16 4.8 (2.1) 5.4 % -0.55 [ -1.26, 0.16 ]
Trombold 2011 (6) 17 1.94 (0.97) 17 2.56 (1.66) 5.6 % -0.45 [ -1.13, 0.24 ]
Total (95% CI) 269 256 100.0 % -0.30 [ -0.56, -0.04 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 44.53, df = 21 (P = 0.002); I2 =53%
Test for overall effect: Z = 2.23 (P = 0.025)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours antioxidant Favours placebo
(1) Soreness at the thigh muscle
(2) 10 hrs post exercise
(3) NAC vs placebo
(4) EGCG vs placebo
(5) Single leg squat
(6) Soreness at elbow
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Analysis 1.2. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 2 Muscle soreness at 24 hours; random-effects model.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 2 Muscle soreness at 24 hours; random-effects model
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Arent 2010 18 1.12 (1.4425) 18 2.09 (1.6971) 3.8 % -0.60 [ -1.27, 0.07 ]
Avery 2003 9 5.9 (3.6) 9 6 (3.9) 2.0 % -0.03 [ -0.95, 0.90 ]
Bailey 2011 20 5 (2) 18 5 (2) 4.1 % 0.0 [ -0.64, 0.64 ]
Bell 2015 8 20.67 (27.6) 8 25 (19.7) 1.8 % -0.17 [ -1.15, 0.81 ]
Bell 2016 8 60 (32.47) 8 93 (50.79) 1.7 % -0.73 [ -1.75, 0.29 ]
Bloomer 2004 9 3.54 (2.25) 9 4.2 (2.25) 2.0 % -0.28 [ -1.21, 0.65 ]
Bloomer 2005 10 5.7 (0.9487) 10 4.8 (0.9487) 2.0 % 0.91 [ -0.02, 1.84 ]
Bloomer 2007 7 7.35 (1.217) 8 5.75 (2.4324) 1.6 % 0.77 [ -0.30, 1.83 ]
Bryer 2006 10 4.2 (2.2136) 8 6.2 (2.2627) 1.8 % -0.85 [ -1.83, 0.13 ]
Close 2006 10 4.49 (2.29) 10 4.54 (2.83) 2.3 % -0.02 [ -0.90, 0.86 ]
Cobley 2011 6 3.2 (1) 6 3.1 (2.3) 1.4 % 0.05 [ -1.08, 1.18 ]
Connolly 2006 12 2.54 (2.46) 12 2.75 (2.14) 2.7 % -0.09 [ -0.89, 0.71 ]
Connolly 2006a 14 3.7 (4.49) 14 4.3 (4.8642) 3.1 % -0.12 [ -0.87, 0.62 ]
Goldfarb 2011 21 2.6 (1.3748) 20 2.3 (1.7889) 4.4 % 0.19 [ -0.43, 0.80 ]
He 2015 (1) 11 1.82 (1.25) 11 3.64 (2.01) 2.1 % -1.05 [ -1.95, -0.14 ]
Howatson 2009 10 91 (39) 10 82 (45) 2.2 % 0.20 [ -0.67, 1.08 ]
Hutchinson 2016 8 2.44 (1.8385) 8 3 (1.7819) 1.8 % -0.29 [ -1.28, 0.69 ]
Kerksick 2009 (2) 10 2.84 (1.7) 5 3.58 (2.3) 1.5 % -0.37 [ -1.45, 0.72 ]
Kerksick 2009 (3) 10 2.14 (3.83) 5 3.58 (2.3) 1.5 % -0.39 [ -1.48, 0.69 ]
Krotkiewski 1994 36 3.9 (1.8) 14 2.7 (1.1225) 4.2 % 0.72 [ 0.08, 1.35 ]
Laupheimer 2014 3 4 (2.96) 4 6.25 (4.44) 0.7 % -0.48 [ -2.03, 1.06 ]
Lynn 2015 11 52.27 (37.57) 10 53 (36.38) 2.4 % -0.02 [ -0.88, 0.84 ]
McBride 1997 6 2.33 (1.9596) 6 3.25 (2.1556) 1.3 % -0.41 [ -1.56, 0.74 ]
McFarlin 2016 16 7.4 (3.6) 12 9.9 (3.1177) 2.9 % -0.71 [ -1.49, 0.06 ]
-4 -2 0 2 4
Favours antioxidant Favours placebo
(Continued . . . )
136Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
McLeay 2012 (4) 10 2.14 (1.73) 10 2.45 (2) 2.3 % -0.16 [ -1.04, 0.72 ]
Meamarbashi 2011 10 1.8 (1.8) 10 3.2 (1.8) 2.1 % -0.74 [ -1.66, 0.17 ]
Michailidis 2013 10 8.4 (0.4) 10 8.8 (0.4) 2.0 % -0.96 [ -1.89, -0.02 ]
Nicol 2015 (5) 17 3.7 (1.32) 17 4.3 (1.98) 3.7 % -0.35 [ -1.03, 0.33 ]
Nie 2004 8 6.2 (1.7) 8 6.7 (1.2) 1.8 % -0.32 [ -1.31, 0.67 ]
O’Connor 2013 20 19.9 (21.4) 20 18.5 (14.3) 4.3 % 0.08 [ -0.54, 0.70 ]
O’Fallon 2012 15 36.03 (16.27) 15 39 (15.67) 3.3 % -0.18 [ -0.90, 0.54 ]
Peschek 2014 8 41 (18) 8 46 (17) 1.8 % -0.27 [ -1.26, 0.72 ]
Shafat 2004 6 9.5 (1.2) 6 10 (1.4) 1.3 % -0.35 [ -1.50, 0.79 ]
Su 2008 8 6.2 (3.1113) 8 7.5 (1.6971) 1.8 % -0.49 [ -1.49, 0.51 ]
Tanabe 2015 14 4.3 (2.5) 14 4.7 (1.9) 3.1 % -0.17 [ -0.92, 0.57 ]
Theodorou 2011 14 3.36 (2.06) 14 2.79 (1.42) 3.1 % 0.31 [ -0.43, 1.06 ]
Thompson 2001 9 4 (3) 9 3 (3) 2.0 % 0.32 [ -0.61, 1.25 ]
Thompson 2001a (6) 8 50 (16.9706) 8 58 (16.9706) 1.8 % -0.45 [ -1.44, 0.55 ]
Thompson 2003 8 6 (2.8284) 8 3 (2.8284) 1.6 % 1.00 [ -0.06, 2.06 ]
Thompson 2004 7 50.4 (20.37) 7 46.7 (24.07) 1.6 % 0.16 [ -0.89, 1.21 ]
Trombold 2010 16 8 (2) 16 8.2 (1.9) 3.5 % -0.10 [ -0.79, 0.59 ]
Trombold 2011 (7) 17 3.59 (2.03) 17 4.17 (1.62) 3.7 % -0.31 [ -0.99, 0.37 ]
Total (95% CI) 488 448 100.0 % -0.13 [ -0.27, 0.00 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 42.93, df = 41 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours antioxidant Favours placebo
(1) Soreness at the thigh muscle
(2) EGCG vs placebo
(3) NAC vs placebo
(4) 12 hrs post exercise
(5) Single leg squat
(6) General soreness (0-100mm)
(7) Soreness at elbow
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Analysis 1.3. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 3 Muscle soreness at 48 hours; random-effects model.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 3 Muscle soreness at 48 hours; random-effects model
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Arent 2010 18 0.88 (1.3576) 18 1.94 (1.9516) 2.8 % -0.62 [ -1.29, 0.05 ]
Avery 2003 9 4.9 (3.3) 9 5.1 (4.2) 2.1 % -0.05 [ -0.97, 0.87 ]
Bailey 2011 20 5 (2) 18 5 (2) 2.9 % 0.0 [ -0.64, 0.64 ]
Beaton 2002a 9 8.8 (3.1) 7 7.5 (2) 1.9 % 0.46 [ -0.55, 1.46 ]
Bell 2015 8 14.92 (22.51) 8 21.8 (18.72) 1.9 % -0.31 [ -1.30, 0.67 ]
Bell 2016 8 45 (27.82) 8 91 (56.08) 1.8 % -0.98 [ -2.04, 0.07 ]
Bloomer 2004 9 3.04 (2.4) 9 5.46 (3) 1.9 % -0.85 [ -1.82, 0.13 ]
Bloomer 2005 10 5.8 (2.5298) 10 4.8 (1.8974) 2.2 % 0.43 [ -0.46, 1.32 ]
Bloomer 2007 7 7.07 (0.926) 8 6.25 (2.7436) 1.8 % 0.37 [ -0.66, 1.39 ]
Bryer 2006 10 6.1 (2.2136) 8 7.5 (2.2627) 2.0 % -0.60 [ -1.55, 0.36 ]
Close 2006 10 4.34 (2.74) 10 5.59 (2.6) 2.1 % -0.45 [ -1.34, 0.44 ]
Cobley 2011 6 2.9 (1.1) 6 2.4 (0.8) 1.6 % 0.48 [ -0.68, 1.64 ]
Connolly 2006 12 2.25 (1.92) 12 2.75 (2.07) 2.4 % -0.24 [ -1.05, 0.56 ]
Connolly 2006a 14 3.3 (4.1158) 14 5 (4.49) 2.6 % -0.38 [ -1.13, 0.37 ]
Drobnic 2014 9 23.3 (7.9) 10 30.6 (7.9) 2.0 % -0.88 [ -1.84, 0.07 ]
Goldfarb 2011 21 2.8 (2.7495) 20 3 (1.3416) 3.0 % -0.09 [ -0.70, 0.52 ]
He 2015 (1) 11 1.91 (1.14) 11 3.09 (1.58) 2.2 % -0.82 [ -1.70, 0.05 ]
Howatson 2009 10 58 (39) 10 46 (28) 2.2 % 0.34 [ -0.55, 1.22 ]
Hutchinson 2016 8 2.75 (2.4324) 8 3.38 (2.1213) 1.9 % -0.26 [ -1.25, 0.72 ]
Kaminski 1992 19 3.7 (2.6) 19 5.4 (2.2) 2.9 % -0.69 [ -1.35, -0.03 ]
Kerksick 2009 (2) 10 3.49 (2.15) 5 5.51 (1.64) 1.6 % -0.95 [ -2.09, 0.20 ]
Kerksick 2009 (3) 10 3.3 (2.08) 5 5.51 (1.64) 1.6 % -1.06 [ -2.23, 0.10 ]
Krotkiewski 1994 36 2.95 (1.8) 14 1.1 (0.7483) 2.8 % 1.15 [ 0.49, 1.81 ]
Lynn 2015 10 24.6 (22.53) 10 17.7 (12.99) 2.2 % 0.36 [ -0.53, 1.24 ]
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Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
McBride 1997 6 2 (2.1311) 6 2.75 (2.278) 1.6 % -0.31 [ -1.46, 0.83 ]
McFarlin 2016 16 11.4 (3.2) 12 12.5 (2.7713) 2.5 % -0.35 [ -1.11, 0.40 ]
McLeay 2012 (4) 10 3.79 (1.88) 10 3.35 (2.25) 2.2 % 0.20 [ -0.68, 1.08 ]
Meamarbashi 2011 10 1.2 (0.7) 10 3.3 (1.6) 1.8 % -1.63 [ -2.67, -0.59 ]
Michailidis 2013 10 8.9 (0.2) 10 9.5 (0.2) 1.3 % -2.87 [ -4.20, -1.55 ]
Nicol 2015 (5) 17 3.32 (1.15) 17 4 (2.14) 2.8 % -0.39 [ -1.07, 0.29 ]
Nie 2004 8 5.1 (1.2) 8 4.9 (1.3) 1.9 % 0.15 [ -0.83, 1.13 ]
O’Connor 2013 20 18.6 (18.7) 20 17.7 (13.9) 3.0 % 0.05 [ -0.57, 0.67 ]
O’Fallon 2012 15 39.6 (21.86) 15 43.43 (17.7) 2.7 % -0.19 [ -0.90, 0.53 ]
Peschek 2014 8 45 (20) 8 34 (24) 1.9 % 0.47 [ -0.53, 1.47 ]
Shafat 2004 6 10 (1.5) 6 10.3 (1.4) 1.6 % -0.19 [ -1.33, 0.94 ]
Silva 2008 (6) 8 5.83 (1) 4 5.43 (0.8) 1.5 % 0.39 [ -0.82, 1.61 ]
Silva 2008 (7) 9 3.86 (0.7) 4 5.43 (0.8) 1.1 % -2.00 [ -3.50, -0.51 ]
Silva 2010 11 3.8 (2.6533) 10 6.2 (1.5811) 2.1 % -1.04 [ -1.97, -0.12 ]
Su 2008 8 6.2 (4.5255) 8 8 (4.2426) 1.9 % -0.39 [ -1.38, 0.60 ]
Tanabe 2015 14 5.5 (2.1) 14 6 (2.2) 2.6 % -0.23 [ -0.97, 0.52 ]
Theodorou 2011 14 6.07 (2.4) 14 5.57 (1.5) 2.6 % 0.24 [ -0.50, 0.99 ]
Thompson 2001 9 3 (3) 9 3 (3) 2.1 % 0.0 [ -0.92, 0.92 ]
Thompson 2001a (8) 8 33 (11.3137) 8 47 (22.6274) 1.8 % -0.74 [ -1.76, 0.28 ]
Thompson 2003 8 4 (2.8284) 8 3 (2.8284) 1.9 % 0.33 [ -0.65, 1.32 ]
Thompson 2004 7 64.3 (16.4) 7 48.6 (27.24) 1.7 % 0.65 [ -0.43, 1.74 ]
Trombold 2010 16 8.1 (1.6) 16 8 (2.2) 2.7 % 0.05 [ -0.64, 0.74 ]
Trombold 2011 (9) 17 2.71 (2.11) 17 3.76 (1.68) 2.8 % -0.54 [ -1.22, 0.15 ]
Total (95% CI) 549 498 100.0 % -0.24 [ -0.42, -0.07 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 86.34, df = 46 (P = 0.00029); I2 =47%
Test for overall effect: Z = 2.72 (P = 0.0065)
Test for subgroup differences: Not applicable
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(1) Soreness at the thigh muscle
(2) NAC vs placebo
(3) EGCG vs placebo
(4) 36 hours post exercise
(5) Single leg squat
(6) 14 days supplementation
(7) 21 days supplementation
(8) General soreness (0-100mm)
(9) Soreness at elbow
Analysis 1.4. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 4 Muscle soreness at 72 hours; random-effects model.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 4 Muscle soreness at 72 hours; random-effects model
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Avery 2003 9 3.6 (4.5) 9 4.3 (5.1) 3.2 % -0.14 [ -1.06, 0.79 ]
Bell 2015 8 10.79 (15.48) 8 24.42 (28.14) 2.8 % -0.57 [ -1.57, 0.44 ]
Bell 2016 8 11 (8.41) 8 33 (25.19) 2.5 % -1.11 [ -2.18, -0.03 ]
Bloomer 2004 9 2.54 (2.94) 9 5.38 (3.3) 2.9 % -0.87 [ -1.84, 0.11 ]
Bloomer 2005 10 4.1 (2.2136) 10 3.3 (1.2649) 3.4 % 0.43 [ -0.46, 1.31 ]
Bryer 2006 10 5 (2.5298) 8 5.8 (2.8284) 3.1 % -0.29 [ -1.22, 0.65 ]
Close 2006 10 2.96 (2.21) 10 3.24 (2.09) 3.4 % -0.12 [ -1.00, 0.75 ]
Cobley 2011 6 3.6 (1.5) 6 2.3 (2.4) 2.2 % 0.60 [ -0.57, 1.77 ]
Connolly 2006 12 2.58 (2.07) 12 2.16 (1.93) 3.9 % 0.20 [ -0.60, 1.01 ]
Connolly 2006a 14 2.2 (1.1225) 3 3 (1.5588) 1.9 % -0.64 [ -1.91, 0.63 ]
Goldfarb 2011 21 1.8 (1.833) 20 2.4 (2.2361) 5.5 % -0.29 [ -0.90, 0.33 ]
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Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
He 2015 (1) 11 0.82 (0.75) 11 1.73 (1.42) 3.4 % -0.77 [ -1.64, 0.10 ]
Hutchinson 2016 8 1.38 (2.0082) 8 1.63 (1.3011) 2.9 % -0.14 [ -1.12, 0.84 ]
Kerksick 2009 (2) 10 3.23 (1.96) 5 4.35 (2.17) 2.4 % -0.52 [ -1.62, 0.58 ]
Kerksick 2009 (3) 10 2.61 (1.99) 5 4.35 (2.17) 2.3 % -0.80 [ -1.92, 0.32 ]
Krotkiewski 1994 36 1.6 (1.8) 14 0.5 (0.7483) 5.3 % 0.68 [ 0.05, 1.32 ]
McFarlin 2016 16 4.4 (3.6) 12 5.2 (3.4641) 4.3 % -0.22 [ -0.97, 0.53 ]
McLeay 2012 (4) 10 2.65 (1.44) 10 2.53 (1.6) 3.4 % 0.08 [ -0.80, 0.95 ]
Michailidis 2013 10 8 (0.2) 10 8.5 (0.2) 2.1 % -2.39 [ -3.60, -1.19 ]
O’Fallon 2012 15 31.2 (26.94) 15 30.9 (23.94) 4.6 % 0.01 [ -0.70, 0.73 ]
Phillips 2003 16 3.69 (9.52) 19 3.18 (7.4101) 5.0 % 0.06 [ -0.61, 0.72 ]
Tanabe 2015 14 4.8 (2.5) 14 5.2 (2.3) 4.3 % -0.16 [ -0.90, 0.58 ]
Theodorou 2011 14 5.21 (1.67) 14 5.79 (1.67) 4.3 % -0.34 [ -1.08, 0.41 ]
Thompson 2001 9 2 (1.2) 9 2 (1.2) 3.2 % 0.0 [ -0.92, 0.92 ]
Thompson 2001a (5) 8 20 (14.1421) 8 18 (11.3137) 2.9 % 0.15 [ -0.83, 1.13 ]
Thompson 2003 8 3 (2.8284) 8 2 (1.1313) 2.8 % 0.44 [ -0.56, 1.43 ]
Thompson 2004 7 39.3 (20.63) 7 35.3 (25.39) 2.6 % 0.16 [ -0.89, 1.21 ]
Trombold 2010 16 5 (2.2) 16 5.9 (2.9) 4.7 % -0.34 [ -1.04, 0.36 ]
Trombold 2011 (6) 17 1.64 (2.09) 17 2.41 (1.7) 4.9 % -0.39 [ -1.07, 0.28 ]
Total (95% CI) 352 305 100.0 % -0.19 [ -0.38, 0.00 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 38.10, df = 28 (P = 0.10); I2 =27%
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
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Favours antioxidant Favours placebo
(1) Soreness at the thigh muscle
(2) NAC vs placebo
(3) EGCG vs placebo
(4) 60 hrs post exercise
(5) General soreness (0-100mm)
(6) Soreness at elbow
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Analysis 1.5. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 5 Muscle soreness at 96 hours; random-effects model.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 5 Muscle soreness at 96 hours; random-effects model
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bloomer 2004 9 1.81 (1.5) 9 3.24 (2.04) 4.5 % -0.76 [ -1.73, 0.21 ]
Bloomer 2005 10 3.7 (2.2136) 10 1.5 (1.2649) 4.5 % 1.17 [ 0.20, 2.13 ]
Bryer 2006 10 3.5 (2.5298) 8 4.8 (2.5456) 4.7 % -0.49 [ -1.44, 0.46 ]
Close 2006 10 1.46 (1.66) 10 1.3 (1.21) 5.2 % 0.11 [ -0.77, 0.98 ]
Cobley 2011 6 2.7 (1.4) 6 2.1 (2) 3.5 % 0.32 [ -0.82, 1.46 ]
Connolly 2006 12 1.66 (1.92) 12 0.71 (0.91) 5.7 % 0.61 [ -0.21, 1.43 ]
Connolly 2006a 14 1.2 (0.7483) 14 1.4 (1.1225) 6.6 % -0.20 [ -0.95, 0.54 ]
Krotkiewski 1994 36 1.5 (1.8) 14 0.2 (0.7483) 7.9 % 0.81 [ 0.17, 1.45 ]
McFarlin 2016 16 1 (4) 12 2.4 (3.1177) 6.4 % -0.37 [ -1.13, 0.38 ]
Michailidis 2013 10 5.2 (1.2) 10 5.6 (0.4) 5.1 % -0.43 [ -1.32, 0.46 ]
O’Fallon 2012 15 18.54 (18.72) 15 16.04 (18.45) 6.9 % 0.13 [ -0.59, 0.85 ]
Silva 2008 (1) 8 1.67 (0.8) 4 1.84 (0.7) 3.2 % -0.20 [ -1.41, 1.00 ]
Silva 2008 (2) 9 1.29 (0.5) 4 1.84 (0.7) 3.0 % -0.91 [ -2.16, 0.34 ]
Silva 2010 11 1.2 (1.6583) 10 2.3 (2.2136) 5.2 % -0.54 [ -1.42, 0.33 ]
Tanabe 2015 14 2.9 (2.9) 14 3.4 (2.6) 6.6 % -0.18 [ -0.92, 0.57 ]
Theodorou 2011 14 2.78 (1.25) 14 3.21 (1.48) 6.5 % -0.30 [ -1.05, 0.44 ]
Trombold 2010 16 3.6 (2.3) 16 3.8 (2.1) 7.1 % -0.09 [ -0.78, 0.60 ]
Trombold 2011 (3) 17 0.71 (1.49) 17 0.88 (0.86) 7.4 % -0.14 [ -0.81, 0.54 ]
Total (95% CI) 237 199 100.0 % -0.05 [ -0.29, 0.19 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 24.46, df = 17 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Favours antioxidant Favours placebo
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(2) 21 days supplementaton
(3) Soreness at elbow
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Analysis 1.6. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 6 Muscle soreness (follow-ups: 120, 144 and 168 hours); random-effects model.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 6 Muscle soreness (follow-ups: 120, 144 and 168 hours); random-effects model
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 at 120 hours
Krotkiewski 1994 36 0.9 (1.2) 14 0.1 (0.3742) 29.6 % 0.75 [ 0.12, 1.39 ]
Michailidis 2013 10 3.5 (1) 10 3.8 (0.2) 19.7 % -0.40 [ -1.29, 0.49 ]
O’Fallon 2012 15 8.79 (11.09) 15 8.77 (16.45) 26.0 % 0.00 [ -0.71, 0.72 ]
Theodorou 2011 14 1.64 (0.84) 14 1.43 (0.65) 24.7 % 0.27 [ -0.47, 1.02 ]
Subtotal (95% CI) 75 53 100.0 % 0.21 [ -0.26, 0.69 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 4.94, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 0.88 (P = 0.38)
2 at 144 hours
Michailidis 2013 10 2.4 (1.7) 10 2.7 (0.4) 100.0 % -0.23 [ -1.11, 0.65 ]
Subtotal (95% CI) 10 10 100.0 % -0.23 [ -1.11, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
3 at 168 hours
Michailidis 2013 10 1.5 (0.8) 10 1.6 (0.6) 26.1 % -0.14 [ -1.01, 0.74 ]
Phillips 2003 16 0.68 (2.04) 19 0.68 (0.741) 45.5 % 0.0 [ -0.67, 0.67 ]
Silva 2008 (1) 9 0.0001 (0.0001) 4 0 (0.0001) 14.5 % 0.0 [ -1.18, 1.18 ]
Silva 2010 (2) 8 0.0001 (0.0001) 4 0 (0.0001) 14.0 % 0.0 [ -1.20, 1.20 ]
Subtotal (95% CI) 43 37 100.0 % -0.04 [ -0.48, 0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
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Analysis 1.7. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 7 Muscle soreness up to 6 hours - all at same scale (0 to 10; worst pain).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 7 Muscle soreness up to 6 hours - all at same scale (0 to 10; worst pain)
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bloomer 2004 9 1.43 (0.9) 9 2.12 (0.84) 6.4 % -0.69 [ -1.49, 0.11 ]
Bloomer 2005 10 5.6 (3.7947) 10 4.2 (0.9487) 2.3 % 1.40 [ -1.02, 3.82 ]
Bloomer 2007 7 4.35 (2.4605) 8 3.77 (2.2345) 2.4 % 0.58 [ -1.81, 2.97 ]
Bryer 2006 10 0.89 (3.514) 8 3.89 (3.457) 1.5 % -3.00 [ -6.24, 0.24 ]
Close 2006 10 2.23 (2.98) 10 2.82 (0.89) 3.2 % -0.59 [ -2.52, 1.34 ]
Cobley 2011 6 2.33 (1.083) 6 2.17 (0.917) 5.3 % 0.16 [ -0.98, 1.30 ]
Goldfarb 2011 21 0.778 (2.037) 20 0.11 (1.491) 5.4 % 0.67 [ -0.42, 1.76 ]
He 2015 (1) 11 2.27 (1.533) 11 3.63 (2.083) 4.1 % -1.36 [ -2.89, 0.17 ]
Howatson 2009 10 5.75 (2.6) 10 5.75 (3) 2.3 % 0.0 [ -2.46, 2.46 ]
Kaminski 1992 (2) 19 5 (2.7) 19 6.7 (2) 4.2 % -1.70 [ -3.21, -0.19 ]
Kerksick 2009 (3) 10 0.33 (0.6) 5 0.31 (0.56) 7.1 % 0.02 [ -0.60, 0.64 ]
Kerksick 2009 (4) 10 0.53 (0.88) 5 0.31 (0.56) 6.7 % 0.22 [ -0.51, 0.95 ]
Kuehl 2010 26 2.26 (1.26) 25 4.53 (2.05) 6.0 % -2.27 [ -3.21, -1.33 ]
Lynn 2015 10 1.39 (1.316) 10 4.08 (2.309) 3.8 % -2.69 [ -4.34, -1.04 ]
Meamarbashi 2011 10 2.5 (2.5) 10 4.17 (3.167) 2.2 % -1.67 [ -4.17, 0.83 ]
Michailidis 2013 10 8.1 (0.8) 10 8.3 (0.6) 7.0 % -0.20 [ -0.82, 0.42 ]
Nicol 2015 (5) 17 2 (1) 17 1 (1.15) 6.7 % 1.00 [ 0.28, 1.72 ]
Nie 2004 8 2.5 (1.1) 8 2.7 (1.6) 4.6 % -0.20 [ -1.55, 1.15 ]
Su 2008 8 2.7 (3.1113) 8 5.1 (0.8485) 2.6 % -2.40 [ -4.63, -0.17 ]
Tanabe 2015 14 1.3 (1.4) 14 1.4 (1.5) 5.5 % -0.10 [ -1.17, 0.97 ]
Trombold 2010 16 3.7 (1.8) 16 4.8 (2.1) 4.6 % -1.10 [ -2.46, 0.26 ]
Trombold 2011 (6) 17 1.94 (0.97) 17 2.56 (1.66) 6.0 % -0.62 [ -1.53, 0.29 ]
Total (95% CI) 269 256 100.0 % -0.52 [ -0.95, -0.08 ]
Heterogeneity: Tau2 = 0.61; Chi2 = 61.90, df = 21 (P<0.00001); I2 =66%
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Not applicable
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(1) Soreness at the thigh muscle
(2) 10 hrs post exercise
(3) EGCG vs placebo
(4) NAC vs placebo
(5) Single leg squat
(6) Soreness at elbow
Analysis 1.8. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 8 Muscle soreness at 24 hours - all at same scale (0 to 10; worst pain).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 8 Muscle soreness at 24 hours - all at same scale (0 to 10; worst pain)
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Arent 2010 18 1.12 (1.4425) 18 2.09 (1.6971) 3.9 % -0.97 [ -2.00, 0.06 ]
Avery 2003 9 5.9 (3.6) 9 6 (3.9) 0.5 % -0.10 [ -3.57, 3.37 ]
Bailey 2011 20 5 (2) 18 5 (2) 2.8 % 0.0 [ -1.27, 1.27 ]
Bell 2015 8 1.03 (1.38) 8 1.25 (0.99) 3.2 % -0.22 [ -1.40, 0.96 ]
Bell 2016 8 3 (1.62) 8 4.65 (2.54) 1.2 % -1.65 [ -3.74, 0.44 ]
Bloomer 2004 9 3.54 (2.25) 9 4.2 (2.25) 1.2 % -0.66 [ -2.74, 1.42 ]
Bloomer 2005 10 5.7 (0.9487) 10 4.8 (0.9487) 5.1 % 0.90 [ 0.07, 1.73 ]
Bloomer 2007 7 7.35 (1.217) 8 5.75 (2.4324) 1.4 % 1.60 [ -0.31, 3.51 ]
Bryer 2006 10 3.56 (2.45) 8 5.78 (2.51) 1.0 % -2.22 [ -4.53, 0.09 ]
Close 2006 10 4.49 (2.29) 10 4.54 (2.83) 1.1 % -0.05 [ -2.31, 2.21 ]
Cobley 2011 6 2.67 (0.83) 6 2.58 (1.92) 1.8 % 0.09 [ -1.58, 1.76 ]
Connolly 2006 12 2.54 (2.46) 12 2.75 (2.14) 1.5 % -0.21 [ -2.05, 1.63 ]
Connolly 2006a 14 3.7 (4.49) 14 4.3 (4.8642) 0.5 % -0.60 [ -4.07, 2.87 ]
Goldfarb 2011 21 1.78 (1.53) 20 1.44 (1.99) 3.6 % 0.34 [ -0.75, 1.43 ]
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(. . . Continued)
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
He 2015 (1) 11 3.03 (2.08) 11 6.06 (3.35) 1.0 % -3.03 [ -5.36, -0.70 ]
Howatson 2009 10 4.55 (1.95) 10 4.1 (2.25) 1.5 % 0.45 [ -1.40, 2.30 ]
Hutchinson 2016 8 2.44 (1.8385) 8 3 (1.7819) 1.6 % -0.56 [ -2.33, 1.21 ]
Kerksick 2009 (2) 10 2.14 (3.83) 5 3.58 (2.3) 0.6 % -1.44 [ -4.55, 1.67 ]
Kerksick 2009 (3) 10 2.84 (1.7) 5 3.58 (2.3) 1.1 % -0.74 [ -3.01, 1.53 ]
Krotkiewski 1994 36 3.9 (1.8) 14 2.7 (1.1225) 5.1 % 1.20 [ 0.37, 2.03 ]
Laupheimer 2014 3 4 (2.96) 4 6.25 (4.44) 0.2 % -2.25 [ -7.74, 3.24 ]
Lynn 2015 11 2.61 (1.88) 10 2.65 (1.82) 2.0 % -0.04 [ -1.62, 1.54 ]
McBride 1997 6 2.33 (1.9596) 6 3.25 (2.1556) 1.0 % -0.92 [ -3.25, 1.41 ]
McFarlin 2016 16 3.7 (1.8) 12 4.95 (1.559) 2.9 % -1.25 [ -2.50, 0.00 ]
McLeay 2012 (4) 10 2.14 (1.73) 10 2.45 (2) 1.9 % -0.31 [ -1.95, 1.33 ]
Meamarbashi 2011 10 3 (3) 10 5.33 (3) 0.8 % -2.33 [ -4.96, 0.30 ]
Michailidis 2013 10 8.4 (0.4) 10 8.8 (0.4) 10.1 % -0.40 [ -0.75, -0.05 ]
Nicol 2015 (5) 17 3.7 (1.32) 17 4.3 (1.98) 3.4 % -0.60 [ -1.73, 0.53 ]
Nie 2004 8 6.2 (1.7) 8 6.7 (1.2) 2.3 % -0.50 [ -1.94, 0.94 ]
O’Connor 2013 20 1.99 (2.14) 20 1.85 (1.43) 3.4 % 0.14 [ -0.99, 1.27 ]
O’Fallon 2012 15 3.6 (1.63) 15 3.9 (1.57) 3.3 % -0.30 [ -1.45, 0.85 ]
Peschek 2014 8 4.1 (1.8) 8 4.6 (1.7) 1.7 % -0.50 [ -2.22, 1.22 ]
Shafat 2004 6 0.28 (0.19) 6 0.21 (0.17) 11.7 % 0.07 [ -0.13, 0.27 ]
Su 2008 8 6.2 (3.1113) 8 7.5 (1.6971) 0.9 % -1.30 [ -3.76, 1.16 ]
Tanabe 2015 14 4.3 (2.5) 14 4.7 (1.9) 1.9 % -0.40 [ -2.04, 1.24 ]
Theodorou 2011 14 3.36 (2.06) 14 2.79 (1.42) 2.7 % 0.57 [ -0.74, 1.88 ]
Thompson 2001 9 3.333 (3.333) 9 2.22 (3.333) 0.6 % 1.11 [ -1.97, 4.19 ]
Thompson 2001a (6) 8 5 (1.7) 8 5.8 (1.7) 1.8 % -0.80 [ -2.47, 0.87 ]
Thompson 2003 8 5.56 (3.144) 8 2.22 (3.144) 0.6 % 3.34 [ 0.26, 6.42 ]
Thompson 2004 7 5.04 (2.04) 7 4.67 (2.41) 1.0 % 0.37 [ -1.97, 2.71 ]
Trombold 2010 16 8 (2) 16 8.2 (1.9) 2.6 % -0.20 [ -1.55, 1.15 ]
Trombold 2011 (7) 17 3.59 (2.03) 17 4.17 (1.62) 3.0 % -0.58 [ -1.81, 0.65 ]
Total (95% CI) 488 448 100.0 % -0.17 [ -0.42, 0.07 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 57.81, df = 41 (P = 0.04); I2 =29%
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
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(1) Soreness at the thigh muscle
(2) NAC vs placebo
(3) EGCG vs placebo
(4) 12 hrs post exercise
(5) Single leg squat
(6) General soreness (0-100mm)
(7) Soreness at elbow
Analysis 1.9. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 9 Muscle soreness at 48 hours - all at same scale (0 to 10; worst pain).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 9 Muscle soreness at 48 hours - all at same scale (0 to 10; worst pain)
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Arent 2010 18 0.88 (1.3576) 18 1.94 (1.9516) 3.1 % -1.06 [ -2.16, 0.04 ]
Avery 2003 9 4.9 (3.3) 9 5.1 (4.2) 0.6 % -0.20 [ -3.69, 3.29 ]
Bailey 2011 20 5 (2) 18 5 (2) 2.6 % 0.0 [ -1.27, 1.27 ]
Beaton 2002a 9 8.8 (3.1) 7 7.5 (2) 1.1 % 1.30 [ -1.21, 3.81 ]
Bell 2015 8 0.746 (1.126) 8 1.09 (0.936) 3.3 % -0.34 [ -1.36, 0.67 ]
Bell 2016 8 2.25 (1.391) 8 4.55 (2.804) 1.3 % -2.30 [ -4.47, -0.13 ]
Bloomer 2004 9 3.04 (2.4) 9 5.46 (3) 1.1 % -2.42 [ -4.93, 0.09 ]
Bloomer 2005 10 5.8 (2.5298) 10 4.8 (1.8974) 1.6 % 1.00 [ -0.96, 2.96 ]
Bloomer 2007 7 7.07 (0.926) 8 6.25 (2.7436) 1.5 % 0.82 [ -1.20, 2.84 ]
Bryer 2006 10 5.667 (2.46) 8 7.22 (2.514) 1.2 % -1.56 [ -3.87, 0.76 ]
Close 2006 10 4.34 (2.74) 10 5.59 (2.6) 1.2 % -1.25 [ -3.59, 1.09 ]
Cobley 2011 6 2.417 (0.917) 6 2 (0.667) 3.6 % 0.42 [ -0.49, 1.32 ]
Connolly 2006 12 2.25 (1.92) 12 2.75 (2.07) 2.0 % -0.50 [ -2.10, 1.10 ]
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Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Connolly 2006a 14 3.3 (4.1158) 14 5 (4.49) 0.7 % -1.70 [ -4.89, 1.49 ]
Drobnic 2014 9 7.281 (2.469) 10 9.56 (2.469) 1.3 % -2.28 [ -4.51, -0.06 ]
Goldfarb 2011 21 2 (3.055) 20 2.22 (1.491) 2.3 % -0.22 [ -1.68, 1.24 ]
He 2015 (1) 11 3.183 (1.9) 11 5.15 (2.633) 1.6 % -1.97 [ -3.89, -0.05 ]
Howatson 2009 10 2.9 (1.95) 10 2.3 (1.4) 2.2 % 0.60 [ -0.89, 2.09 ]
Hutchinson 2016 8 2.75 (2.4324) 8 3.38 (2.1213) 1.3 % -0.63 [ -2.87, 1.61 ]
Kaminski 1992 19 3 (2.889) 19 4.89 (2.444) 1.9 % -1.89 [ -3.59, -0.19 ]
Kerksick 2009 (2) 10 3.3 (2.08) 5 5.51 (1.64) 1.6 % -2.21 [ -4.14, -0.28 ]
Kerksick 2009 (3) 10 3.49 (2.15) 5 5.51 (1.64) 1.6 % -2.02 [ -3.98, -0.06 ]
Krotkiewski 1994 36 2.95 (1.8) 14 1.1 (0.7483) 4.1 % 1.85 [ 1.14, 2.56 ]
Lynn 2015 10 1.23 (1.127) 10 0.89 (0.65) 3.8 % 0.35 [ -0.46, 1.15 ]
McBride 1997 6 2 (2.1311) 6 2.75 (2.278) 1.1 % -0.75 [ -3.25, 1.75 ]
McFarlin 2016 16 5.7 (1.6) 12 6.25 (1.386) 3.0 % -0.55 [ -1.66, 0.56 ]
McLeay 2012 (4) 10 3.79 (1.88) 10 3.35 (2.25) 1.7 % 0.44 [ -1.38, 2.26 ]
Meamarbashi 2011 10 2 (1.167) 10 5.5 (2.667) 1.7 % -3.50 [ -5.30, -1.70 ]
Michailidis 2013 10 8.9 (0.2) 10 9.5 (0.2) 5.4 % -0.60 [ -0.78, -0.42 ]
Nicol 2015 (5) 17 3.32 (1.15) 17 4 (2.14) 2.9 % -0.68 [ -1.83, 0.47 ]
Nie 2004 8 5.1 (1.2) 8 4.9 (1.3) 2.8 % 0.20 [ -1.03, 1.43 ]
O’Connor 2013 20 1.86 (1.87) 20 1.77 (1.39) 3.2 % 0.09 [ -0.93, 1.11 ]
O’Fallon 2012 15 3.96 (2.186) 15 4.34 (1.77) 2.3 % -0.38 [ -1.81, 1.04 ]
Peschek 2014 8 4.5 (2) 8 3.4 (2.4) 1.3 % 1.10 [ -1.06, 3.26 ]
Shafat 2004 6 0.278 (0.208) 6 0.32 (0.194) 5.3 % -0.04 [ -0.27, 0.19 ]
Silva 2008 (6) 9 3.86 (0.7) 4 5.43 (0.8) 3.6 % -1.57 [ -2.48, -0.66 ]
Silva 2008 (7) 8 5.83 (1) 4 5.43 (0.8) 3.2 % 0.40 [ -0.65, 1.45 ]
Silva 2010 11 3.8 (2.6533) 10 6.2 (1.5811) 1.7 % -2.40 [ -4.25, -0.55 ]
Su 2008 8 6.2 (4.5255) 8 8 (4.2426) 0.4 % -1.80 [ -6.10, 2.50 ]
Tanabe 2015 14 5.5 (2.1) 14 6 (2.2) 2.0 % -0.50 [ -2.09, 1.09 ]
Theodorou 2011 14 6.07 (2.4) 14 5.57 (1.5) 2.2 % 0.50 [ -0.98, 1.98 ]
Thompson 2001 9 2.222 (3.333) 9 2.22 (3.333) 0.8 % 0.0 [ -3.08, 3.08 ]
Thompson 2001a (8) 8 3.3 (1.131) 8 4.7 (2.263) 1.8 % -1.40 [ -3.15, 0.35 ]
Thompson 2003 8 3.333 (3.143) 8 2.22 (3.143) 0.8 % 1.11 [ -1.97, 4.19 ]
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Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Thompson 2004 7 6.43 (1.64) 7 4.86 (2.724) 1.2 % 1.57 [ -0.79, 3.93 ]
Trombold 2010 16 8.1 (1.6) 16 8 (2.2) 2.5 % 0.10 [ -1.23, 1.43 ]
Trombold 2011 (9) 17 2.71 (2.11) 17 3.76 (1.68) 2.6 % -1.05 [ -2.33, 0.23 ]
Total (95% CI) 549 498 100.0 % -0.41 [ -0.69, -0.12 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 127.20, df = 46 (P<0.00001); I2 =64%
Test for overall effect: Z = 2.76 (P = 0.0058)
Test for subgroup differences: Not applicable
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Favours antioxidant Favours placebo
(1) Soreness at the thigh muscle
(2) EGCG vs placebo
(3) NAC vs placebo
(4) 36 hours post exercise
(5) Single leg squat
(6) 21 days supplementation
(7) 14 days supplementation
(8) General soreness (0-100mm)
(9) Soreness at elbow
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Analysis 1.10. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 10 Muscle soreness at 72 hours - all at same scale (0 to 10; worst pain).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 10 Muscle soreness at 72 hours - all at same scale (0 to 10; worst pain)
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Avery 2003 9 3.6 (4.5) 9 4.3 (5.1) 0.5 % -0.70 [ -5.14, 3.74 ]
Bell 2015 8 0.54 (0.774) 8 1.22 (1.407) 5.3 % -0.68 [ -1.79, 0.43 ]
Bell 2016 8 0.55 (0.421) 8 1.65 (1.26) 6.8 % -1.10 [ -2.02, -0.18 ]
Bloomer 2004 9 2.54 (2.94) 9 5.38 (3.3) 1.0 % -2.84 [ -5.73, 0.05 ]
Bloomer 2005 10 4.1 (2.2136) 10 3.3 (1.2649) 3.1 % 0.80 [ -0.78, 2.38 ]
Bryer 2006 10 4.44 (2.811) 8 5.33 (3.143) 1.1 % -0.89 [ -3.68, 1.90 ]
Close 2006 10 2.96 (2.21) 10 3.24 (2.09) 2.3 % -0.28 [ -2.17, 1.61 ]
Cobley 2011 6 3 (1.25) 6 1.92 (2) 2.3 % 1.08 [ -0.81, 2.97 ]
Connolly 2006 12 2.58 (2.07) 12 2.16 (1.93) 3.0 % 0.42 [ -1.18, 2.02 ]
Connolly 2006a 14 2.2 (1.1225) 3 3 (1.5588) 2.3 % -0.80 [ -2.66, 1.06 ]
Goldfarb 2011 21 0.89 (2.037) 20 1.56 (2.485) 3.8 % -0.67 [ -2.06, 0.72 ]
He 2015 (1) 11 1.37 (1.25) 11 2.88 (2.367) 3.1 % -1.51 [ -3.09, 0.07 ]
Hutchinson 2016 8 1.38 (2.0082) 8 1.63 (1.3011) 2.8 % -0.25 [ -1.91, 1.41 ]
Kerksick 2009 (2) 10 2.61 (1.99) 5 4.35 (2.17) 1.6 % -1.74 [ -4.01, 0.53 ]
Kerksick 2009 (3) 10 3.23 (1.96) 5 4.35 (2.17) 1.6 % -1.12 [ -3.38, 1.14 ]
Krotkiewski 1994 36 1.6 (1.8) 14 0.5 (0.7483) 9.2 % 1.10 [ 0.39, 1.81 ]
McFarlin 2016 16 4.4 (3.6) 12 5.2 (3.4641) 1.2 % -0.80 [ -3.44, 1.84 ]
McLeay 2012 (4) 10 2.65 (1.44) 10 2.53 (1.6) 4.0 % 0.12 [ -1.21, 1.45 ]
Michailidis 2013 10 8 (0.2) 10 8.5 (0.2) 17.1 % -0.50 [ -0.68, -0.32 ]
O’Fallon 2012 15 3.12 (2.694) 15 3.09 (2.394) 2.4 % 0.03 [ -1.79, 1.85 ]
Phillips 2003 16 3.69 (9.52) 19 3.18 (7.4101) 0.3 % 0.51 [ -5.22, 6.24 ]
Tanabe 2015 14 4.8 (2.5) 14 5.2 (2.3) 2.5 % -0.40 [ -2.18, 1.38 ]
Theodorou 2011 14 4.68 (1.856) 14 5.32 (1.856) 3.8 % -0.64 [ -2.01, 0.73 ]
Thompson 2001 9 1.11 (1.333) 9 1.11 (1.333) 4.6 % 0.0 [ -1.23, 1.23 ]
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(. . . Continued)
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Thompson 2001a (5) 8 2 (1.41421) 8 1.8 (1.13137) 4.4 % 0.20 [ -1.05, 1.45 ]
Thompson 2003 8 2.222 (3.143) 8 1.11 (1.257) 1.5 % 1.11 [ -1.23, 3.46 ]
Thompson 2004 7 3.93 (2.063) 7 3.53 (2.539) 1.4 % 0.40 [ -2.02, 2.82 ]
Trombold 2010 16 5 (2.2) 16 5.9 (2.9) 2.5 % -0.90 [ -2.68, 0.88 ]
Trombold 2011 (6) 17 1.64 (2.09) 17 2.41 (1.7) 4.3 % -0.77 [ -2.05, 0.51 ]
Total (95% CI) 352 305 100.0 % -0.29 [ -0.59, 0.02 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 38.47, df = 28 (P = 0.09); I2 =27%
Test for overall effect: Z = 1.86 (P = 0.062)
Test for subgroup differences: Not applicable
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Favours antioxidant Favours placebo
(1) Soreness at the thigh muscle
(2) EGCG vs placebo
(3) NAC vs placebo
(4) 60 hrs post exercise
(5) General soreness (0-100mm)
(6) Soreness at elbow
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Analysis 1.11. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 11 Muscle soreness at 96 hours - all at same scale (0 to 10; worst pain).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 11 Muscle soreness at 96 hours - all at same scale (0 to 10; worst pain)
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bloomer 2004 9 1.81 (1.5) 9 3.24 (2.04) 3.9 % -1.43 [ -3.08, 0.22 ]
Bloomer 2005 10 3.7 (2.2136) 10 1.5 (1.2649) 4.2 % 2.20 [ 0.62, 3.78 ]
Bryer 2006 10 2.78 (2.8108889) 8 4.22 (2.83) 1.9 % -1.44 [ -4.07, 1.18 ]
Close 2006 10 1.46 (1.66) 10 1.3 (1.21) 5.5 % 0.16 [ -1.11, 1.43 ]
Cobley 2011 6 1.55 (1.27) 6 1 (1.82) 3.6 % 0.55 [ -1.23, 2.33 ]
Connolly 2006 12 1.66 (1.92) 12 0.71 (0.91) 5.8 % 0.95 [ -0.25, 2.15 ]
Connolly 2006a 14 1.2 (0.7483) 14 1.4 (1.1225) 8.9 % -0.20 [ -0.91, 0.51 ]
Krotkiewski 1994 36 1.5 (1.8) 14 0.2 (0.7483) 8.9 % 1.30 [ 0.59, 2.01 ]
McFarlin 2016 16 1 (4) 12 2.4 (3.1177) 1.9 % -1.40 [ -4.04, 1.24 ]
Michailidis 2013 10 5.2 (1.2) 10 5.6 (0.4) 8.4 % -0.40 [ -1.18, 0.38 ]
O’Fallon 2012 15 1.85 (1.87) 15 1.6 (1.85) 5.2 % 0.25 [ -1.09, 1.58 ]
Silva 2008 (1) 8 1.67 (0.8) 4 1.84 (0.7) 7.7 % -0.17 [ -1.05, 0.71 ]
Silva 2008 (2) 9 1.29 (0.5) 4 1.84 (0.7) 8.5 % -0.55 [ -1.31, 0.21 ]
Silva 2010 11 1.2 (1.6583) 10 2.3 (2.2136) 3.8 % -1.10 [ -2.79, 0.59 ]
Tanabe 2015 14 2.9 (2.9) 14 3.4 (2.6) 2.9 % -0.50 [ -2.54, 1.54 ]
Theodorou 2011 14 1.98 (1.39) 14 2.46 (1.64) 6.2 % -0.48 [ -1.60, 0.65 ]
Trombold 2010 16 3.6 (2.3) 16 3.8 (2.1) 4.4 % -0.20 [ -1.73, 1.33 ]
Trombold 2011 (3) 17 0.71 (1.49) 17 0.88 (0.86) 8.1 % -0.17 [ -0.99, 0.65 ]
Total (95% CI) 237 199 100.0 % -0.03 [ -0.43, 0.37 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 34.76, df = 17 (P = 0.01); I2 =51%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Not applicable
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Favours antioxidant Favours placebo
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(2) 21 days supplementaton
(3) Soreness at elbow
152Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.12. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 12 Muscle soreness at 24 hours. Subgroup analysis by type of exercise (whole body
aerobic vs. mechanically induced).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 12 Muscle soreness at 24 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically induced)
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Whole body aerobic exercise
Bailey 2011 20 5 (2) 18 5 (2) 4.1 % 0.0 [ -0.64, 0.64 ]
Bell 2015 8 20.67 (27.6) 8 25 (19.7) 1.8 % -0.17 [ -1.15, 0.81 ]
Bell 2016 8 60 (32.47) 8 93 (50.79) 1.7 % -0.73 [ -1.75, 0.29 ]
Close 2006 10 4.49 (2.29) 10 4.54 (2.83) 2.3 % -0.02 [ -0.90, 0.86 ]
Cobley 2011 6 3.2 (1) 6 3.1 (2.3) 1.4 % 0.05 [ -1.08, 1.18 ]
He 2015 (1) 11 1.82 (1.25) 11 3.64 (2.01) 2.1 % -1.05 [ -1.95, -0.14 ]
Howatson 2009 10 91 (39) 10 82 (45) 2.2 % 0.20 [ -0.67, 1.08 ]
Krotkiewski 1994 36 3.9 (1.8) 14 2.7 (1.1225) 4.2 % 0.72 [ 0.08, 1.35 ]
Laupheimer 2014 3 4 (2.96) 4 6.25 (4.44) 0.7 % -0.48 [ -2.03, 1.06 ]
Lynn 2015 11 52.27 (37.57) 10 53 (36.38) 2.4 % -0.02 [ -0.88, 0.84 ]
Meamarbashi 2011 10 1.8 (1.8) 10 3.2 (1.8) 2.1 % -0.74 [ -1.66, 0.17 ]
Peschek 2014 8 41 (18) 8 46 (17) 1.8 % -0.27 [ -1.26, 0.72 ]
Su 2008 8 6.2 (3.1113) 8 7.5 (1.6971) 1.8 % -0.49 [ -1.49, 0.51 ]
Thompson 2001 9 4 (3) 9 3 (3) 2.0 % 0.32 [ -0.61, 1.25 ]
Thompson 2001a (2) 8 50 (16.9706) 8 58 (16.9706) 1.8 % -0.45 [ -1.44, 0.55 ]
Thompson 2003 8 6 (2.8284) 8 3 (2.8284) 1.6 % 1.00 [ -0.06, 2.06 ]
Thompson 2004 7 50.4 (20.37) 7 46.7 (24.07) 1.6 % 0.16 [ -0.89, 1.21 ]
Subtotal (95% CI) 181 157 35.5 % -0.07 [ -0.33, 0.18 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 21.08, df = 16 (P = 0.18); I2 =24%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Mechanically induced
Arent 2010 18 1.12 (1.4425) 18 2.09 (1.6971) 3.8 % -0.60 [ -1.27, 0.07 ]
Avery 2003 9 5.9 (3.6) 9 6 (3.9) 2.0 % -0.03 [ -0.95, 0.90 ]
Bloomer 2004 9 3.54 (2.25) 9 4.2 (2.25) 2.0 % -0.28 [ -1.21, 0.65 ]
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Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bloomer 2005 10 5.7 (0.9487) 10 4.8 (0.9487) 2.0 % 0.91 [ -0.02, 1.84 ]
Bloomer 2007 7 7.35 (1.217) 8 5.75 (2.4324) 1.6 % 0.77 [ -0.30, 1.83 ]
Bryer 2006 10 4.2 (2.2136) 8 6.2 (2.2627) 1.8 % -0.85 [ -1.83, 0.13 ]
Connolly 2006 12 2.54 (2.46) 12 2.75 (2.14) 2.7 % -0.09 [ -0.89, 0.71 ]
Connolly 2006a 14 3.7 (4.49) 14 4.3 (4.8642) 3.1 % -0.12 [ -0.87, 0.62 ]
Goldfarb 2011 21 2.6 (1.3748) 20 2.3 (1.7889) 4.4 % 0.19 [ -0.43, 0.80 ]
Hutchinson 2016 8 2.44 (1.8385) 8 3 (1.7819) 1.8 % -0.29 [ -1.28, 0.69 ]
Kerksick 2009 (3) 10 2.14 (3.83) 5 3.58 (2.3) 1.5 % -0.39 [ -1.48, 0.69 ]
Kerksick 2009 (4) 10 2.84 (1.7) 5 3.58 (2.3) 1.5 % -0.37 [ -1.45, 0.72 ]
McBride 1997 6 2.33 (1.9596) 6 3.25 (2.1556) 1.3 % -0.41 [ -1.56, 0.74 ]
McFarlin 2016 16 7.4 (3.6) 12 9.9 (3.1177) 2.9 % -0.71 [ -1.49, 0.06 ]
McLeay 2012 (5) 10 2.14 (1.73) 10 2.45 (2) 2.3 % -0.16 [ -1.04, 0.72 ]
Michailidis 2013 10 8.4 (0.4) 10 8.8 (0.4) 2.0 % -0.96 [ -1.89, -0.02 ]
Nicol 2015 (6) 17 3.7 (1.32) 17 4.3 (1.98) 3.7 % -0.35 [ -1.03, 0.33 ]
Nie 2004 8 6.2 (1.7) 8 6.7 (1.2) 1.8 % -0.32 [ -1.31, 0.67 ]
O’Connor 2013 20 19.9 (21.4) 20 18.5 (14.3) 4.3 % 0.08 [ -0.54, 0.70 ]
O’Fallon 2012 15 36.03 (16.27) 15 39 (15.67) 3.3 % -0.18 [ -0.90, 0.54 ]
Shafat 2004 6 9.5 (1.2) 6 10 (1.4) 1.3 % -0.35 [ -1.50, 0.79 ]
Tanabe 2015 14 4.3 (2.5) 14 4.7 (1.9) 3.1 % -0.17 [ -0.92, 0.57 ]
Theodorou 2011 14 3.36 (2.06) 14 2.79 (1.42) 3.1 % 0.31 [ -0.43, 1.06 ]
Trombold 2010 16 8 (2) 16 8.2 (1.9) 3.5 % -0.10 [ -0.79, 0.59 ]
Trombold 2011 (7) 17 3.59 (2.03) 17 4.17 (1.62) 3.7 % -0.31 [ -0.99, 0.37 ]
Subtotal (95% CI) 307 291 64.5 % -0.18 [ -0.34, -0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 21.05, df = 24 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.034)
Total (95% CI) 488 448 100.0 % -0.13 [ -0.27, 0.00 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 42.93, df = 41 (P = 0.39); I2 =5%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.51), I2 =0.0%
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(1) Soreness at the thigh muscle
(2) General soreness (0-100mm)
(3) NAC vs placebo
(4) EGCG vs placebo
(5) 12 hrs post exercise
(6) Single leg squat
(7) Soreness at elbow
Analysis 1.13. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 13 Muscle soreness at 48 hours. Subgroup analysis by type of exercise (whole body
aerobic vs. mechanically induced).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 13 Muscle soreness at 48 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically induced)
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Whole body aerobic exercise
Bailey 2011 20 5 (2) 18 5 (2) 2.9 % 0.0 [ -0.64, 0.64 ]
Bell 2015 8 14.92 (22.51) 8 21.8 (18.72) 1.9 % -0.31 [ -1.30, 0.67 ]
Bell 2016 8 45 (27.82) 8 91 (56.08) 1.8 % -0.98 [ -2.04, 0.07 ]
Close 2006 10 4.34 (2.74) 10 5.59 (2.6) 2.1 % -0.45 [ -1.34, 0.44 ]
Cobley 2011 6 2.9 (1.1) 6 2.4 (0.8) 1.6 % 0.48 [ -0.68, 1.64 ]
Drobnic 2014 9 23.3 (7.9) 10 30.6 (7.9) 2.0 % -0.88 [ -1.84, 0.07 ]
He 2015 (1) 11 1.91 (1.14) 11 3.09 (1.58) 2.2 % -0.82 [ -1.70, 0.05 ]
Howatson 2009 10 58 (39) 10 46 (28) 2.2 % 0.34 [ -0.55, 1.22 ]
Krotkiewski 1994 36 2.95 (1.8) 14 1.1 (0.7483) 2.8 % 1.15 [ 0.49, 1.81 ]
Lynn 2015 10 24.6 (22.53) 10 17.7 (12.99) 2.2 % 0.36 [ -0.53, 1.24 ]
Meamarbashi 2011 10 1.2 (0.7) 10 3.3 (1.6) 1.8 % -1.63 [ -2.67, -0.59 ]
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Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Peschek 2014 8 45 (20) 8 34 (24) 1.9 % 0.47 [ -0.53, 1.47 ]
Su 2008 8 6.2 (4.5255) 8 8 (4.2426) 1.9 % -0.39 [ -1.38, 0.60 ]
Thompson 2001 9 3 (3) 9 3 (3) 2.1 % 0.0 [ -0.92, 0.92 ]
Thompson 2001a (2) 8 33 (11.3137) 8 47 (22.6274) 1.8 % -0.74 [ -1.76, 0.28 ]
Thompson 2003 8 4 (2.8284) 8 3 (2.8284) 1.9 % 0.33 [ -0.65, 1.32 ]
Thompson 2004 7 64.3 (16.4) 7 48.6 (27.24) 1.7 % 0.65 [ -0.43, 1.74 ]
Subtotal (95% CI) 186 163 34.7 % -0.12 [ -0.47, 0.23 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 39.26, df = 16 (P = 0.00100); I2 =59%
Test for overall effect: Z = 0.66 (P = 0.51)
2 Mechanically induced
Arent 2010 18 0.88 (1.3576) 18 1.94 (1.9516) 2.8 % -0.62 [ -1.29, 0.05 ]
Avery 2003 9 4.9 (3.3) 9 5.1 (4.2) 2.1 % -0.05 [ -0.97, 0.87 ]
Beaton 2002a 9 8.8 (3.1) 7 7.5 (2) 1.9 % 0.46 [ -0.55, 1.46 ]
Bloomer 2004 9 3.04 (2.4) 9 5.46 (3) 1.9 % -0.85 [ -1.82, 0.13 ]
Bloomer 2005 10 5.8 (2.5298) 10 4.8 (1.8974) 2.2 % 0.43 [ -0.46, 1.32 ]
Bloomer 2007 7 7.07 (0.926) 8 6.25 (2.7436) 1.8 % 0.37 [ -0.66, 1.39 ]
Bryer 2006 10 6.1 (2.2136) 8 7.5 (2.2627) 2.0 % -0.60 [ -1.55, 0.36 ]
Connolly 2006 12 2.25 (1.92) 12 2.75 (2.07) 2.4 % -0.24 [ -1.05, 0.56 ]
Connolly 2006a 14 3.3 (4.1158) 14 5 (4.49) 2.6 % -0.38 [ -1.13, 0.37 ]
Goldfarb 2011 21 2.8 (2.7495) 20 3 (1.3416) 3.0 % -0.09 [ -0.70, 0.52 ]
Hutchinson 2016 8 2.75 (2.4324) 8 3.38 (2.1213) 1.9 % -0.26 [ -1.25, 0.72 ]
Kaminski 1992 19 3.7 (2.6) 19 5.4 (2.2) 2.9 % -0.69 [ -1.35, -0.03 ]
Kerksick 2009 (3) 10 3.49 (2.15) 5 5.51 (1.64) 1.6 % -0.95 [ -2.09, 0.20 ]
Kerksick 2009 (4) 10 3.3 (2.08) 5 5.51 (1.64) 1.6 % -1.06 [ -2.23, 0.10 ]
McBride 1997 6 2 (2.1311) 6 2.75 (2.278) 1.6 % -0.31 [ -1.46, 0.83 ]
McFarlin 2016 16 11.4 (3.2) 12 12.5 (2.7713) 2.5 % -0.35 [ -1.11, 0.40 ]
McLeay 2012 (5) 10 3.79 (1.88) 10 3.35 (2.25) 2.2 % 0.20 [ -0.68, 1.08 ]
Michailidis 2013 10 8.9 (0.2) 10 9.5 (0.2) 1.3 % -2.87 [ -4.20, -1.55 ]
Nicol 2015 (6) 17 3.32 (1.15) 17 4 (2.14) 2.8 % -0.39 [ -1.07, 0.29 ]
Nie 2004 8 5.1 (1.2) 8 4.9 (1.3) 1.9 % 0.15 [ -0.83, 1.13 ]
O’Connor 2013 20 18.6 (18.7) 20 17.7 (13.9) 3.0 % 0.05 [ -0.57, 0.67 ]
O’Fallon 2012 15 39.6 (21.86) 15 43.43 (17.7) 2.7 % -0.19 [ -0.90, 0.53 ]
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Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Shafat 2004 6 10 (1.5) 6 10.3 (1.4) 1.6 % -0.19 [ -1.33, 0.94 ]
Silva 2008 (7) 8 5.83 (1) 4 5.43 (0.8) 1.5 % 0.39 [ -0.82, 1.61 ]
Silva 2008 (8) 9 3.86 (0.7) 4 5.43 (0.8) 1.1 % -2.00 [ -3.50, -0.51 ]
Silva 2010 11 3.8 (2.6533) 10 6.2 (1.5811) 2.1 % -1.04 [ -1.97, -0.12 ]
Tanabe 2015 14 5.5 (2.1) 14 6 (2.2) 2.6 % -0.23 [ -0.97, 0.52 ]
Theodorou 2011 14 6.07 (2.4) 14 5.57 (1.5) 2.6 % 0.24 [ -0.50, 0.99 ]
Trombold 2010 16 8.1 (1.6) 16 8 (2.2) 2.7 % 0.05 [ -0.64, 0.74 ]
Trombold 2011 (9) 17 2.71 (2.11) 17 3.76 (1.68) 2.8 % -0.54 [ -1.22, 0.15 ]
Subtotal (95% CI) 363 335 65.3 % -0.31 [ -0.50, -0.12 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 44.12, df = 29 (P = 0.04); I2 =34%
Test for overall effect: Z = 3.13 (P = 0.0017)
Total (95% CI) 549 498 100.0 % -0.24 [ -0.42, -0.07 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 86.34, df = 46 (P = 0.00029); I2 =47%
Test for overall effect: Z = 2.72 (P = 0.0065)
Test for subgroup differences: Chi2 = 0.88, df = 1 (P = 0.35), I2 =0.0%
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(1) Soreness at the thigh muscle
(2) General soreness (0-100mm)
(3) NAC vs placebo
(4) EGCG vs Placebo
(5) 36 hours post exercise
(6) Single leg squat
(7) 14 days supplementation
(8) 21 days supplementation
(9) Soreness at elbow
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Analysis 1.14. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 14 Muscle soreness at 24 hours. Subgroup analysis by funding sources (funded by food
company or provider of antioxidant supplements vs. not funded by food company or provider of antioxidant
supplements).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 14 Muscle soreness at 24 hours. Subgroup analysis by funding sources (funded by food company or provider of antioxidant supplements vs. not funded by
food company or provider of antioxidant supplements)
Study or subgroup Antioxidants Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Company funding
Arent 2010 18 1.12 (1.4425) 18 2.09 (1.6971) 3.9 % -0.60 [ -1.27, 0.07 ]
Bailey 2011 20 5 (2) 18 5 (2) 4.3 % 0.0 [ -0.64, 0.64 ]
Bell 2015 8 20.67 (27.6) 8 25 (19.7) 1.8 % -0.17 [ -1.15, 0.81 ]
Bell 2016 8 60 (32.47) 8 93 (50.79) 1.7 % -0.73 [ -1.75, 0.29 ]
Bloomer 2005 10 5.7 (0.9487) 10 4.8 (0.9487) 2.0 % 0.91 [ -0.02, 1.84 ]
Bloomer 2007 7 7.35 (1.217) 8 5.75 (2.4324) 1.5 % 0.77 [ -0.30, 1.83 ]
Connolly 2006a 14 3.7 (4.49) 14 4.3 (4.8642) 3.2 % -0.12 [ -0.87, 0.62 ]
Kerksick 2009 (1) 10 2.84 (1.7) 5 3.58 (2.3) 1.5 % -0.37 [ -1.45, 0.72 ]
Kerksick 2009 (2) 10 2.14 (3.83) 5 3.58 (2.3) 1.5 % -0.39 [ -1.48, 0.69 ]
McFarlin 2016 16 7.4 (3.6) 12 9.9 (3.1177) 2.9 % -0.71 [ -1.49, 0.06 ]
O’Connor 2013 20 19.9 (21.4) 20 18.5 (14.3) 4.6 % 0.08 [ -0.54, 0.70 ]
Peschek 2014 8 41 (18) 8 46 (17) 1.8 % -0.27 [ -1.26, 0.72 ]
Tanabe 2015 14 4.3 (2.5) 14 4.7 (1.9) 3.2 % -0.17 [ -0.92, 0.57 ]
Thompson 2001 9 4 (3) 9 3 (3) 2.0 % 0.32 [ -0.61, 1.25 ]
Thompson 2001a (3) 8 50 (16.9706) 8 58 (16.9706) 1.8 % -0.45 [ -1.44, 0.55 ]
Thompson 2003 8 6 (2.8284) 8 3 (2.8284) 1.6 % 1.00 [ -0.06, 2.06 ]
Trombold 2010 16 8 (2) 16 8.2 (1.9) 3.6 % -0.10 [ -0.79, 0.59 ]
Trombold 2011 (4) 17 3.59 (2.03) 17 4.17 (1.62) 3.8 % -0.31 [ -0.99, 0.37 ]
Subtotal (95% CI) 221 206 46.7 % -0.11 [ -0.31, 0.08 ]
Heterogeneity: Chi2 = 19.92, df = 17 (P = 0.28); I2 =15%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Other funding
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Study or subgroup Antioxidants Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Avery 2003 9 5.9 (3.6) 9 6 (3.9) 2.0 % -0.03 [ -0.95, 0.90 ]
Bloomer 2004 9 3.54 (2.25) 9 4.2 (2.25) 2.0 % -0.28 [ -1.21, 0.65 ]
Bryer 2006 10 4.2 (2.2136) 8 6.2 (2.2627) 1.8 % -0.85 [ -1.83, 0.13 ]
Close 2006 10 4.49 (2.29) 10 4.54 (2.83) 2.3 % -0.02 [ -0.90, 0.86 ]
Cobley 2011 6 3.2 (1) 6 3.1 (2.3) 1.4 % 0.05 [ -1.08, 1.18 ]
Connolly 2006 12 2.54 (2.46) 12 2.75 (2.14) 2.7 % -0.09 [ -0.89, 0.71 ]
Goldfarb 2011 21 2.6 (1.3748) 20 2.3 (1.7889) 4.6 % 0.19 [ -0.43, 0.80 ]
He 2015 (5) 11 1.82 (1.25) 11 3.64 (2.01) 2.1 % -1.05 [ -1.95, -0.14 ]
Howatson 2009 10 91 (39) 10 82 (45) 2.3 % 0.20 [ -0.67, 1.08 ]
Hutchinson 2016 8 2.44 (1.8385) 8 3 (1.7819) 1.8 % -0.29 [ -1.28, 0.69 ]
Krotkiewski 1994 36 3.9 (1.8) 14 2.7 (1.1225) 4.3 % 0.72 [ 0.08, 1.35 ]
Laupheimer 2014 3 4 (2.96) 4 6.25 (4.44) 0.7 % -0.48 [ -2.03, 1.06 ]
Lynn 2015 11 52.27 (37.57) 10 53 (36.38) 2.4 % -0.02 [ -0.88, 0.84 ]
McBride 1997 6 2.33 (1.9596) 6 3.25 (2.1556) 1.3 % -0.41 [ -1.56, 0.74 ]
McLeay 2012 (6) 10 2.14 (1.73) 10 2.45 (2) 2.3 % -0.16 [ -1.04, 0.72 ]
Meamarbashi 2011 10 1.8 (1.8) 10 3.2 (1.8) 2.1 % -0.74 [ -1.66, 0.17 ]
Michailidis 2013 10 8.4 (0.4) 10 8.8 (0.4) 2.0 % -0.96 [ -1.89, -0.02 ]
Nicol 2015 (7) 17 3.7 (1.32) 17 4.3 (1.98) 3.8 % -0.35 [ -1.03, 0.33 ]
Nie 2004 8 6.2 (1.7) 8 6.7 (1.2) 1.8 % -0.32 [ -1.31, 0.67 ]
O’Fallon 2012 15 36.03 (16.27) 15 39 (15.67) 3.4 % -0.18 [ -0.90, 0.54 ]
Shafat 2004 6 9.5 (1.2) 6 10 (1.4) 1.3 % -0.35 [ -1.50, 0.79 ]
Theodorou 2011 14 3.36 (2.06) 14 2.79 (1.42) 3.1 % 0.31 [ -0.43, 1.06 ]
Thompson 2004 7 50.4 (20.37) 7 46.7 (24.07) 1.6 % 0.16 [ -0.89, 1.21 ]
Subtotal (95% CI) 259 234 53.3 % -0.14 [ -0.32, 0.05 ]
Heterogeneity: Chi2 = 22.48, df = 22 (P = 0.43); I2 =2%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 480 440 100.0 % -0.13 [ -0.26, 0.01 ]
Heterogeneity: Chi2 = 42.43, df = 40 (P = 0.37); I2 =6%
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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(1) EGCG vs placebo
(2) NAC vs placebo
(3) General soreness (0-100mm)
(4) Soreness at elbow
(5) Soreness at the thigh muscle
(6) 12 hrs post exercise
(7) Single leg squat
Analysis 1.15. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 15 Muscle soreness at 48 hours. Subgroup analysis by funding sources (funded by food
company or provider of antioxidant supplements vs. not funded by food company or provider of antioxidant
supplements).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 15 Muscle soreness at 48 hours. Subgroup analysis by funding sources (funded by food company or provider of antioxidant supplements vs. not funded by
food company or provider of antioxidant supplements)
Study or subgroup Antioxidants Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Company funding
Arent 2010 18 0.88 (1.3576) 18 1.94 (1.9516) 3.6 % -0.62 [ -1.29, 0.05 ]
Bailey 2011 20 5 (2) 18 5 (2) 4.0 % 0.0 [ -0.64, 0.64 ]
Beaton 2002a 9 8.8 (3.1) 7 7.5 (2) 1.6 % 0.46 [ -0.55, 1.46 ]
Bell 2015 8 14.92 (22.51) 8 21.8 (18.72) 1.6 % -0.31 [ -1.30, 0.67 ]
Bell 2016 8 45 (27.82) 8 91 (56.08) 1.4 % -0.98 [ -2.04, 0.07 ]
Bloomer 2005 10 5.8 (2.5298) 10 4.8 (1.8974) 2.0 % 0.43 [ -0.46, 1.32 ]
Bloomer 2007 7 7.07 (0.926) 8 6.25 (2.7436) 1.5 % 0.37 [ -0.66, 1.39 ]
Connolly 2006a 14 3.3 (4.1158) 14 5 (4.49) 2.9 % -0.38 [ -1.13, 0.37 ]
Kerksick 2009 (1) 10 3.49 (2.15) 5 5.51 (1.64) 1.2 % -0.95 [ -2.09, 0.20 ]
Kerksick 2009 (2) 10 3.3 (2.08) 5 5.51 (1.64) 1.2 % -1.06 [ -2.23, 0.10 ]
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Study or subgroup Antioxidants Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McFarlin 2016 16 11.4 (3.2) 12 12.5 (2.7713) 2.8 % -0.35 [ -1.11, 0.40 ]
O’Connor 2013 20 18.6 (18.7) 20 17.7 (13.9) 4.2 % 0.05 [ -0.57, 0.67 ]
Peschek 2014 8 45 (20) 8 34 (24) 1.6 % 0.47 [ -0.53, 1.47 ]
Tanabe 2015 14 5.5 (2.1) 14 6 (2.2) 2.9 % -0.23 [ -0.97, 0.52 ]
Thompson 2001 9 3 (3) 9 3 (3) 1.9 % 0.0 [ -0.92, 0.92 ]
Thompson 2001a (3) 8 33 (11.3137) 8 47 (22.6274) 1.5 % -0.74 [ -1.76, 0.28 ]
Thompson 2003 8 4 (2.8284) 8 3 (2.8284) 1.6 % 0.33 [ -0.65, 1.32 ]
Trombold 2010 16 8.1 (1.6) 16 8 (2.2) 3.3 % 0.05 [ -0.64, 0.74 ]
Trombold 2011 (4) 17 2.71 (2.11) 17 3.76 (1.68) 3.4 % -0.54 [ -1.22, 0.15 ]
Subtotal (95% CI) 230 213 44.4 % -0.19 [ -0.38, 0.00 ]
Heterogeneity: Chi2 = 19.09, df = 18 (P = 0.39); I2 =6%
Test for overall effect: Z = 1.96 (P = 0.051)
2 Other funding
Avery 2003 9 4.9 (3.3) 9 5.1 (4.2) 1.9 % -0.05 [ -0.97, 0.87 ]
Bloomer 2004 9 3.04 (2.4) 9 5.46 (3) 1.7 % -0.85 [ -1.82, 0.13 ]
Bryer 2006 10 6.1 (2.2136) 8 7.5 (2.2627) 1.8 % -0.60 [ -1.55, 0.36 ]
Close 2006 10 4.34 (2.74) 10 5.59 (2.6) 2.0 % -0.45 [ -1.34, 0.44 ]
Cobley 2011 6 2.9 (1.1) 6 2.4 (0.8) 1.2 % 0.48 [ -0.68, 1.64 ]
Connolly 2006 12 2.25 (1.92) 12 2.75 (2.07) 2.5 % -0.24 [ -1.05, 0.56 ]
Drobnic 2014 9 23.3 (7.9) 10 30.6 (7.9) 1.8 % -0.88 [ -1.84, 0.07 ]
Goldfarb 2011 21 2.8 (2.7495) 20 3 (1.3416) 4.3 % -0.09 [ -0.70, 0.52 ]
He 2015 (5) 11 1.91 (1.14) 11 3.09 (1.58) 2.1 % -0.82 [ -1.70, 0.05 ]
Howatson 2009 10 58 (39) 10 46 (28) 2.1 % 0.34 [ -0.55, 1.22 ]
Hutchinson 2016 8 2.75 (2.4324) 8 3.38 (2.1213) 1.7 % -0.26 [ -1.25, 0.72 ]
Kaminski 1992 19 3.7 (2.6) 19 5.4 (2.2) 3.7 % -0.69 [ -1.35, -0.03 ]
Krotkiewski 1994 36 2.95 (1.8) 14 1.1 (0.7483) 3.7 % 1.15 [ 0.49, 1.81 ]
Lynn 2015 10 24.6 (22.53) 10 17.7 (12.99) 2.1 % 0.36 [ -0.53, 1.24 ]
McBride 1997 6 2 (2.1311) 6 2.75 (2.278) 1.2 % -0.31 [ -1.46, 0.83 ]
McLeay 2012 (6) 10 3.79 (1.88) 10 3.35 (2.25) 2.1 % 0.20 [ -0.68, 1.08 ]
Meamarbashi 2011 10 1.2 (0.7) 10 3.3 (1.6) 1.5 % -1.63 [ -2.67, -0.59 ]
Michailidis 2013 10 8.9 (0.2) 10 9.5 (0.2) 0.9 % -2.87 [ -4.20, -1.55 ]
Nicol 2015 (7) 17 3.32 (1.15) 17 4 (2.14) 3.5 % -0.39 [ -1.07, 0.29 ]
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Study or subgroup Antioxidants Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nie 2004 8 5.1 (1.2) 8 4.9 (1.3) 1.7 % 0.15 [ -0.83, 1.13 ]
O’Fallon 2012 15 39.6 (21.86) 15 43.43 (17.7) 3.1 % -0.19 [ -0.90, 0.53 ]
Shafat 2004 6 10 (1.5) 6 10.3 (1.4) 1.2 % -0.19 [ -1.33, 0.94 ]
Silva 2008 (8) 9 3.86 (0.7) 4 5.43 (0.8) 0.7 % -2.00 [ -3.50, -0.51 ]
Silva 2008 (9) 8 5.83 (1) 4 5.43 (0.8) 1.1 % 0.39 [ -0.82, 1.61 ]
Silva 2010 11 3.8 (2.6533) 10 6.2 (1.5811) 1.9 % -1.04 [ -1.97, -0.12 ]
Theodorou 2011 14 6.07 (2.4) 14 5.57 (1.5) 2.9 % 0.24 [ -0.50, 0.99 ]
Thompson 2004 7 64.3 (16.4) 7 48.6 (27.24) 1.4 % 0.65 [ -0.43, 1.74 ]
Subtotal (95% CI) 311 277 55.6 % -0.23 [ -0.40, -0.06 ]
Heterogeneity: Chi2 = 67.04, df = 26 (P = 0.00002); I2 =61%
Test for overall effect: Z = 2.66 (P = 0.0079)
Total (95% CI) 541 490 100.0 % -0.21 [ -0.34, -0.09 ]
Heterogeneity: Chi2 = 86.23, df = 45 (P = 0.00021); I2 =48%
Test for overall effect: Z = 3.29 (P = 0.0010)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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(4) Soreness at elbow
(5) Soreness at the thigh muscle
(6) 36 hours post exercise
(7) Single leg squat
(8) 21 days supplementation
(9) 14 days supplementation
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Analysis 1.16. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 16 Muscle tenderness measured in Newtons (all follow-up times).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 16 Muscle tenderness measured in Newtons (all follow-up times)
Study or subgroup Antioxidants Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 hours
Connolly 2006 12 33.9 (10.64) 12 35.2 (10.64) 50.5 % -1.30 [ -9.81, 7.21 ]
Connolly 2006a 14 -11.9 (11.5991) 14 -10 (11.5991) 49.5 % -1.90 [ -10.49, 6.69 ]
Subtotal (95% CI) 26 26 100.0 % -1.60 [ -7.64, 4.45 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
2 at 48 hours
Connolly 2006 12 33.9 (21.3) 12 35.2 (10.6) 29.7 % -1.30 [ -14.76, 12.16 ]
Connolly 2006a 14 -13.1 (13.8441) 14 -10.6 (9.3541) 70.3 % -2.50 [ -11.25, 6.25 ]
Subtotal (95% CI) 26 26 100.0 % -2.14 [ -9.48, 5.19 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
3 at 72 hours
Connolly 2006 12 37.2 (11.9) 12 37.2 (11.9) 42.5 % 0.0 [ -9.52, 9.52 ]
Connolly 2006a 14 -7.5 (11.5991) 14 -6.9 (10.4766) 57.5 % -0.60 [ -8.79, 7.59 ]
Subtotal (95% CI) 26 26 100.0 % -0.34 [ -6.55, 5.86 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
4 at 96 hours
Connolly 2006 12 38.6 (11.7) 12 41.9 (13.3) 53.2 % -3.30 [ -13.32, 6.72 ]
Connolly 2006a 14 -6.2 (13.8441) 14 -5 (14.9666) 46.8 % -1.20 [ -11.88, 9.48 ]
Subtotal (95% CI) 26 26 100.0 % -2.32 [ -9.62, 4.99 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
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Analysis 1.17. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 17 Muscle tenderness measured in kg (all follow-up times).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 17 Muscle tenderness measured in kg (all follow-up times)
Study or subgroup Antioxidants Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 6 hours
Close 2006 10 14.055 (16.2225) 10 14.67 (14.5149) 100.0 % -0.61 [ -14.10, 12.88 ]
Subtotal (95% CI) 10 10 100.0 % -0.61 [ -14.10, 12.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 at 24 hours
Close 2006 10 13.52 (12.1431) 10 11.85 (9.8347) 2.3 % 1.67 [ -8.02, 11.36 ]
Peschek 2014 8 5.9 (1.2) 8 5.4 (1.8) 97.7 % 0.50 [ -1.00, 2.00 ]
Subtotal (95% CI) 18 18 100.0 % 0.53 [ -0.95, 2.01 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
3 at 48 hours
Close 2006 10 14.075 (14.9576) 10 12.33 (13.3132) 1.7 % 1.75 [ -10.66, 14.16 ]
Peschek 2014 8 6 (1.6) 8 5.5 (1.7) 98.3 % 0.50 [ -1.12, 2.12 ]
Subtotal (95% CI) 18 18 100.0 % 0.52 [ -1.08, 2.13 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
4 at 72 hours
Close 2006 10 14.195 (14.8311) 10 15.22 (12.3961) 100.0 % -1.03 [ -13.01, 10.95 ]
Subtotal (95% CI) 10 10 100.0 % -1.03 [ -13.01, 10.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
5 at 96 hours
Close 2006 10 16.575 (16.8866) 10 17.97 (14.3251) 100.0 % -1.39 [ -15.12, 12.33 ]
Subtotal (95% CI) 10 10 100.0 % -1.39 [ -15.12, 12.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 1.18. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 18 30-second Wingate average peak power output (W/kg) (post 7 days of intervention).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 18 30-second Wingate average peak power output (W/kg) (post 7 days of intervention)
Study or subgroup Antioxidants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Arent 2010 18 10.9 (4.1578) 18 10.6 (5.0912) 0.30 [ -2.74, 3.34 ]
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Analysis 1.19. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 19 20 m Sprint time (s).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 19 20 m Sprint time (s)
Study or subgroup Antioxidants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 hours
Cobley 2011 6 3.2 (0.21) 6 3.61 (0.18) -0.41 [ -0.63, -0.19 ]
2 at 48 hours
Cobley 2011 6 3.41 (0.15) 6 3.71 (0.23) -0.30 [ -0.52, -0.08 ]
3 at 120 hours
Cobley 2011 6 3.36 (0.16) 6 3.66 (0.25) -0.30 [ -0.54, -0.06 ]
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Analysis 1.20. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 20 Maximal oxygen consumption (mL/kg/min) (post 42 days of supplementation).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 20 Maximal oxygen consumption (mL/kg/min) (post 42 days of supplementation)
Study or subgroup Antioxidants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
O’Connor 2013 20 43 (9.3) 20 42.8 (9.6) 0.20 [ -5.66, 6.06 ]
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Analysis 1.21. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 21 Agility (seconds).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 21 Agility (seconds)
Study or subgroup Antioxidants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 hours
Bell 2016 8 2.42 (0.17) 8 2.41 (0.17) 0.01 [ -0.16, 0.18 ]
2 at 48 hours
Bell 2016 8 2.38 (0.1) 8 2.43 (0.17) -0.05 [ -0.19, 0.09 ]
3 at 72 hours
Bell 2016 8 2.35 (0.12) 8 2.37 (0.18) -0.02 [ -0.17, 0.13 ]
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Analysis 1.22. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 22 6 second sprint maximal power (Watts) (all follow-up times).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 22 6 second sprint maximal power (Watts) (all follow-up times)
Study or subgroup Antioxidants Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 hours
Bell 2015 8 865 (256) 8 826 (191) 39.00 [ -182.33, 260.33 ]
2 at 48 hours
Bell 2015 8 908 (293) 8 858 (199) 50.00 [ -195.44, 295.44 ]
3 at 72 hours
Bell 2015 8 911 (272) 8 858 (184) 53.00 [ -174.56, 280.56 ]
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Analysis 1.23. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all
studies), Outcome 23 Maximal voluntary isometric contraction measured as percentage change from baseline.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 23 Maximal voluntary isometric contraction measured as percentage change from baseline
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 6 hours
Beaton 2002a 9 50 (19.2) 7 53 (15.3) 2.3 % -3.00 [ -19.91, 13.91 ]
Bloomer 2004 9 63.08 (24.3) 9 56.05 (21.3) 1.5 % 7.03 [ -14.08, 28.14 ]
Bryer 2006 10 62.3 (42.0583) 8 59.1 (28.2843) 0.6 % 3.20 [ -29.41, 35.81 ]
Close 2006 (1) 10 83.3 (10.1193) 10 80.8 (17.7088) 4.1 % 2.50 [ -10.14, 15.14 ]
Goldfarb 2011 21 71.1 (20.1633) 20 64.4 (23.2551) 3.7 % 6.70 [ -6.65, 20.05 ]
Meamarbashi 2011 10 112.6 (7) 10 105.8 (6.9) 17.8 % 6.80 [ 0.71, 12.89 ]
Shafat 2004 6 76.8 (6) 6 66.1 (4.2) 19.2 % 10.70 [ 4.84, 16.56 ]
Tanabe 2015 14 -33 (8) 14 -40 (9) 16.6 % 7.00 [ 0.69, 13.31 ]
Thompson 2001a (2) 8 85 (2.8284) 8 79 (11.3137) 10.1 % 6.00 [ -2.08, 14.08 ]
Trombold 2010 16 71.5 (7.3) 16 72.8 (10) 17.9 % -1.30 [ -7.37, 4.77 ]
Trombold 2011 (3) 17 75.4 (13.3) 17 64.9 (16.9) 6.3 % 10.50 [ 0.28, 20.72 ]
Subtotal (95% CI) 130 125 100.0 % 5.86 [ 3.29, 8.42 ]
Heterogeneity: Chi2 = 10.36, df = 10 (P = 0.41); I2 =3%
Test for overall effect: Z = 4.47 (P < 0.00001)
2 at 24 hours
Beaton 2002a 9 71.1 (26.9) 7 78.8 (15.4) 0.5 % -7.70 [ -28.65, 13.25 ]
Bloomer 2004 9 82.08 (20.4) 9 83.46 (12) 1.0 % -1.38 [ -16.84, 14.08 ]
Bryer 2006 10 72.3 (41.4258) 8 70.1 (39.8808) 0.2 % 2.20 [ -35.52, 39.92 ]
Close 2006 (4) 10 75.3 (18.6574) 10 75.7 (13.914) 1.1 % -0.40 [ -14.83, 14.03 ]
Connolly 2006 12 -34 (21.7) 12 -26.3 (20.6) 0.8 % -7.70 [ -24.63, 9.23 ]
Connolly 2006a 14 89 (11.225) 14 70 (7.4833) 4.7 % 19.00 [ 11.93, 26.07 ]
Goldfarb 2011 21 60.2 (16.039) 20 60.5 (18.3358) 2.1 % -0.30 [ -10.87, 10.27 ]
Herrlinger 2015 (5) 12 97 (3.4641) 13 94 (3.6056) 30.4 % 3.00 [ 0.23, 5.77 ]
Herrlinger 2015 (6) 12 93 (3.4641) 13 94 (3.6056) 30.4 % -1.00 [ -3.77, 1.77 ]
Meamarbashi 2011 10 28.67 (7) 10 34.88 (6.9) 6.3 % -6.21 [ -12.30, -0.12 ]
-100 -50 0 50 100
Favours placebo Favours antioxidants
(Continued . . . )
168Antioxidants for preventing and reducing muscle soreness after exercise (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shafat 2004 6 85.9 (5.8) 6 73.3 (4.6) 6.6 % 12.60 [ 6.68, 18.52 ]
Tanabe 2015 14 -32 (14) 14 -40 (8) 3.3 % 8.00 [ -0.45, 16.45 ]
Thompson 2001 (7) 9 85 (12) 9 96 (15) 1.5 % -11.00 [ -23.55, 1.55 ]
Thompson 2001a (8) 8 92 (8.4853) 8 80 (14.1421) 1.8 % 12.00 [ 0.57, 23.43 ]
Trombold 2010 16 77.3 (11.8) 16 75.7 (11.3) 3.6 % 1.60 [ -6.41, 9.61 ]
Trombold 2011 (9) 17 90.8 (9.9) 17 85.2 (8.9) 5.8 % 5.60 [ -0.73, 11.93 ]
Subtotal (95% CI) 189 186 100.0 % 2.51 [ 0.99, 4.04 ]
Heterogeneity: Chi2 = 58.88, df = 15 (P<0.00001); I2 =75%
Test for overall effect: Z = 3.23 (P = 0.0012)
3 at 48 hours
Beaton 2002a 9 92.4 (28.8) 7 86.5 (17.4) 0.4 % 5.90 [ -16.91, 28.71 ]
Bloomer 2004 9 86.32 (16.8) 9 83.05 (13.8) 1.1 % 3.27 [ -10.93, 17.47 ]
Bryer 2006 10 75.3 (50.9127) 8 73.1 (39.8808) 0.1 % 2.20 [ -39.75, 44.15 ]
Close 2006 (10) 10 80.1 (13.914) 10 77 (24.3495) 0.8 % 3.10 [ -14.28, 20.48 ]
Connolly 2006 12 -31.7 (23.4) 12 -20.4 (22.3) 0.7 % -11.30 [ -29.59, 6.99 ]
Connolly 2006a 14 93 (14.9666) 14 74 (7.4833) 3.0 % 19.00 [ 10.23, 27.77 ]
Goldfarb 2011 21 62.8 (20.6216) 20 63.1 (18.3358) 1.6 % -0.30 [ -12.23, 11.63 ]
Herrlinger 2015 (11) 12 98 (3.4641) 13 92 (3.6056) 30.0 % 6.00 [ 3.23, 8.77 ]
Herrlinger 2015 (12) 12 94 (3.4641) 13 92 (3.6056) 30.0 % 2.00 [ -0.77, 4.77 ]
Meamarbashi 2011 10 28.67 (7) 10 33.88 (6.9) 6.2 % -5.21 [ -11.30, 0.88 ]
Shafat 2004 6 90.2 (3.8) 6 83.6 (5.2) 8.7 % 6.60 [ 1.45, 11.75 ]
Tanabe 2015 14 -28 (9) 14 -40 (13) 3.4 % 12.00 [ 3.72, 20.28 ]
Thompson 2001 (13) 9 89 (12) 9 96 (15) 1.5 % -7.00 [ -19.55, 5.55 ]
Thompson 2001a (14) 8 92 (8.4853) 8 84 (14.1421) 1.8 % 8.00 [ -3.43, 19.43 ]
Trombold 2010 16 85.4 (10.1) 16 78.3 (10.1) 4.7 % 7.10 [ 0.10, 14.10 ]
Trombold 2011 (15) 17 95 (9.3) 17 87.4 (9.1) 6.0 % 7.60 [ 1.41, 13.79 ]
Subtotal (95% CI) 189 186 100.0 % 4.46 [ 2.94, 5.98 ]
Heterogeneity: Chi2 = 36.96, df = 15 (P = 0.001); I2 =59%
Test for overall effect: Z = 5.76 (P < 0.00001)
4 at 72 hours
Bloomer 2004 9 84.76 (14.7) 9 84.7 (17.4) 4.2 % 0.06 [ -14.82, 14.94 ]
Bryer 2006 10 79.1 (41.4258) 8 78.3 (31.3955) 0.8 % 0.80 [ -32.85, 34.45 ]
Close 2006 (16) 10 84.9 (10.7517) 10 84.7 (21.1873) 4.3 % 0.20 [ -14.53, 14.93 ]
-100 -50 0 50 100
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Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Connolly 2006 12 -31.8 (26.9) 12 -17.6 (20.6) 2.5 % -14.20 [ -33.37, 4.97 ]
Connolly 2006a 14 96 (14.9666) 14 82 (7.4833) 12.1 % 14.00 [ 5.23, 22.77 ]
Goldfarb 2011 21 71.3 (14.6642) 20 69.8 (15.6525) 10.7 % 1.50 [ -7.79, 10.79 ]
Tanabe 2015 14 -21 (12) 14 -35 (17) 7.8 % 14.00 [ 3.10, 24.90 ]
Thompson 2001 (17) 9 93 (15) 9 105 (9) 7.1 % -12.00 [ -23.43, -0.57 ]
Thompson 2001a (18) 8 96 (19.799) 8 93 (5.6569) 4.5 % 3.00 [ -11.27, 17.27 ]
Trombold 2010 16 88.9 (7.9) 16 84 (7.8) 31.3 % 4.90 [ -0.54, 10.34 ]
Trombold 2011 (19) 17 96.8 (11.7) 17 93.4 (11.9) 14.7 % 3.40 [ -4.53, 11.33 ]
Subtotal (95% CI) 140 137 100.0 % 3.92 [ 0.88, 6.96 ]
Heterogeneity: Chi2 = 20.21, df = 10 (P = 0.03); I2 =51%
Test for overall effect: Z = 2.52 (P = 0.012)
5 at 96 hours
Bloomer 2004 9 83.97 (7.5) 9 88.27 (12.6) 2.9 % -4.30 [ -13.88, 5.28 ]
Bryer 2006 10 88.3 (46.8017) 8 86.1 (39.3151) 0.2 % 2.20 [ -37.59, 41.99 ]
Close 2006 (20) 10 93 (16.4438) 10 94.4 (11.7004) 1.7 % -1.40 [ -13.91, 11.11 ]
Connolly 2006 12 -26.7 (28.8) 12 -11.1 (23.6) 0.6 % -15.60 [ -36.67, 5.47 ]
Connolly 2006a 14 105 (14.9666) 14 87 (11.225) 2.8 % 18.00 [ 8.20, 27.80 ]
Herrlinger 2015 (21) 12 96 (3.4641) 13 93 (3.6056) 34.7 % 3.00 [ 0.23, 5.77 ]
Herrlinger 2015 (22) 12 102 (3.4641) 13 93 (3.6056) 34.7 % 9.00 [ 6.23, 11.77 ]
Tanabe 2015 14 -15 (15) 14 -31 (13) 2.5 % 16.00 [ 5.60, 26.40 ]
Trombold 2010 16 91.3 (6.9) 16 90.4 (7.3) 11.0 % 0.90 [ -4.02, 5.82 ]
Trombold 2011 (23) 17 99.7 (8.7) 17 95.6 (7.5) 8.9 % 4.10 [ -1.36, 9.56 ]
Subtotal (95% CI) 126 126 100.0 % 5.29 [ 3.65, 6.92 ]
Heterogeneity: Chi2 = 32.03, df = 9 (P = 0.00020); I2 =72%
Test for overall effect: Z = 6.35 (P < 0.00001)
6 at 168 hours
Beaton 2002a 9 94.2 (21.2) 7 88.5 (13.5) 22.0 % 5.70 [ -11.38, 22.78 ]
Close 2006 (24) 10 90.4 (9.1706) 10 102.2 (11.3842) 78.0 % -11.80 [ -20.86, -2.74 ]
Subtotal (95% CI) 19 17 100.0 % -7.96 [ -15.96, 0.05 ]
Heterogeneity: Chi2 = 3.15, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 1.95 (P = 0.051)
-100 -50 0 50 100
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(1) Concentrique quad torque at 1.04 rad/s
(2) Left flexor
(3) Isometric strength during elbow flexion
(4) Concentrique quad torque at 1.04 rad/s
(5) high dose vs. placebo
(6) Low dose vs. placebo
(7) left flexor
(8) left elbow flexors
(9) Isometric strength during elbow flexion
(10) Concentrique quad torque at 1.04 rad/s
(11) high dose vs. placebo
(12) low dose vs. placebo
(13) left flexor
(14) left elbow flexors
(15) Isometric strength during elbow flexion
(16) Concentrique quad torque at 1.04 rad/s
(17) left flexor
(18) left elbow flexors
(19) Isometric strength during elbow flexion
(20) Concentrique quad torque at 1.04 rad/s
(21) low dose vs. placebo
(22) high dose vs. placebo
(23) Isometric strength during elbow flexion
(24) Concentrique quad torque at 1.04 rad/s
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Analysis 1.24. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 24 Maximal voluntary isometric contraction measured in Newton metres.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 24 Maximal voluntary isometric contraction measured in Newton metres
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 6 hours
Bailey 2011 (1) 20 269 (59) 18 259 (46) 1.0 % 10.00 [ -23.47, 43.47 ]
O’Fallon 2012 15 30.27 (13.9) 15 28.56 (14.46) 10.3 % 1.71 [ -8.44, 11.86 ]
Thompson 2003 8 83 (3) 8 85 (4) 88.7 % -2.00 [ -5.46, 1.46 ]
Subtotal (95% CI) 43 41 100.0 % -1.50 [ -4.77, 1.76 ]
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
2 at 24 hours
Bailey 2011 (2) 20 282 (66) 18 276 (57) 2.1 % 6.00 [ -33.12, 45.12 ]
McLeay 2012 (3) 10 133.91 (30.78) 10 131 (33.56) 4.0 % 2.91 [ -25.31, 31.13 ]
O’Fallon 2012 15 28.3 (16.13) 15 34.37 (18.94) 20.1 % -6.07 [ -18.66, 6.52 ]
Peschek 2014 8 149.6 (26.2) 8 141.5 (21.6) 5.7 % 8.10 [ -15.43, 31.63 ]
Theodorou 2011 14 194.36 (32.65) 14 196.93 (39.32) 4.4 % -2.57 [ -29.34, 24.20 ]
Thompson 2003 8 84 (5.6569) 8 84 (8.4853) 63.7 % 0.0 [ -7.07, 7.07 ]
Subtotal (95% CI) 75 73 100.0 % -0.63 [ -6.27, 5.01 ]
Heterogeneity: Chi2 = 1.47, df = 5 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
3 at 48 hours
Bailey 2011 (4) 20 281 (65) 18 292 (57) 2.6 % -11.00 [ -49.79, 27.79 ]
McLeay 2012 (5) 10 161.73 (29.63) 10 140.25 (43.58) 3.7 % 21.48 [ -11.18, 54.14 ]
O’Fallon 2012 15 29.18 (14.37) 15 37.95 (19.62) 25.9 % -8.77 [ -21.08, 3.54 ]
Peschek 2014 8 159.6 (31.8) 8 141.4 (15.3) 6.6 % 18.20 [ -6.25, 42.65 ]
Theodorou 2011 14 172.64 (29.95) 14 167.43 (46.51) 4.7 % 5.21 [ -23.77, 34.19 ]
Thompson 2003 8 85 (8.4853) 8 83 (8.4853) 56.6 % 2.00 [ -6.32, 10.32 ]
Subtotal (95% CI) 75 73 100.0 % 0.80 [ -5.46, 7.06 ]
Heterogeneity: Chi2 = 6.33, df = 5 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.25 (P = 0.80)
4 at 72 hours
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Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McLeay 2012 (6) 10 168.52 (26.77) 10 164.93 (40.52) 7.6 % 3.59 [ -26.51, 33.69 ]
O’Fallon 2012 15 33.26 (13.85) 15 41.31 (22.68) 38.0 % -8.05 [ -21.50, 5.40 ]
Theodorou 2011 14 164.29 (29.11) 14 176 (38.15) 10.9 % -11.71 [ -36.85, 13.43 ]
Thompson 2003 8 89 (11.3137) 8 88 (14.1421) 43.6 % 1.00 [ -11.55, 13.55 ]
Subtotal (95% CI) 47 47 100.0 % -3.62 [ -11.91, 4.67 ]
Heterogeneity: Chi2 = 1.56, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
5 at 96 hours
Bailey 2011 (7) 20 328 (71) 18 298 (57) 8.0 % 30.00 [ -10.76, 70.76 ]
O’Fallon 2012 15 36.15 (17.14) 15 44.25 (20.01) 75.2 % -8.10 [ -21.43, 5.23 ]
Theodorou 2011 14 180.5 (37.15) 14 186.29 (39.11) 16.7 % -5.79 [ -34.05, 22.47 ]
Subtotal (95% CI) 49 47 100.0 % -4.65 [ -16.21, 6.92 ]
Heterogeneity: Chi2 = 3.04, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.79 (P = 0.43)
6 at 120 hours
O’Fallon 2012 15 39.96 (16.6) 15 46.06 (24.6) 77.9 % -6.10 [ -21.12, 8.92 ]
Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 22.1 % -5.15 [ -33.33, 23.03 ]
Subtotal (95% CI) 29 29 100.0 % -5.89 [ -19.14, 7.36 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
7 at 168 hours
Bailey 2011 (8) 20 336 (66) 18 278 (73) 100.0 % 58.00 [ 13.57, 102.43 ]
Subtotal (95% CI) 20 18 100.0 % 58.00 [ 13.57, 102.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.011)
-200 -100 0 100 200
Favours placebo Favours antioxidants
(1) Extension
(2) Extension
(3) 12 hrs post
(4) Extension
(5) 36 hours post
(6) 60 hrs post
(7) Extension
(8) Extension
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Analysis 1.25. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 25 Maximal voluntary isometric contraction measured in Newtons.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 25 Maximal voluntary isometric contraction measured in Newtons
Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 6 hours
Avery 2003 (1) 9 1750 (450) 9 1853 (600) 1.6 % -103.00 [ -592.99, 386.99 ]
Bloomer 2005 (2) 10 510 (126.4911) 10 660 (252.9822) 12.3 % -150.00 [ -325.30, 25.30 ]
Bloomer 2007 7 772 (253.9921) 8 775 (195.1615) 7.1 % -3.00 [ -234.72, 228.72 ]
Howatson 2009 10 310 (88) 10 276 (69) 79.0 % 34.00 [ -35.31, 103.31 ]
Subtotal (95% CI) 36 37 100.0 % 6.50 [ -55.11, 68.10 ]
Heterogeneity: Chi2 = 3.86, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.21 (P = 0.84)
2 at 24 hours
Bell 2015 8 632.67 (86.65) 8 657.2 (98.95) 25.7 % -24.53 [ -115.67, 66.61 ]
Bell 2016 8 601 (126.26) 8 553 (60.22) 22.7 % 48.00 [ -48.93, 144.93 ]
Bloomer 2005 (3) 10 450 (205.548) 10 615 (189.7367) 7.1 % -165.00 [ -338.38, 8.38 ]
Bloomer 2007 7 996 (232.8261) 8 971 (130.1076) 5.6 % 25.00 [ -169.62, 219.62 ]
Howatson 2009 10 387 (94) 10 313 (74) 38.8 % 74.00 [ -0.15, 148.15 ]
Subtotal (95% CI) 43 44 100.0 % 23.03 [ -23.18, 69.24 ]
Heterogeneity: Chi2 = 7.63, df = 4 (P = 0.11); I2 =48%
Test for overall effect: Z = 0.98 (P = 0.33)
3 at 48 hours
Bell 2015 8 620.67 (118.07) 8 635.2 (85.58) 27.2 % -14.53 [ -115.58, 86.52 ]
Bell 2016 8 638 (136.46) 8 584 (58.65) 26.2 % 54.00 [ -48.92, 156.92 ]
Bloomer 2005 (4) 10 480 (189.7367) 10 605 (221.3594) 8.5 % -125.00 [ -305.70, 55.70 ]
Bloomer 2007 7 1039 (325.4274) 8 889 (164.0488) 3.9 % 150.00 [ -116.53, 416.53 ]
Howatson 2009 10 435 (109) 10 349 (96) 34.2 % 86.00 [ -4.02, 176.02 ]
Subtotal (95% CI) 43 44 100.0 % 34.87 [ -17.80, 87.55 ]
Heterogeneity: Chi2 = 6.01, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 1.30 (P = 0.19)
4 at 72 hours
Avery 2003 (5) 9 1550 (150) 9 1750 (375) 6.7 % -200.00 [ -463.87, 63.87 ]
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Study or subgroup Antioxidant Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bell 2015 8 665.22 (137.91) 8 641 (87.86) 36.3 % 24.22 [ -89.09, 137.53 ]
Bell 2016 8 641 (137.85) 8 610 (55.17) 44.1 % 31.00 [ -71.89, 133.89 ]
Bloomer 2005 (6) 10 545 (252.9822) 10 655 (173.9253) 12.9 % -110.00 [ -300.28, 80.28 ]
Subtotal (95% CI) 35 35 100.0 % -5.11 [ -73.42, 63.19 ]
Heterogeneity: Chi2 = 3.99, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.15 (P = 0.88)
5 at 96 hours
Bloomer 2005 (7) 10 540 (158.1139) 10 652 (189.7367) 100.0 % -112.00 [ -265.08, 41.08 ]
Subtotal (95% CI) 10 10 100.0 % -112.00 [ -265.08, 41.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
6 at 168 hours
Avery 2003 (8) 9 1600 (150) 9 1825 (450) 100.0 % -225.00 [ -534.90, 84.90 ]
Subtotal (95% CI) 9 9 100.0 % -225.00 [ -534.90, 84.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
-1000 -500 0 500 1000
Favours placebo Favours antioxidants
(1) Isometric squat
(2) Muscle isometric force
(3) Muscle isometric force
(4) Muscle isometric force
(5) Isometric squat
(6) Muscle isometric force
(7) Muscle isometric force
(8) Isometric squat
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Analysis 1.26. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 26 Maximal voluntary isometric contraction measured in Newton metres per kg of
body mass.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 26 Maximal voluntary isometric contraction measured in Newton metres per kg of body mass
Study or subgroup Antioxidant Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 6 hours
Kerksick 2009 (1) 10 2.01 (0.4237) 5 1.98 (0.6325) 0.03 [ -0.58, 0.64 ]
Kerksick 2009 (2) 10 2.4 (0.6641) 5 1.98 (0.6325) 0.42 [ -0.27, 1.11 ]
Michailidis 2013 (3) 10 1.9 (0.1) 10 1.75 (0.1) 0.15 [ 0.06, 0.24 ]
2 at 24 hours
Kerksick 2009 (4) 10 2.14 (0.6325) 5 2 (0.5376) 0.14 [ -0.47, 0.75 ]
Kerksick 2009 (5) 10 1.98 (0.3162) 5 2 (0.5376) -0.02 [ -0.53, 0.49 ]
Michailidis 2013 10 1.85 (0.1) 10 1.4 (0.1) 0.45 [ 0.36, 0.54 ]
3 at 48 hours
Kerksick 2009 (6) 10 1.98 (0.4111) 5 2.14 (0.6325) -0.16 [ -0.77, 0.45 ]
Kerksick 2009 (7) 10 2.24 (0.6325) 5 2.14 (0.6325) 0.10 [ -0.58, 0.78 ]
Michailidis 2013 10 1.6 (0.1) 10 1.2 (0.05) 0.40 [ 0.33, 0.47 ]
4 at 72 hours
Kerksick 2009 (8) 10 2.48 (0.6325) 5 2.28 (0.6325) 0.20 [ -0.48, 0.88 ]
Kerksick 2009 (9) 10 2.24 (0.4111) 5 2.28 (0.6325) -0.04 [ -0.65, 0.57 ]
Michailidis 2013 10 1.8 (0.1) 10 1.5 (0.1) 0.30 [ 0.21, 0.39 ]
5 at 96 hours
Michailidis 2013 10 1.95 (0.15) 10 1.75 (0.05) 0.20 [ 0.10, 0.30 ]
6 at 120 hours
Michailidis 2013 10 2.15 (0.15) 10 2.1 (0.1) 0.05 [ -0.06, 0.16 ]
7 at 144 hours
Michailidis 2013 10 2.35 (0.2) 10 2.45 (0.1) -0.10 [ -0.24, 0.04 ]
8 at 168 hours
Michailidis 2013 10 2.5 (0.2) 10 2.7 (0.2) -0.20 [ -0.38, -0.02 ]
-1 -0.5 0 0.5 1
Favours placebo Favours antioxidants
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(1) EGCG vs placebo (only half group shown here)
(2) NAC vs placebo (only half group shown here)
(3) 2 hrs post
(4) NAC vs placebo (only half group shown here)
(5) EGCG vs placebo (only half group shown here)
(6) EGCG vs placebo (only half group shown here)
(7) NAC vs placebo (only half group shown here)
(8) NAC vs placebo (only half group shown here)
(9) EGCG (only half group shown here)
Analysis 1.27. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 27 Maximal voluntary isometric contraction measured in kg.
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 27 Maximal voluntary isometric contraction measured in kg
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 hours
O’Connor 2013 20 6.3 (2.7) 20 5.7 (2.3) 0.23 [ -0.39, 0.86 ]
2 at 48 hours
O’Connor 2013 20 6.7 (3) 20 6.2 (2.5) 0.18 [ -0.44, 0.80 ]
-4 -2 0 2 4
Favours placebo Favours antioxidants
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Analysis 1.28. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness
(all studies), Outcome 28 Range of motion (all follow-up times).
Review: Antioxidants for preventing and reducing muscle soreness after exercise
Comparison: 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)
Outcome: 28 Range of motion (all follow-up times)
Study or subgroup Antioxidants Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 6 hours
Bailey 2011 (1) 20 106 (8) 18 106 (6) 46.9 % 0.0 [ -4.47, 4.47 ]
Bloomer 2004 (2) 9 76.69 (7.5) 9 83.15 (11.7) 11.4 % -6.46 [ -15.54, 2.62 ]
Bryer 2006 (3) 10 118 (10.7517) 8 116.7 (9.3338) 10.9 % 1.30 [ -7.99, 10.59 ]
Goldfarb 2011 (4) 21 117 (46.284) 20 121 (28.1745) 1.7 % -4.00 [ -27.33, 19.33 ]
Meamarbashi 2011 (5) 10 129 (5) 10 128.7 (9.7) 20.5 % 0.30 [ -6.46, 7.06 ]
Tanabe 2015 14 116 (14) 14 112 (14) 8.7 % 4.00 [ -6.37, 14.37 ]
Subtotal (95% CI) 84 79 100.0 % -0.25 [ -3.31, 2.81 ]
Heterogeneity: Chi2 = 2.69, df = 5 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
2 at 24 hours
Bailey 2011 (6) 20 106 (10) 18 105 (10) 9.2 % 1.00 [ -5.37, 7.37 ]
Bloomer 2004 (7) 9 86.22 (16.8) 9 82.3 (20.1) 1.3 % 3.92 [ -13.19, 21.03 ]
Bryer 2006 (8) 10 110 (11.3842) 8 103.3 (8.7681) 4.3 % 6.70 [ -2.61, 16.01 ]
Connolly 2006a (9) 14 -4.29 (4.3029) 14 -4.78 (6.1737) 24.0 % 0.49 [ -3.45, 4.43 ]
Goldfarb 2011 (10) 21 113 (39.8684) 20 113 (40.6964) 0.6 % 0.0 [ -24.68, 24.68 ]
Meamarbashi 2011 (11) 10 127.3 (5.4) 10 122.4 (10.6) 6.9 % 4.90 [ -2.47, 12.27 ]
O’Connor 2013 (12) 20 114 (9) 20 118 (9) 12.0 % -4.00 [ -9.58, 1.58 ]
Tanabe 2015 14 117 (12) 14 113 (10) 5.6 % 4.00 [ -4.18, 12.18 ]
Theodorou 2011 (13) 14 117.7 (2.49) 14 116.6 (5.61) 36.1 % 1.10 [ -2.12, 4.32 ]
Subtotal (95% CI) 132 127 100.0 % 1.03 [ -0.91, 2.96 ]
Heterogeneity: Chi2 = 6.30, df = 8 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
3 at 48 hours
Bailey 2011 (14) 20 105 (11) 18 106 (10) 12.1 % -1.00 [ -7.68, 5.68 ]
Bloomer 2004 (15) 9 90.55 (13.5) 9 77.87 (16.8) 2.7 % 12.68 [ -1.40, 26.76 ]
Bryer 2006 (16) 10 112 (6.6408) 8 100 (8.2024) 11.0 % 12.00 [ 4.98, 19.02 ]
-20 -10 0 10 20
Favours placebo Favours antioxidants
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(. . . Continued)
Study or subgroup Antioxidants Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Connolly 2006a (17) 14 -4.95 (7.4085) 14 -6.27 (6.1737) 21.2 % 1.32 [ -3.73, 6.37 ]
Goldfarb 2011 (18) 21 116 (41.7014) 20 115 (32.1994) 1.0 % 1.00 [ -21.74, 23.74 ]
Meamarbashi 2011 (19) 10 130.8 (6.1) 10 123.1 (8.9) 12.1 % 7.70 [ 1.01, 14.39 ]
O’Connor 2013 (20) 20 115 (11) 20 121 (8) 15.2 % -6.00 [ -11.96, -0.04 ]
Tanabe 2015 14 118 (13) 14 114 (10) 7.3 % 4.00 [ -4.59, 12.59 ]
Theodorou 2011 (21) 14 111.9 (5.88) 14 108.6 (8.86) 17.4 % 3.30 [ -2.27, 8.87 ]
Subtotal (95% CI) 132 127 100.0 % 2.71 [ 0.39, 5.04 ]
Heterogeneity: Chi2 = 20.63, df = 8 (P = 0.01); I2 =61%
Test for overall effect: Z = 2.29 (P = 0.022)
4 at 72 hours
Bloomer 2004 (22) 9 91.04 (9) 9 80.84 (12.6) 8.5 % 10.20 [ 0.08, 20.32 ]
Bryer 2006 (23) 10 117 (9.4868) 8 109 (8.2024) 13.0 % 8.00 [ -0.18, 16.18 ]
Connolly 2006a (24) 14 -4.45 (6.7724) 14 -5.11 (4.939) 45.0 % 0.66 [ -3.73, 5.05 ]
Goldfarb 2011 (25) 21 122 (35.7441) 20 117 (39.802) 1.6 % 5.00 [ -18.19, 28.19 ]
Phillips 2003 (26) 16 156 (33.8) 19 159.3 (31.3) 1.8 % -3.30 [ -25.03, 18.43 ]
Tanabe 2015 (27) 14 119 (11) 14 114 (15) 9.1 % 5.00 [ -4.74, 14.74 ]
Theodorou 2011 (28) 14 109.1 (9.24) 14 107.9 (8.09) 21.0 % 1.20 [ -5.23, 7.63 ]
Subtotal (95% CI) 98 98 100.0 % 2.93 [ -0.02, 5.87 ]
Heterogeneity: Chi2 = 5.28, df = 6 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
5 at 96 hours
Bailey 2011 (29) 20 102 (5) 18 102 (6) 33.6 % 0.0 [ -3.53, 3.53 ]
Bloomer 2004 (30) 9 92.08 (9.6) 9 87.57 (9.6) 5.3 % 4.51 [ -4.36, 13.38 ]
Bryer 2006 (31) 10 119 (6.6408) 8 116 (5.374) 13.6 % 3.00 [ -2.55, 8.55 ]
Connolly 2006a (32) 14 -1.81 (6.1737) 14 -2.47 (4.3029) 27.0 % 0.66 [ -3.28, 4.60 ]
Tanabe 2015 (33) 14 122 (11) 14 116 (11) 6.3 % 6.00 [ -2.15, 14.15 ]
Theodorou 2011 (34) 14 112.7 (7.22) 14 115.6 (7.42) 14.2 % -2.90 [ -8.32, 2.52 ]
Subtotal (95% CI) 81 77 100.0 % 0.79 [ -1.26, 2.84 ]
Heterogeneity: Chi2 = 4.83, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
6 at 120 hours
Phillips 2003 (35) 16 170.3 (21.3) 19 172.1 (19.1) 2.4 % -1.80 [ -15.32, 11.72 ]
Theodorou 2011 (36) 14 117.9 (2.74) 14 118.2 (2.97) 97.6 % -0.30 [ -2.42, 1.82 ]
Subtotal (95% CI) 30 33 100.0 % -0.34 [ -2.43, 1.76 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
-20 -10 0 10 20
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(. . . Continued)
Study or subgroup Antioxidants Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 0.31 (P = 0.75)
7 at 168 hours
Bailey 2011 (37) 20 108 (4) 18 103 (3) 100.0 % 5.00 [ 2.77, 7.23 ]
Subtotal (95% CI) 20 18 100.0 % 5.00 [ 2.77, 7.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.39 (P = 0.000012)
-20 -10 0 10 20
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(1) knee extensors and flexors
(2) elbow flexors
(3) elbow flexors
(4) elbow flexors
(5) knee flexion
(6) knee extensors and flexors
(7) elbow flexors
(8) elbow flexors
(9) relaxed elbow angle
(10) elbow flexors
(11) knee flexion
(12) elbow flexors
(13) knee flexion
(14) knee extensors and flexors
(15) elbow flexors
(16) elbow flexors
(17) relaxed elbow angle
(18) elbow flexors
(19) knee flexion
(20) elbow flexors
(21) knee flexion
(22) elbow flexors
(23) elbow flexors
(24) relaxed elbow angle
(25) elbow flexors
(26) Active arm flexion
(27) elbow flexors
(28) knee flexion
(29) knee extensors and flexors
(30) elbow flexors
(31) elbow flexors
(32) relaxed elbow angle
(33) elbow flexors
(34) knee flexion
(35) Active arm flexion
(36) knee flexion
(37) knee extensors and flexors
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A D D I T I O N A L T A B L E S
Table 1. Antioxidant supplements tested in the included trials
Study ID Antiox-
idant (type: Ex;
Vit; Whole)*
Dose** Form taken Regimen Started: before
exercise
Duration
Arent 2010 Ex: black tea ex-
tract; theaflavin
700 mg/day Capsule 4 capsules daily 9 days 11 days
Avery 2003 Vit: vitamin E 992 mg (1200
IU)/day
Capsule Not known
(daily)
21 days 31 days
Bailey 2011 Ex: mixed sup-
plement: vi-
tamins C, E, B6,
B9, B12 and zinc
400 mg vitamin
C
268 mg vitamin
E
etc
Capsule 1 capsule daily 42 days 6 weeks
Beaton 2002a Vit: vitamin E 1200 IU Capsule ? 30 days 30 days
Bell 2015 Whole: tart
cherry
9.2 mg/mL an-
thocyanins
Drink 30 mL twice
daily
3 days 8 days
Bell 2016 Whole: tart
cherry
73.5 mg/L to-
tal anthocyanin
content
Drink 30 mL twice
daily
4 days 7 days
Bloomer 2004 Vit: vitaminC, E
and selenium
268 mg vitamin
E
1 g vitamin C
90 µg selenium
Capsule 3 capsules daily 14 days 18 days
Bloomer 2005 Ex: astaxanthin 4mg astaxanthin
480 mg lutein
Capsule 2 capsules daily 21 days 25 days
Bloomer 2007 Vit: vitamin C
and E
1000 mg of vita-
min C
378 mg vitamin
E
Capsule 2 capsules daily 14 days 14 days
Bryer 2006 Vit: vitamin C 3 g/day vitamin
C
Capsule 3 capsules daily 14 days 18 days
Close 2006 Vit: vitamin C 1 g/day vitamin
C
? ? 0 days (day of ex-
ercise)
14 days
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Table 1. Antioxidant supplements tested in the included trials (Continued)
Cobley 2011 Ex: N-acetyl-
cysteine
50 mg/kg/day Powder dissolved
in water
50
mg/kg/day once
daily dissolved in
500 mL water
1 hour 6 days
Connolly 2006 Vit: vitamin C 1 g/day vitamin
C
Capsule 3 capsules daily 3 days 8 days
Connolly 2006a Whole: cherry 600 mg phenolic
compounds
40 mg antho-
cyanins
Drink 2 x 12 oz bottle
daily
4 days 8 days
Drobnic 2014 Ex: curcumin 400 mg/day cur-
cumin
Capsule 2 capsules daily 2 days 5 days
Goldfarb 2011 Ex: Juice Plus
powder
7.5 mg beta-
carotene
276 mg vitamin
C
108 IU of vita-
min E
Capsule 6 capsules daily 4 days 8 days
He 2015 Vit: vitamin C
and vitamin E
100 mg of vita-
min C
268mg (400 IU)
of vitamin E
Capsule ? 14 days 17 days
Herrlinger 2015 Ex: black and
green tea
High-dose =
2000 mg per
day polypheno-
lic blend
Low-
dose = 1000 mg
per day polyphe-
nolic blend
Capsule 4 capsules daily 91 days 91 days
Howatson 2009 Whole: cherry 600 mg phenolic
compounds ex-
pressed as gallic
acid equivalents,
32 g of carbohy-
drate and at least
40 mg of antho-
cyanins
Drink 2 x 8 fl oz bottles
per day
5 days 7 days
Hutchinson
2016
Whole: black-
currant nectar
193.25 mg/day
of malvidin glu-
cosides
Drink 16 oz bottle per
day
8 days 8 days
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Table 1. Antioxidant supplements tested in the included trials (Continued)
175.69 mg/day
of cyanidin glu-
cosides
Kaminski 1992 Vit: vitamin C 1 g/day vitamin
C
Capsule 3 capsules daily 3 days 10 days
Kerksick 2009 Ex: N-acetyl-
cysteine and epi-
gallocatechin
gallate (EGCG)
1800 mg/day N-
acetyl-cysteine
(NAC)
1800
mg/day epigallo-
catechin gallate
(EGCG)
Drink ? 14 days 14 days
Krotkiewski
1994
Ex: pollen ex-
tract
30,000 units per
gram of Polbax
? ? 28 days 28 days
Kuehl 2010 Whole: cherry 600 mg phenolic
compounds
40 mg antho-
cyanins
Drink 2 x 335 mL bot-
tles daily
7 days 15 days
Laupheimer
2014
Ex: resveratrol 600 mg/day of
resveratrol
Capsules 6 capsules daily 7 days 9 days
Lynn 2015 Whole: bilberry
juice
Total phenol
content per 200
mL serving was
744.14 ± 81.75
mg (n = 3) and
80.04 ± 3.51 mg
(n = 3) of total
anthocyanins
Drink 2 x 200 mL daily 5 days 8 days
McBride 1997 Vit: vitamin E 992 mg/day of
vitamin E (1200
IU)
Capsules 1 capsule daily 14 days 14 days
McCormick
2016
Whole: cherry 9.117 mg/mL
anthocyanins
Drink 90 mL daily (2 x
30 mL)
6 days 6 days
McFarlin 2016 Ex: curcumin 400 mg/day cur-
cumin
Capsules Capsules 2 days 6 days
McLeay 2012 Whole: blue-
berry smoothie
Per 100 mL: to-
tal phenolics 168
mg/gallic
acid equ.; antho-
Drink 200 g blueber-
ries, 50 g banana
+ 200 mL apple
juice daily
0 days (day of ex-
ercise)
4 days
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Table 1. Antioxidant supplements tested in the included trials (Continued)
cyanins 96.6 mg;
phenolic acid 26
mg,
flavonoids 10.2
mg; vitamin C
45mg; vitaminE
3 mg
Meamarbashi
2011
Ex: purslane ex-
tract
1200 mg/day
purslane extract
Capsules 2 capsules daily 3 days 5 days
Michailidis 2013 Vit: N-acetyl-
cysteine
20 mg/
kg/day N-acetyl-
cysteine
Drink 3 x500mLdrink
daily
0 days (day of ex-
ercise)
9 days
Nicol 2015 Ex: curcumin 2.5 g/day of cur-
cumin
Capsules 10 capsules daily
(2 x 5 capsules)
2.5 days 5 days
Nie 2004 Vit: vitamin C 800mg/day vita-
min C
Capsules ? 3 hours 2 days
O’Connor 2013 Whole: grape
juice
1.75 mg/kg
resveratrol
19.7 mg/kg cate-
chin
12.6 mg/kg
31.7 mg/kg pe-
onidin
125 mg/kg
cyanidin
145.2 mg/kg
32.6 mg/kg
quercetin
5.6 mg/kg
kaempferol
6.8 mg/kg
isorhamnetin
Drink (dissolved
powder)
1 serving of pow-
der daily mixed
with 236 mL of
water
45 days 50 days
O’Fallon 2012 Ex: quercetin 1000 mg/day
quercetin
Bar 2 bars daily 7 days 7 days
Peschek 2014 Whole: cocoa 350 mg/day fla-
vanols
Drink 240 mL daily 0 days (day of ex-
ercise)
3 days
Phillips 2003 Ex: mixed an-
tioxidants
300 mg/day to-
copherols
800 mg/day do-
cosahexaenoate
300 mg/
Capsules Vi-
tamin E: 1 cap-
sule; docosahex-
aenoate: 3 cap-
sules; flavonoids:
14 days 14 days
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Table 1. Antioxidant supplements tested in the included trials (Continued)
day flavonoids of
which
was 100 mg hes-
peretin and 200
mg quercetin
3 capsules
Shafat 2004 Vit: vitamin C +
vitamin E
500mg/day vita-
min C
992 mg/
day (1200 IU/
day) vitamin E
Capsules ? ? 37 days
Silva 2008 Ex: N-acetyl-
cysteine
10 mg/kg/day of
body mass N-
acetyl-cysteine
Capsules 1 capsule daily 14 days 21 days
Silva 2010 Vit: vitamin E 536
mg/day (800 IU/
day) vitamin E
Capsules 1 capsule daily 14 days 21 days
Su 2008 Ex: allicin 80 mg/day al-
licin
Capsules Capsules 14 days 16 days
Tanabe 2015 Ex: curcumin 150 mg/day cur-
cumin
Capsules 6 capsules daily 0 days (day of ex-
ercise; 1 hour be-
fore)
1 day
Theodorou
2011
Vit: vitamin C +
vitamin E
1 g/day vitamin
C
268 mg/
day (1200 IU/
day) vitamin E
Capsules 1 capsule daily 28 days 77 days
Thompson 2001 Vit: vitamin C 1 g/day vitamin
C
Drink ? 0 days (day of
exercise; 2 hours
before)
1 day
Thompson
2001a
Vit: vitamin C 1 g/day of vita-
min C on day 1
followed by 400
mg/day divided
into 2 doses for
12 days
Drink and cap-
sules
1 g given in a so-
lution followed
by 400 mg/day
doses in capsules
14 days 14 days
Thompson 2003 Vit: vitamin C 200mg/day vita-
min C
Drink Daily drink 0 days (day of ex-
ercise)
3 days
Thompson 2004 Vit: vitamin C 200mg/day vita-
min C
Drink Daily drink 14 days 14 days
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Table 1. Antioxidant supplements tested in the included trials (Continued)
Trombold 2010 Whole:
pomegranate
juice
650 mg/
day polyphenols,
consisting of 95.
5%
ellagitannins, 3.
5% ellagic acid
and 1% antho-
cyanins
Drink 960 mL per day
(as 2 x 480 mL
drinks)
9 days 32 days
Trombold 2011 Whole:
pomegranate
juice
3958 mg/L of
tannins
768mg/L antho-
cyanins
242 mg/L of el-
lagic derivatives
Drink 500 mL per day
(as 2 x 250 mL
drinks)
15 days 44 days
* Types: Extract, mixed or other (e.g. amino-acid derivative) antioxidants; Vitamin; andWhole natural food source.
** Every study included in this review used a dose higher than the recommended daily amount.
Table 2. Details of measurement of muscle soreness in the included trials
Study ID Outcome measure Score (higher = worse) Timing post-exercise Data extraction
Arent 2010 Muscle soreness during a
squat
VAS (0 to 10 cm) 24, 48 hours Text (SDs from SEs)
Avery 2003 Muscle
soreness during shoulder
abduction, shoulder hori-
zontal adduction and hip
flexion (unloaded squat)
VAS (0 to 10 cm) 24, 48, 72 hours Text
Bailey 2011 General soreness at the
quadriceps
VAS (1 to 10 cm) 24, 48 hours Text
Beaton 2002a General soreness at the
quadriceps
VAS (0 to 10 cm) 48 hours Text
Bell 2015 Muscle soreness during a
squat
VAS (0 to 200 mm) 24, 48, 72 hours Raw data provided by the
authors
Bell 2016 Muscle soreness during a
squat
VAS (0 to 200 mm) 24, 48, 72 hours Raw data provided by the
authors
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Table 2. Details of measurement of muscle soreness in the included trials (Continued)
Bloomer 2004 Active movement of el-
bow flexion or extension,
as well as following light
palpitation by the investi-
gators
VAS (0 to 10 cm) 0, 2, 6, 24, 48, 72, 96
hours
Raw data provided by the
authors
Immediate pain data used
for the up to 6 hours anal-
ysis
Bloomer 2005 Dominant leg during
knee extension
VAS (0 to 10 cm) 0, 10, 24, 48, 72, 96 hours Raw data provided by the
authors
Immediate pain data used
for the up to 6 hours anal-
ysis
Bloomer 2007 Performance of 2 (con-
centric-eccentric) repeti-
tions of the barbell bench
press exercise using a stan-
dard 20 kg barbell
VAS (0 to 10 cm) 0, 24, 48 hours Raw data provided by the
authors
Immediate pain data used
for the up to 6 hours anal-
ysis
Bryer 2006 Delayed onset muscle
soreness was assessed in a
rested position and in re-
sponse to palpation on the
muscle of the arms
VAS (1 to 10 cm) 0, 4, 24, 48, 72, 96 hours Text (SDs from SEs)
Immediate pain data used
for the up to 6 hours anal-
ysis
Close 2006 Delayed onset mus-
cle soreness was measured
at the gastrocnemius, an-
terior tibialis, hamstrings,
quadriceps, gluteals (both
sides) and lower back
muscles
VAS (0 to 10 cm) 0, 24, 48, 72, 96, 168, 336
hours
Raw data provided by the
authors
Immediate pain data used
for the up to 6 hours anal-
ysis
Cobley 2011 Total muscle soreness af-
ter performing a 90degree
squat
VAS (0 to 12 cm) 0, 24, 48, 50, 72, 96, 98
hours
Raw data provided by the
authors
Immediate pain data used
for the up to 6 hours anal-
ysis
Connolly 2006 General delayed onset
muscle soreness assessed
at the quadriceps
VAS (0 to 10 cm) 24, 48, 72, 96 hours Text
Connolly 2006a Pain scores were obtained
by asking participants to
verbally rate their overall
discomfort during active
elbow flexion and exten-
sion
VAS (0 to 10 cm) 24, 48, 72, 96 hours Text (SDs from SEs)
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Table 2. Details of measurement of muscle soreness in the included trials (Continued)
Drobnic 2014 Muscle soreness during
descending and climbing
stairs. The following 8
sites were measured: ante-
rior right thigh, posterior
right thigh, anterior right
leg, posterior right leg, an-
terior left thigh, poste-
rior left thigh, anterior left
leg, posterior left leg and
added together for a total
score
VAS (0 to 4) 48 hours Raw data provided by the
authors
Goldfarb 2011 Delayed onset muscle
soreness was measured at
the elbow flexor with the
arm rested
VAS (1 to 10 cm) 0, 2, 6, 24, 48, 72 hours Text (SDs from SEs)
Immediate pain data used
for the up to 6 hours anal-
ysis
He 2015 Delayed onset mus-
cle soreness of the quadri-
ceps, hamstrings, gluteus,
gastrocnemius and tibialis
anterior
VAS (0 to 6) 0, 24, 48, 72 hours Raw data provided by the
authors
Immediate pain data used
for the up to 6 hours anal-
ysis
Herrlinger 2015 Soreness was assessed in a
variety of muscle groups
including the gastrocne-
mius, hamstrings, quadri-
ceps, gluteus maximus,
lower back, abdominals
and the whole body
Likert (0 to 7) 24, 48, 72, 96 hours The authors of Herrlinger
2015 were contacted on 2
February 2017 and again
on 18February 2017 for
missing data as these
were not available in the
manuscript and could not
be extracted from graphs.
No response was received
and this study was there-
fore included in the quali-
tative analysis but not the
quantitative analysis
Howatson 2009 Squat down to 90 degrees
(internal joint angle) rise
to the start position
VAS (0 to 200 mm) 0, 24, 48 hours Text
Immediate pain data used
for the up to 6 hours anal-
ysis
Hutchinson 2016 Full range squat with no
external weight
VAS (0 to 10 cm) 24, 48, 72 hours Text (SDs from SEs)
Kaminski 1992 General delayed onset
muscle soreness was mon-
itored by self-reporting
VAS (1 to 10 cm) 0, 10, 24, 48, 58, 72, 96
hours
Raw data provided by the
authors
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Table 2. Details of measurement of muscle soreness in the included trials (Continued)
Immediate pain data used
for the up to 6 hours anal-
ysis
Kerksick 2009 Delayed
onset muscle soreness was
assessed at the quadriceps
VAS (0 to 10 cm) 6, 24, 48 hours Raw data provided by the
authors
6 hours post-exercise data
used for the up to 6 hours
analysis
Krotkiewski 1994 General soreness VAS (0 to 10 cm) 24, 48, 72, 96, 120 hours Text (SDs from SEs)
Kuehl 2010 General soreness in the
legs
VAS (0 to 100 mm) 0 hours Text
Immediate pain data used
for the up to 6 hours anal-
ysis
Laupheimer 2014 General soreness in both
legs
VAS (0 to 10 cm) 24 hours Raw data provided by the
authors
Lynn 2015 Squat to a 90 angle and re-
turning to a standing po-
sition
VAS (0 to 200 mm) 0, 24, 48 hours Text
Immediate pain data used
for the up to 6 hours anal-
ysis
McBride 1997 General soreness VAS (0 to 10 cm) 24, 48 hours Text (SDs from SEs)
McCormick 2016 Upper body, upper legs,
lower legs and overall
body
VAS (0 to 10 cm) 24, 48, 72, 96, 120, 144
hours
This study was only in-
cluded in the qualitative
analysis because the exer-
cise paradigm was com-
pletely different to all the
other studies included in
this review
McFarlin 2016 Muscle soreness measured
using a gauge. Pressure
was applied using stan-
dard force (20 to 30 N)
over the distal, middle
and proximal thigh in a
seated position with the
knee fully extended and
relaxed. The 3 ratings
for each quadricep were
added together
VAS (0 to 10 cm) 24, 48, 72, 96 hours Text (SDs from SEs)
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Table 2. Details of measurement of muscle soreness in the included trials (Continued)
McLeay 2012 Step up (concentric mus-
cle action) onto a 40 cm
box then step down (ec-
centric muscular contrac-
tion) and the soreness was
rated
VAS (0 to 10 cm) 24, 48, 72 hours Text
Meamarbashi 2011 Participants
were requested to rate the
general discomfort in only
the quadriceps and calf re-
gions of the right leg
VAS (0 to 6) 0, 24, 48 hours Text
Immediate pain data used
for the up to 6 hours anal-
ysis
Michailidis 2013 Palpation of the muscle
belly and the distal region
of the vastusmedialis, vas-
tus lateralis and rectus
femoris after a squat
VAS (1 to 10 cm) 0, 2, 24, 48, 72, 96, 120,
144, 168 hours
Text
Immediate pain data used
for the up to 6 hours anal-
ysis
Nicol 2015 Pain was rated for single
leg squat, walking down-
stairs, passive strength of
the gluteals and single leg
vertical jump
VAS (0 to 10 cm) 0, 24, 48 hours Raw data provided by the
authors
Immediate pain data used
for the up to 6 hours anal-
ysis
Nie 2004 Perceived soreness was
done during quadriceps
extension
VAS (0 to 10 cm) 0, 24, 48 hours Text
Immediate pain data used
for the up to 6 hours anal-
ysis
O’Connor 2013 Delayed on-
set muscle soreness in the
arm was rated in response
to isometric strengthmea-
surement
VAS (0 to 100 mm) 24, 48 hours Text
O’Fallon 2012 Delayed on-
set muscle soreness at the
elbow flexor
VAS (0 to 100 mm) 24, 48, 72, 96, 120 hours Raw data provided by the
authors
Peschek 2014 Delayed onset muscle
soreness at the legs
VAS (0 to 10 cm) 24, 48 hours Text
Phillips 2003 Soreness measures
were subjectively evalu-
ated through palpitation
for oedema at he elbow
VAS (0 to 10 cm) 72, 168 hours Text (SDs from SEs)
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Table 2. Details of measurement of muscle soreness in the included trials (Continued)
Shafat 2004 Delayed onset mus-
cle soreness was evaluated
using a questionnaire em-
ploying a visual analogue
scale for a total of 8 sites (6
sites on the anterior mus-
cle of the upper leg and 2
sites on the posteriormus-
cles of the upper leg). The
participants were asked to
palpate the relaxedmuscle
and rate soreness
VAS (1 to 10 cm)
(x 8): 8 to 80 score
24, 48 hours Text
Silva 2008 Delayed on-
set muscle soreness at the
elbow flexor
VAS (0 to 10 cm) 48, 96, 168 hours Text
Silva 2010 Muscle soreness of the bi-
ceps muscle was assessed
VAS (0 to 10 cm) 48, 96, 168 hours Text (SDs from SEs)
Su 2008 At the beginning of the
exercise test, participants
were instructed to give
CR-10 values
Borg CR (0-10) 0, 24, 48 hours Text (SDs from SEs)
Immediate pain data used
for the up to 6 hours anal-
ysis
Tanabe 2015 Palpitation of the upper
arm and passively extend-
ing the elbow joint
VAS (0 to 100 mm) 0, 24. 48, 72, 96 hours Raw data provided by the
authors
Immediate pain data used
for the up to 6 hours anal-
ysis
Theodorou 2011 Squat using body weight VAS (0 to 10 cm) 24, 48, 72, 96, 120 hours Text
Thompson 2001 Actively contracted the
quadriceps
VAS (1 to 10 cm) 24, 48, 72 hours Text (SDs from SEs)
; there are no decimal
places; where SE = 0, we
have put this as 0.4 (SD =
1.2)
Thompson 2001a Actively contracted the
quadriceps
VAS (0 to 100 mm) 24, 48, 72 hours Text (SDs from SEs)
Thompson 2003 Actively contracted the
quadriceps
VAS (1 to 10 cm) 24, 48, 72 hours Text (SDs from SEs)
; there are no decimal
places; where SE = 0, we
have put this as 0.4 (SD =
1.1313)
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Table 2. Details of measurement of muscle soreness in the included trials (Continued)
Thompson 2004 Actively contracting the
leg extensors against resis-
tance equivalent to 75%
of each individual’s 1 rep-
etition maximum
VAS (0 to 10 cm) 24, 48, 72 hours Raw data provided by the
authors
Trombold 2010 Unloaded elbow flexion
of the tested arm
VAS (0 to 10 cm) 2, 24, 48, 72, 96 hours Raw data provided by the
authors
2 hours post-exercise data
used for the up to 6 hours
analysis
Trombold 2011 Unloaded elbow flexion
and knee extension on the
tested arm and leg
VAS (0 to 10 cm) 2, 24, 48, 72, 96 hours Raw data provided by the
authors
2 hours post-exercise data
used for the up to 6 hours
analysis
SD: standard deviation
SE: standard error
VAS: visual analogue scale
Table 3. Muscle soreness sensitivity analyses: fixed-effect model
Follow-up times
(post-exercise)
No. studies No. participants SMD (95% CI)
Up to 6 hours 21 525 -0.31 (-0.49 to -0.13)
24 hours 41 936 -0.13 (-0.26 to -0.00)
48 hours 45 1047 -0.22 (-0.34 to -0.09)
72 hours 28 657 -0.17 (-0.33 to -0.02)
96 hours 17 436 -0.04 (-0.23 to 0.16)
120 hours 4 128 0.25 (-0.12 to 0.61)
144 hours 1 20 -0.23 (-1.11 to 0.65)
168 hours 4 80 -0.04 (-0.48 to 0.41)
CI: confidence interval
SMD: standardised mean difference
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Table 4. Muscle soreness sensitivity analyses: removal of cross-over trials
Follow-up times
(post-exercise)
All studies Parallel group studies only
No. studies SMD (95% CI) No. studies SMD (95% CI)
Up to 6 hours 21 -0.30 (-0.56 to -0.04) 15 -0.35 (-0.67 to -0.03)
24 hours 41 -0.13 (-0.27 to 0.00) 32 -0.08 (-0.25 to 0.08)
48 hours 45 -0.24 (-0.42 to -0.07) 34 -0.19 (-0.40 to 0.01)
72 hours 28 -0.19 (-0.38 to -0.00) 22 -0.11 (-0.30 to 0.08)
96 hours 17 -0.05 (-0.29 to 0.19) 12 0.01 (-0.33 to 0.34)
Table produced independently of the authors by Newton Opiyo and checked by Helen Handoll
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (Wiley Online Library)
#1 MeSH descriptor: [Exercise] explode all trees (18173)
#2 MeSH descriptor: [Exercise Test] this term only (7428)
#3 MeSH descriptor: [Physical Exertion] this term only (3598)
#4 (#1 or #2 or #3) (25438)
#5 MeSH descriptor: [Muscle, Skeletal] this term only and with qualifier(s): [Drug effects - DE, Physiopathology - PP] (2094)
#6 MeSH descriptor: [Muscle Contraction] this term only and with qualifier(s): [Drug effects - DE, Physiopathology - PP] (640)
#7 MeSH descriptor: [Muscle Cramp] this term only (150)
#8 MeSH descriptor: [Spasm] this term only (191)
#9 MeSH descriptor: [Muscle Rigidity] this term only (61)
#10 MeSH descriptor: [Sprains and Strains] this term only (326)
#11 MeSH descriptor: [Muscle Weakness] this term only (303)
#12 MeSH descriptor: [Creatine Kinase] this term only and with qualifier(s): [Blood - BL] (970)
#13 (#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12) (4397)
#14 #4 and #13 (1134)
#15 (exercise and (muscle* near/2 (damage* or injur*))):ti,ab,kw (579)
#16 (sore* near/3 musc*):ti,ab,kw (561)
#17 (DOMS or EIMD):ti,ab,kw (190)
#18 (#14 or #15 or #16 or #17) (1772)
#19 MeSH descriptor: [Antioxidants] explode all trees (3991)
#20 MeSH descriptor: [Ascorbic Acid] explode all trees (1721)
#21 MeSH descriptor: [Tocopherols] explode all trees (448)
#22 MeSH descriptor: [Vitamin A] explode all trees (1706)
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#23 MeSH descriptor: [Vitamin E] explode all trees (2122)
#24 MeSH descriptor: [beta Carotene] explode all trees (741)
#25 MeSH descriptor: [Oxidants] explode all trees (455)
#26 MeSH descriptor: [Oxidation-Reduction] explode all trees (2133)
#27 MeSH descriptor: [Reactive Oxygen Species] this term only and with qualifier(s): [Antagonists & inhibitors - AI] (7)
#28 MeSH descriptor: [Peroxides] explode all trees and with qualifier(s): [Antagonists & inhibitors - AI] (11)
#29 MeSH descriptor: [Ubiquinone] this term only (355)
#30 MeSH descriptor: [Phenol] this term only (66)
#31 MeSH descriptor: [Glutathione] this term only (580)
#32 MeSH descriptor: [Glutathione Peroxidase] this term only (402)
#33 MeSH descriptor: [Curcumin] this term only (100)
#34 MeSH descriptor: [Flavonoids] explode all trees (2148)
#35 (antioxidant* or anti-oxidant*):ti,ab,kw (7674)
#36 “vitamin c” or ascorbic acid:ti,ab,kw (3913)
#37 “vitamin E” or alpha-tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol*:ti,ab,kw (4630)
#38 (betacarotene or beta carotene or carotene or carotenoid*):ti,ab,kw (2083)
#39 (n-acetyl cysteine or n-acetylcysteine or n-acetyl-l-cysteine or acetylcysteine):ti,ab,kw (1441)
#40 (superoxide dismutase or SODor dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene
or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin*):ti,ab,kw (8882)
#41 (#19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36
or #37 or #38 or #39 or #40) (23501)
#42 (#18 and #41) (194)
MEDLINE (Ovid Web)
1 Exercise/ or Exercise Test/ or Physical Exertion/ (178530)
2 Muscle, Skeletal/de, pp [Drug Effects, Physiopathology] (25164)
3 Muscle Contraction/de, pp [Drug Effects, Physiopathology] (37380)
4 Muscle Cramp/ or Spasm/ or Muscle Rigidity/ or “Sprains and Strains”/ or Muscle Weakness/ (22384)
5 Creatine Kinase/bl [Blood] (14287)
6 or/2-5 (95850)
7 and/1,6 (4164)
8 (exercise and (muscle* adj2 (damage* or injur*))).tw. (2188)
9 (sore* adj3 musc*).tw. (1635)
10 (DOMS or EIMD).tw. (629)
11 or/7-10 (6846)
12 exp Antioxidants/ (397449)
13 exp Ascorbic Acid/ or exp Tocopherols/ or exp Vitamin A/ or exp Vitamin E/ or beta Carotene/ (106065)
14 exp Oxidants/ (109419)
15 exp Oxidation-Reduction/ (219323)
16 Reactive Oxygen Species/ai [Antagonists & Inhibitors] (1156)
17 exp Peroxides/ai [Antagonists & Inhibitors] (1602)
18 Ubiquinone/ or Phenol/ or Glutathione/ or Glutathione Peroxidase/ or Curcumin/ or exp Flavonoids/ (162838)
19 (antioxidant* or anti-oxidant*).tw. (153352)
20 (“vitamin c” or ascorbic acid).tw. (42561)
21 (“vitamin E” or alpha-tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol*).tw. (38259)
22 (betacarotene or beta carotene or carotene or carotenoid*).tw. (25604)
23 (n-acetyl cysteine or n-acetylcysteine or n-acetyl-l-cysteine or acetylcysteine).tw. (16312)
24 (superoxide dismutase or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene
or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin*).tw. (241246)
25 or/12-24 (908015)
26 and/11,25 (701)
27 Randomized controlled trial.pt. (446926)
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28 Controlled clinical trial.pt. (91808)
29 randomized.ab. (387435)
30 placebo.ab. (183299)
31 Drug therapy.fs. (1928982)
32 randomly.ab. (270638)
33 trial.ab. (405897)
34 groups.ab. (1669773)
35 or/27-34 (3968345)
36 exp Animals/ not Humans/ (4312930)
37 35 not 36 (3428779)
38 and/26,37 (302)
Embase (Ovid Web)
1 Exercise/ or Exercise Test/ (308139)
2 Skeletal Muscle/ (110436)
3 Muscle Contraction/ (68260)
4 Muscle Cramp/ or Spasm/ or Muscle Rigidity/ or Sprain/ or Muscle Weakness/ (66779)
5 Creatine Kinase/ (43734)
6 2 or 3 or 4 or 5 (267718)
7 1 and 6 (24273)
8 (exercise and (muscle* adj2 (damage* or injur*))).tw. (2372)
9 (sore* adj3 musc*).tw. (1733)
10 (DOMS or EIMD).tw. (662)
11 7 or 8 or 9 or 10 (26382)
12 exp antioxidant/ (185205)
13 exp Ascorbic Acid/ or exp Tocopherol/ or exp Retinol/ or Beta Carotene/ (167284)
14 exp Oxidizing Agent/ (226287)
15 exp Oxidation Reduction Reaction/ (86850)
16 Reactive Oxygen Metabolite/ (130471)
17 exp Peroxide/ (40960)
18 Ubiquinone/ or Phenol/ or Glutathione/ or Glutathione peroxidise/ or Curcumin/ or exp Flavonoid/ (242322)
19 (antioxidant* or anti-oxidant*).tw. (202054)
20 (“vitamin C” or ascorbic acid).tw. (49233)
21 (“vitamin E” or alpha-tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol*).tw. (43945)
22 (betacarotene or beta carotene or carotene or carotenoid*).tw. (28360)
23 (n-acetyl cysteine or n-acetylcysteine or n-acetyl-l-cysteine or acetylcysteine).tw. (20567)
24 (superoxide dismutase or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene
or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin*).tw. (294093)
25 or/12-24 (897856)
26 11 and 25 (1859)
27 Randomized controlled trial/ (476005)
28 Clinical trial/ (1026775)
29 Controlled clinical trial/ (470380)
30 Randomization/ (84507)
31 Single blind procedure/ (29183)
32 Double blind procedure/ (139527)
33 Crossover procedure/ (54944)
34 Placebo/ (327195)
35 Prospective study/ (396959)
36 ((clinical or controlled or comparative or placebo or prospective* or randomi#ed) adj3 (trial or study)).tw. (995276)
37 (random* adj7 (allocat* or allot* or assign* or basis* or divid* or order*)).tw. (246237)
38 ((singl* or doubl* or trebl* or tripl*) adj7 (blind* or mask*)).tw. (200629)
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39 (cross?over* or (cross adj1 over*)).tw. (86814)
40 ((allocat* or allot* or assign* or divid*) adj3 (condition* or experiment* or intervention* or treatment* or therap* or control* or
group*)).tw. (330995)
41 RCT.tw. (23208)
42 or/27-41 (2480033)
43 Case Study/ or Abstract Report/ or Letter/ (1091413)
44 42 not 43 (2427252)
45 26 and 44 (476)
SPORTDiscus (Ebsco)
S1 DE “EXERCISE” OR DE “EXERCISE tests” (84,781)
S2 (((((DE “MYALGIA”)OR (DE “DELAYEDonsetmuscle soreness”))OR (DE “MUSCLE cramps”))OR (DE “MUSCLE rigidity”))
OR (DE “SPRAINS”)) OR (DE “MUSCLE weakness”) (4,207)
S3 (DE “SKELETAL muscle”) (1,747)
S4 DE “MUSCLE contraction” (10,331)
S5 DE “CREATINE kinase” (1,275)
S6 S2 OR S3 OR S4 OR S5 (16,480)
S7 S1 AND S6 (3,922)
S8 TX (exercise and (muscle* n2 (damage* or injur*))) (2,482)
S9 TX sore* n3 musc* (2,055)
S10 TX DOMS or EIMD (1,006)
S11 S7 OR S8 OR S9 OR S10 (7,601)
S12 DE “ANTIOXIDANTS” (2,399)
S13 (DE “VITAMIN C”) OR (DE “VITAMIN E”) OR (DE “VITAMIN A”) (1,531)
S14 DE “OXIDATION-reduction reaction” (280)
S15 DE “FREE radicals (Chemistry)” (485)
S16 ((DE “UBIQUINONES”) OR (DE “PHENOLS”)) OR (DE “GLUTATHIONE”) (612)
S17 TI ( antioxidant* or anti-oxidant* ) OR AB ( antioxidant* or anti-oxidant* ) (4,527)
S18 TI ( “vitamin c” or ascorbic acid ) OR AB ( “vitamin c” or ascorbic acid ) (1,367)
S19 TI ( “vitamin E” or alpha-tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol* ) OR AB ( “vitamin E” or alpha-
tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol* ) (1,049)
S20 TI ( betacarotene or beta carotene or carotene or carotenoid* ) OR AB ( betacarotene or beta carotene or carotene or carotenoid*
) (788)
S21 TI ( n-acetyl cysteine or n-acetylcysteine or n-acetyl-l-cysteine or acetylcysteine ) OR AB ( n-acetyl cysteine or n-acetylcysteine or
n-acetyl-l-cysteine or acetylcysteine ) (178)
S22 TI ( superoxide dismutase or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or
lycopene or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin* ) OR AB ( superoxide dismutase
or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene or pentoxifylline or
polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin* ) (3,919)
S23 S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 (9,624)
S24 S11 AND S23 (312)
S25 TX ( (clinic* N3 trial) or (controlled N3 trial) or (comparative N3 trial) or (placebo N3 trial) or (prospective N3 trial) or (randomi?
ed N3 trial) ) or TX ( (clinic* N3 study) or (controlled N3 study) or (comparative N3 study) or (placebo N3 study) or (prospective
N3 study) or (randomi?ed N3 study) ) (74,987)
S26 (random* N7 allot*) or (random* N7 assign*) or (random* N7 basis*) or (random* N7 divid*) or (random* N7 order*) (10,503)
S27 TX ( (singl* N7 blind*) or (doubl* N7 blind*) or (trebl* N7 blind*) or (tripl* N7 blind*) ) or TX ( (singl* N7 mask*) or (doubl*
N7 mask*) or (trebl* N7 mask*) or (tripl* N7 mask*) ) (6,354)
S28 TX (cross#over*) or TX (cross N1 over*) (5,072)
S29 TX randomi?ed control* trial* (12,817)
S30 TX ( (allocat* N3 condition*) or (allocat* N3 experiment*) or (allocat* N3 intervention*) or (allocat* N3 treatment*) or (allocat*
N3 therap*) or (allocat* N3 control*) or (allocat* N3 group*) ) or TX ( (allot* N3 condition*) or (allot* N3 experiment*) or (allot*
N3 intervention*) or (allot* N3 treatment*) or (allot* N3 therap*) or (allot* N3 control*) or (allot* N3 group*) ) or TX ( (assign* N3
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condition*) or (assign* N3 experiment*) or (assign* N3 intervention*) or (assign* N3 treatment*) or (assign* N3 therap*) or (assign*
N3 control*) or (assign* N3 group*) ) or TX ( (divid* N3 condition*) or (divid* N3 experiment*) or (divid* N3 intervention*) or
(divid* N3 treatment*) or (divid* N3 therap*) or (divid* N3 control*) or (divid* N3 group*) ) (11,741)
S31 TX placebo* (9,181)
S32 S25 or S26 or S27 or S28 or S29 or S30 or S31 (93,140)
S33 (S26 or S28 or S30 or S25 or S27 or S29 or S31) AND (S24 AND S32) (117)
Appendix 2. WHO International Clinical Trials Registry Platform
1. musc* AND oxidative OR musc* AND antioxidant OR musc* AND exercis* AND supplement*
2. exercis* AND oxidative OR exercis* AND antioxidant OR exercis* AND vitamin
Total = 282
Appendix 3. ClinicalTrials.gov
1. muscle AND (oxidative OR antioxidant) AND exercise
Total = 162
C O N T R I B U T I O N S O F A U T H O R S
Mayur Ranchordas identified the research idea for the review, wrote the protocol, extracted the data, wrote the review and is the
guarantor.
David Rogerson assisted with drafting the protocol and data extraction.
Hora Soltani provided feedback on the draft protocol and review.
Joseph Costello assisted with data analysis and drafted the final review.
D E C L A R A T I O N S O F I N T E R E S T
Mayur Ranchordas co-authored one of the included studies (Lynn 2015). Decisions on inclusion of this study, the ’Risk of bias’
assessment and data extraction were undertaken by other review authors (JC, DR), who had no involvement in the study.
David Rogerson: none known.
Hora Soltani: none known.
Joseph Costello: none known.
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Internal sources
• Sheffield Hallam University, UK.
• University of Portsmouth, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since publication of the protocol (Ranchordas 2012), we made the following changes.
We updated the Background to reflect current evidence on the potential negative effects of antioxidant supplementation (in particularly
long-term use) by impairing exercise adaptations.
In Types of outcome measures, we stipulated that trials that did not record muscle soreness (pain) would be excluded. We included
a new primary outcome (subjective recovery) and we elevated adverse effects, originally listed as a secondary outcome, to primary
outcome status.
Linked with this was our selection of outcome measures for presentation in Summary of findings for the main comparison. This
included limiting the measurement of DOMS to five follow-up periods up to 96 hours.
In Subgroup analysis and investigation of heterogeneity, we removed the subgroup analysis “Type of antioxidants supplement (an-
tioxidants supplements vs. antioxidants-enriched food)”. This is because we realised that it was not possible to categorise studies into
’antioxidant supplement’ or ’antioxidant-enriched food’ as they usually belonged to both categories; for example, tart cherry juice is an
antioxidant-enriched food but it is also an antioxidant supplement containing vitamins such as vitamin C.
We merged two previous subgroup comparisons on types of exercise (“Normal sporting activities and laboratory induced DOMS”;
“Exercise that requires high oxygen consumption (e.g. running, cycling) and exercise that requires low oxygen consumption (e.g.
eccentric exercise in one arm)”) as the comparison of “whole body aerobic exercise” versus “mechanical exercise” captured both of these.
We included an additional subgroup analysis on sources of funding where we compared DOMS for studies that were funded by a food
company or provider of antioxidant supplements versus studies that were not funded by a food company or provider of antioxidant
supplements.
We could not compare the subgroup analysis ’timing of exercise’ because of insufficient studies in the ’supplementation after exercise’
group.
In Sensitivity analysis, we modified the sensitivity analysis testing the effects of high risk of selection bias to include also trials at unclear
risk of selection bias, relating to random sequence generation, allocation concealment or both. Additional sensitivity analysis to explore
the effects of excluding cross-over studies on the pooled data for muscle soreness at five time periods were conducted at screening by
the Cochrane Editorial Unit.
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